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Abstract 
Pathological manifestations of Lymphatic filariasis (LF), namely: hydrocele 
and lymphoedema (LE), results in severe chronic morbidity, remaining a 
leading cause of global disability. Treatment for the ~40 million symptomatic 
LF patients worldwide is currently limited to morbidity management to slow 
progression of disease. There is an urgent need to identify and translate 
novel therapeutic strategies to improve on standard care and effectively 
reverse LF pathology. A novel in vivo murine limb pathology model, utilising 
Brugia malayi infective L3 larvae (BmL3) was developed and an in vivo 
intravital optical imaging system utilised to longitudinally track lymphatic 
alterations and developing pathology following infection. Lymphatic 
fluorescent reporter mice (Prox1-GFP) were also used to image changes in 
lymphatic architecture. Multiplex (Luminex) protein assays on harvested 
plasma were undertaken to investigate associations between changes in 
circulating lymphangiogenic factors and lymphatic remodelling following 
filarial infection. Immune-deficient murine knockout strains, targeted immune 
cell ablations, and manipulation of specific lymphangiogenic molecules were 
utilised in the model to investigate cellular, molecular and immunological 
mechanisms of lymphatic pathology. Significant lymphatic remodelling and 
lymphatic insufficiency were consistently observed as rapidly as 6 days 
following BmL3 infection in lymphatic tissues where active parasitism could 
be determined by fluorescent BmL3 labelling experiments. Severity of BmL3 
induced lymphatic remodelling and pathology was mouse strain-dependent 
and associated with significantly altered plasma concentrations of a milieu of 
lymphangiogenic factors including: Vascular Endothelial Growth Factors 
(VEGFA, C), Transforming Growth Factor-β superfamily members (BMP-10, 
endoglin, follistatin, sALK-1, TGF-β) and prolactin. Both elevated 
prolymphangiogenic secretions and pathology persisted for 12 weeks post-
infection at a point where active parasitism was not evident (no adult 
infections or blood microfilaraemias). Monocytes and macrophages isolated 
from pathological lymphatic tissues and adjacent draining lymph nodes, 
secreted significant levels of prolymphangiogenic factors including sALK-1 
and VEGF-C. Macrophages isolated from pathological lymphatic / lymphoid 
17 
 
tissues expressed markers consistent with blood monocyte recruitment and 
alternative activation. Clodronate liposome mediated ablations of phagocytic 
cells, including monocytes and macrophages or specific anti-CCR2 antibody 
ablation of CCR2+ monocytes in wild type (WT) mice also ameliorated filarial 
lymphatic insufficiency and dilation. BmL3 infected Severe-Combined or Th2 
adaptive immune deficient (SCID, IL-4Rα-/-) mice displayed significantly 
abrogated lymphatic remodelling and pathology. Human lymphatic 
endothelial cells proliferated in response to monocyte-differentiated 
macrophage secretions after stimulation with live BmL3, L3 extracts or 
recombinant IL-4+IL-13. Together, the data demonstrates that lymphatic 
remodelling and insufficiency is rapidly induced following BmL3 infection. 
Further, the data highlights a novel Th2/monocyte/macrophage signalling 
axis as a key driver of filarial lymphatic remodelling and pathology. Inhibiting, 
or reversing, filarial remodelling, through targeting the identified adaptive Th2 
signalling mechanisms may represent novel therapeutic strategies to 
ameliorate LF-related pathology. 
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Chapter 1 
Introduction 
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1.1-The Global Burden, Consequences and Clinical 
Manifestations of Lymphatic Filariasis 
Lymphatic Filariasis (LF) is a disease encompassing a group of clinical 
pathologies/symptoms, associated with parasitic infection of humans by the 
filarial nematode families: Wuchereria bancrofti (90% of cases), Brugia 
malayi, and Brugia Timori (Taylor, Hoerauf and Bockarie, 2010; Chandy et 
al., 2011). Recent  World Health Organization (WHO) estimates suggest that 
68 million people remain infected with LF worldwide, with highest prevalence 
lying around the tropical belts of Africa, Asia and Latin America (Hotez et al., 
2008; Hotez and Kamath, 2009; Hotez, Savioli and Fenwick, 2012), while the 
WHO predicts 1.2 billion remain at high risk of infection (Michael, Bundy and 
Grenfell, 1996; Michael and Bundy, 1997) (Figure 1.1A). The high global 
burden of infection, the chronic nature of LF and its heavy concentration of 
infection in low and middle income countries (LF is endemic in 32 of the 
world’s 38 lesser economically developed countries) makes it a primary 
contributor to neglected disease burden, subsequently ranking it as 4th 
highest, as ranked by highest causes of Disability Adjusted Life Years 
(DALYs), in the list of 13 neglected tropical diseases (NTDs (Hotez et al., 
2007; Chandy et al., 2011). While a proportion of those infected remain 
clinically asymptomatic, it is estimated that at least a 40 million patient subset 
suffer severely debilitating pathology and high morbidity as clinical 
manifestations of filarial infection(Nutman, 2013).  
Clinically, LF manifests in a group of chronic and acute pathologies, often 
occurring months to years after initial infection (Pfarr et al., 2009). While 
some success has been observed in reversing early stages of LF related 
pathology (Debrah et al., 2006; Shenoy, 2008), progression to later stages 
results in incurable, chronic pathology. In addition, chronic LF related 
pathology persist beyond the clearing of active filarial infection through 
therapeutic intervention (Grenfell, Michael and Denham, 1991; Chan et al., 
1998). Chronic manifestations of LF include severe lymphoedema (LE) in: 
the limbs, genitals or breasts of individuals, resulting in severe disfigurement 
(Pani and Srividya, 1995) (Examples in figure 1.1B-C). In addition to 
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 Figure 1.1: Global burden of Lymphatic Filariasis and associated 
pathologies 
A) Map detailing the global distribution of LF endemic countries, notice the 
distribution round the tropical belts and correlation with lower economically 
developed countries.    B) Images demonstrating the severely disfiguring 
effects of filarial lymphoedema (LE) / elephantiasis. The overt swelling leads 
to not only huge physical disability, but psychological disability, associated 
with mental health complications arising from disease as well as social 
stigma attached to LF patients. C) Scrotal lymphoedema, describe as 
hydrocoele. Hydrocoele is a common form of LF-related pathology with 25 
million males estimated to suffer from this condition. 
Images Sources: World Health Organization, 2019 
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LE, affected limbs often display progressively worse skin abnormalities, 
namely severe skin pitting, thickening (hyper-keratosis and hyper-
pigmentation), fibrosis and localised inflammation (Partono, 1987). Other 
chronic manifestations can include acute swelling of the penis and scrotum, 
a condition known as hydrocoele that is thought to affect around 27 million 
males globally (Nutman, 2013). Due to the spectrum of lymphoedematous 
pathology observed in LF, Dreyer and colleagues (Gillespie, 2004) have 
characterised a sliding scale of filarial related lymphoedema, classified in 
stages 1-7 as shown in Table 1 . Importantly, recent work has suggested 
revisiting this classification by addition of a “Stage 0”, taking into account 
patients who do not present with clinical symptoms, but present with “covert” 
or “sub-clinical” pathologies (Douglass et al., 2017). These “Stage 0 sub-
clinical pathologies”, described as changes to skin elasticity, firmness, 
increased tissue “free fluid” and possible alterations to the lymphatic 
architecture is argued to be a key window in which therapeutic interventions 
may prevent progression to later stages of severity (Douglass et al., 2019). 
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STAGE DESCRIPTION EXAMPLE 
1 Mild lymphoedema which is 
reversible overnight, rarely have 
acute attacks, entry lesions or 
odour 
 
2 Mild lymphoedema which is not 
reversible overnight. Very 
occasional acute attacks, entry 
lesions or mild bad odour 
 
3 Noticeable lymphoedema which is 
not reversible overnight. Presence 
of shallow skin folds and 
occasional acute attacks, entry 
lesions and bad odour  
 
4 Severe lymphoedema which is not 
reversible overnight. Clear 
presence of knobs/swellings or 
protrusions on skin. Frequent entry 
lesions and bad odours which may 
be occasionally accompanied by 
acute attacks  
 
5 Severe lymphoedema not 
reversible overnight. Many deep 
skin folds/pitting with common 
entry lesions and bad odour. 
Occasional to frequent acute 
attacks 
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6 Severe lymphoedema not 
reversible overnight. Small 
clustered round protrusions/knobs 
give rise to appearance of “mossy 
foot”. Lymphoedema can extend to 
above the knee. Frequent entry 
lesions, bad odour and acute 
attacks 
 
7 Severe lymphoedema not 
reversible overnight. Severe 
disability to patient who cannot 
adequately perform simple daily 
routines. Extremely large affected 
limb which extends above knee 
with deep skin folds, thickening and 
pitting. Frequent entry lesions, bad 
odour and acute attacks 
 
Table 1.1: Dreyer classification of lymphoedematous pathologies 
associated with Lymphatic Filariasis. 
Description of different stages of filarial LE increasing in severity. Some data 
suggests therapeutic intervention at earlier stages can arrest progression or 
even be reversed while later stages are irreversible and lifelong in duration. 
Images and descriptions from (Dreyer et al., 2001) 
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The high prevalence of LF in lesser economically developed countries 
(LEDC’s) in conjunction with associated high morbidity results in significant 
impacts on patient household income, due to lost earning opportunity from 
being unable to work as well as carer duties. This has led to LF being 
described as a “disease of poverty” (Durrheim et al., 2004).   Aside from 
physical morbidity, LF pathology is associated with accompanying secondary 
complications including an incredibly high psychological burden through 
mental health problems, associated with levels of disfigurement (Zeldenryk et 
al., 2011; Ton, Mackenzie and Molyneux, 2015) and marginalisation from 
communities due to the social stigma attached to LF (Weiss, 2008). 
Chronic infection is often accompanied by acute, ‘inflammatory episode’ type 
manifestations of LF, although such episodes are also observed following 
initial infection in asymptomatic patient cohorts. The most common acute 
manifestation is adeno-lymphangitis (ADL) characterised by: systemic fever, 
lymphadenopathy of affected lymph nodes (LN’s), and general inflammation 
and pain of affected limbs (Shenoy, 2008). It is hypothesised that ADL 
‘episodes’ are a result of inflammatory reactions to filarial worm death events 
and the associated release of antigens, triggering inflammatory immune 
responses (Kar, Mania, & Kar, 1987). Additional evidence suggests that ADL 
may be triggered by secondary bacterial infections, either from loss of skin 
barrier protection in patients suffering from high grade lymphoedemas, or 
due to improper clearance/dysfunction of lymphatic drainage (lymphostasis) 
in affected limbs providing an ideal environment for opportunistic bacterial 
and fungal infection (Pani et al., 1995). In chronic cases of LF, it is believed 
that recurring attacks of ADL is a contributing factor to the worsening severity 
or ‘grade’ of lymphoedema in affected limbs (Pani et al., 1995.). The severity 
of ADL episodes has resulted in it being highlighted as the single largest 
cause of lost wages in LEDC countries by LF patients (Ramaiah et al., 1998; 
Krishnamoorthy, 1999).   
The extremely high morbidity and socio-economic burden of LF results in it 
consistently being ranked as a leading cause of global disability (Ottesen, 
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2000). The high prevalence and global concentration of endemicity of LF in 
LEDC’s, results in it ranking highly in the list of neglected tropical diseases 
(NTDs). Resultantly, the World Health Organization produced an ambitious 
policy of the elimination of LF as a public health problem, creating the Global 
Programme to Eliminate Lymphatic Filariasis (GPELF) in 2000, which initially 
targeted global ‘elimination’ (reduction of transmission to <1%) by 2020 
(Ottesen, 2006; Addiss and Brady, 2007; Hotez et al., 2007). Elimination 
efforts centre around preventing transmission by mass drug administration 
(MDA) with standard anti-filarial drugs and latterly bednet distribution. After 
13 years, estimates of LF infection had effectively halved, from 120 to 67 
million (Ramaiah and Ottesen, 2014). While excellent progress has been 
achieved in halting disease transmission and eradication of active infection, 
due to MDA drugs having no curative effects on LF morbidity, the 40 million 
pathology cases persist with no measurable drop in pathology cases over the 
same 13 year period (Ramaiah and Ottesen, 2014).  
1.2-The filarial life cycle and aetiology of filariasis 
 
LF is transmitted through mosquito vectors. Infectious, third-stage filarial 
larvae (L3) infect the host when L3 infected mosquitoes take a second blood 
meal. L3 larvae migrate from the bite site into subcutaneous tissues  (Taylor, 
Hoerauf and Bockarie, 2010). L3 larvae penetrate the surrounding dermal 
lymphatic capillaries before migrating through pre-collector and collector 
lymphatic vessels to reside in the host peripheral lymphatics and LNs 
proximal to the infection site. During migration, the filarial larvae undergo a 
series of moults from L3 to L4 stage, before reaching a final adult male or 
female stage, where they reside in ‘worm nests’ (dilated lymphatic channels) 
(R. K. Shenoy et al., 2007; Pfarr et al., 2009). Male and female worms 
sexually reproduce resulting in the release of microfilariae (mf) into the host 
vascular systemic circulation. It has been well documented that the highest 
concentration of mf in circulation coincides with night-time hours, while lower 
to no circulating mf is observed in day time hours. This is a process known 
as periodicity (Paily, Hoti and Das, 2009) and is thought to coincide with 
periods of highest mosquito activity, maximising the chance of a successful 
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infection from blood meals. Mf infect mosquito vectors upon these further 
blood meals, where they unsheathe and migrate through the proventriculus 
and cardiac portion of the mosquito's midgut, reaching the thoracic muscles. 
Here, the MF grow firstly into L1 larvae before developing into infective L3 
larvae, were the cycle can repeat through further bloodmeals on animal 
hosts from infected mosquitos (Paily, Hoti and Das, 2009). The life cycle is 
summarised in figure 1.2 where the key lymphatic structures involved in the 
infection process are highlighted and discussed. 
Populations in filarial endemic areas are known to fall into three distinct 
subsets (Partono, 1987; Ottesen, 1992; Chandy et al., 2011): (1) so called 
'endemic normals’ or ‘putative immunes’ are individuals repeatedly exposed 
to filarial infection, as assessed by parasite-specific antibody responses, but 
fail to establish active infection and thus are considered to be naturally 
immune, (2) ‘Asymptomatic carriers’ are individuals carrying active filarial 
infection, testing positive for mf in their blood (and therefore classed as 
microfilaraemic) but exhibit no clinical manifestations or pathology related to 
disease and (3) pathological filariasis where patients often have low or even 
an absence of mf in the blood ‘amicrofilaraemic’, may or may not be positive 
for adult infection and suffer a sliding scale of clinical disease, ultimately 
culminating in LE and elephantiasis (Partono, 1987; Pfarr et al., 2009). 
Filariasis is known to be the leading cause of secondary LE (acquired rather 
than genetically predisposed primary / congenital) globally (Shenoy, 2008). 
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3-24hrs:Mosquito Blood meal deposits L3 larvae 
on/into skin epidermis. L3 larvae migrate to dermal 
lymphatic capillaries beds and/or pre-collector ducts  
1 
7ds-12wks: Larvae 
undergo L4 moult 
before eventual moult 
to become adult 
worms. Adult worms 
migrate and reside in 
Lymphatic collector 
ducts (lymphangions) 
and lymph nodes 
2 
12 wks-onwards: Adults 
worms residing in 
lymphangions/lymph 
nodes release microfilariae 
(MF) into systemic  
lymphatic and vascular 
network, This includes 
possible retrograde 
backwash to dermal 
capillaries 
3 
Mosquito takes a blood 
meal, MF unsheath and 
invade mosquito from 
peripheral lymphatics or 
vascular network 
4 
MF undergoes 
several moults in 
mosquito (L1 and L2 
stages) until it 
reaches the 
infectious L3 larvae 
stage, ready for 
infection of animal 
host on next blood 
meal 
5 
INSECT STAGES 
HUMAN STAGES 
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Figure 1.2: The Life cycle of filarial nematodes 
Schematic detailing the filarial life cycle and were they reside in the lymphatic 
architecture during the varying life stages.   
Image adapted from life cycle figure displayed at:  
https://www.cdc.gov/parasites/lymphaticfilariasis/biology_w_bancrofti.html 
Accessed: 20/03/2019 
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1.3-The human lymphatic system and lymphatic remodelling in 
health and disease 
 
The lymphatic vessels, together with blood vessels, form the human vascular 
system. Once thought of as a passive conduit, maintaining homeostasis by 
resorbing extravasated and interstitial fluid, as well as aiding in the 
absorption of proteins, lipids and macromolecules from the intestine, the 
lymphatic system is now implicated in playing an important role in a variety of 
functions including immunity and immunomodulation (Randolph et al., 2017). 
It is currently agreed that the three main functions of the lymphatic 
vasculature are: 1) Control absorbance of nutrients from the blood into 
peripheral tissues, as well as act as a ‘highway’ by transporting small 
molecules such as chemokines and cytokines in interstitial fluid (Vranova 
and Halin, 2014), 2) A transport network for the trafficking of immune cells, 
particularly from the peripheral tissues to lymph nodes, where appropriate 
immune responses are coordinated and, 3) Maintenance of fluid 
homeostasis, transporting interstitial fluid back to systemic blood circulation 
via the thoracic duct. 
While the blood and lymphatic vasculature often work in conjunction, 
structurally, there are key differences between the two, most notably the 
pressurised pump system of the blood vasculature contrasts the 
unidirectional passive flow of the lymphatics (Randolph et al., 2017). Lymph 
fluid enters the lymphatic vasculature via the complex, branched network of 
collecting lymphatic capillaries. Lymphatic capillaries consist of a single cell 
layer of Lymphatic Endothelial Cells (LECs), anchored to discontinuous 
basement membrane as well as extracellular matrix (ECM). In contrast to 
blood capillaries, lymphatic capillaries lack pericytes and are held together by 
weak intercellular “button like” junctions between LECs (Coso, Bovay and 
Petrova, 2014). Together, the single cell layer and weak junctions allow 
antigens, small molecules and immune cells easy entrance to the lumen of 
lymphatic capillaries entering the lymph fluid. Collected lymph in capillary 
beds then travel into lymphatic pre-collector ducts which, together with LECs, 
are sparsely covered by smooth muscle cells which produce contractility that 
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propels the lymph forward to lymphatic collector ducts (Alitalo, 2011). 
Retrograde channel flow is prevented in capillary beds, as well as the pre-
collector and collector vessels through intraluminal valves that line the 
lymphatic vessels (Bazigou et al., 2014). Collecting lymphatic vessels act as 
final, primary vessels of the hierarchal capillary-pre-collector-collector 
structure and are more continuously lined by smooth muscle cells, which 
together with proximal skeletal muscle and arterial pulsations, provide the 
contractile function required for unidirectional lymph propulsion (Coso, Bovay 
and Petrova, 2014). Collecting lymphatic vessels channel lymph into the 
subcapsular sinus of draining lymph nodes, which act as sentinels of immune 
surveillance by monitoring antigens passing through lymph and coordinating 
appropriate immune responses from incoming migrating immune cells (Liao 
and Padera, 2013). ‘Filtered’ efferent lymph fluid leaving lymph nodes 
channel through further collecting vessels before finally draining into blood 
systemic circulation, through the thoracic ducts which channels lymph into 
the subclavian veins. An overview of the lymphatic architecture can be found 
in figure 1.3. 
Pre-natal lymphangiogenesis is responsible for the preliminary construction 
of the lymphatic vascular system (Semo, Nicenboim and Yaniv, 2016). The 
lymphatic architecture, however, remains highly dynamic with frequent 
remodelling of lymphatic vessels and associated architecture occurring in 
response to a variety of stimuli including: tissue injury, wound healing and 
inflammation (Flister et al., 2010; Lund et al., 2012; Coso, Bovay and 
Petrova, 2014; Hirosue et al., 2014; Vranova and Halin, 2014). Lymphatic 
remodelling, induced by post-natal lymphangiogenesis, is crucial to maintain 
physiological homeostasis and optimal function in humans (Tammela and 
Alitalo, 2010). Post-natal lymphangiogenesis and associated lymphatic 
remodelling is usually initiated by the sprouting of novel vessels from the 
existing lymphatic architecture (Tammela and Alitalo, 2010). In order for 
sprouting initiation to occur, careful molecular regulation must promote the 
proliferation and subsequent survival of existing LECs at the points of 
sprouting (Tammela, Petrova and Alitalo, 2005). Further, migration and 
subsequent recruitment of: LECs (Coso, Bovay and Petrova, 2014), bone 
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marrow progenitor cells (Lee et al., 2010.; Maertens et al., 2014) , as well as 
the trans-differentiation of myeloid derived macrophages into LECs (Attout et 
al., 2009; Ran and Montgomery, 2012) have all been demonstrated to be 
important in the initial sprouting steps of lymphangiogenic mediated 
lymphatic remodelling. The ‘immature’ newly sprouted vessels then undergo 
a ‘maturation’ step involving correct valvular development (Kazenwadel et 
al., 2012; Sabine et al., 2012; Bazigou et al., 2014), tube formation and 
recruitment of smooth muscle cells (Sweet et al., 2015) to become fully 
functioning, novel lymphatic vessels. Finally, correct lymphatic patterning is 
crucial for the functionality of the novel lymphatic vessels (Gale et al., 2002; 
Liebl et al., 2015). Mutations in any of the key genes identified in the 
regulation of lymphatic sprouting, valvular development, 
recruitment/migration and lymphatic patterning have been intrinsically linked 
with dysfunctional lymphatics and development of primary LE.  
While the above demonstrates the importance of lymphatic remodelling in 
homeostasis and health, aberrant or dysregulated lymphatic remodelling has 
been implicated in a range of varied pathologies. Several ‘Hallmarks’ of 
pathological lymphatic remodelling have been defined. Lymphatic dilation, 
sometimes described as lymphangiectasia, is the abnormal widening of 
lymphatic channels (Faul et al., 2000; Bellini et al., 2006; Wang and Oliver, 
2010). Dilation of lymphatic vessels in the lungs (pulmonary 
lymphangectiasia) has been demonstrated to cause severe respiratory 
distress and render individuals highly susceptible to infection, primary 
pulmonary lymphangectiasia has a high mortality rate and is a leading cause 
of neonatal death (Esther and Barker, 2004; Bellini et al., 2006). Lymphatic 
remodelling can also manifest in neovascularisation and hyperplasia, defined 
by aberrant growth of LECs and dysregulated lymphangiogenesis, leading to 
poorly functioning immature lymphatics that manifest as increased lymphatic 
vessel density (Cursiefen et al., 2004; Attout et al., 2009; Park, Lee and 
Yoon, 2011). Lymphatic neovascularisation is commonly observed in the 
affected skin of psoriasis and thought to contribute to disease pathogenesis 
(Kunstfeld et al., 2004). Hyperplasia and neovascularisation is significantly 
associated with diseases as diverse as: arthritic joints (Zhang et al., 2007), 
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allergy (including asthma) (Kim et al., 2010; Moldobaeva et al., 2017) and 
inflammatory bowel disease (Alexander et al., 2010; Linares and Gisbert, 
2010). Finally, tortuous collateral lymphatic vessels, described as aberrantly 
patterned or shaped dysfunctional vessels (Liu, Yan and Wu, 2012) is a key 
facet of pathological lymphatic remodelling (Gale et al., 2002). 
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Figure 1.3: A schematic of the human lymphatic architecture 
Diagrammatic representation of human lymphatic architecture. The blunt 
ended, single cell layer held together by weak button junctions and 
discontinuous basement membrane of lymphatic capillaries allows interstitial 
lymph fluid to easily diffuse across into the lumen of vessels. Lymph flow 
then travels unidirectionally across hierarchically organised vessels 
structures from branching lymphatic capillaries that converge into larger pre-
collector vessels before finally adjoining to main collector vessels. 
Unidirectional flow is maintained by: placement of semi-lunar valves that 
prevent retrograde travel in pre-collector and collector lymphatic vessels, the 
lining of these vessels with smooth muscle that provides a contractile force 
and exterior surrounding skeletal muscles that contribute to the contractile 
force and pressure gradient. The size and integrity of lymphatic vessels 
increases across the hierarchal structure, with an eventual  ‘zipper like’ 
basement membrane in the main collector vessels  preventing lymph 
extravasation. 
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1.4-Lymphatic dysfunction, insufficiency and LE  
 
Correct lymphatic function is crucial for fluid balance, homeostasis and a 
variety of other functions. Dysfunction of lymphatic vessels, or disruption to 
the normal lymphatic architecture, often lead to perturbations in normal 
homeostatic lymphatic drainage, resulting in lymphatic insufficiency. 
Lymphatic insufficiency results in the breakdown of proper lymph fluid 
clearance, resulting in aberrant retention, or pooling of lymph fluid (known as 
lymphostasis). This can result in areas where lymphatic drainage is no longer 
able to fulfil the demand of building up interstitial or extravasated fluid. The 
causes of lymphatic dysfunction are hugely varied and still not fully 
understood. Mutations in the key regulatory drivers of lymphangiogenesis 
can result in poorly developed, immature or improperly patterned lymphatic 
vessels and architecture, resulting in poorly functioning vessels, that are 
insufficient to handle drainage demand of lymph fluid (Mellor et al., 2011; 
Brouillard, Boon and Vikkula, 2014). Additionally, perturbations to lymphatic 
contractility can result in lymphatic dysfunction, characterised by the 
breakdown of the normal pumping action of lymphatic vessels to transport 
fluid along the lymphatic system, resulting in retarded lymph drainage and 
further insufficiency (Zawieja et al., 2012; Chakraborty, Davis and 
Muthuchamy, 2015). Impairments to the normal function of lymphatic valves 
(valvular dysfunction) is an additional, well characterised cause of 
dysfunction. Valvular insufficiency allows aberrant retrograde travel of lymph 
fluid back into pre-collector vessels of capillaries (Petrova et al., 2004; 
Zawieja, 2009) resulting in the retardation, or complete breakdown of 
unidirectional lymphatic drainage. Finally, dilation of lymphatic vessels have 
been demonstrated to contribute to dysfunction. Aberrant dilation can result 
in a weakening of necessary intraluminal pressure, created by lymphatic 
vessel contractile forces (Zawieja, 2009; Zawieja et al., 2012). The 
weakened pressure results in perturbed lymph flow rates which can 
contribute to lymphatic insufficiency.   
The main pathological manifestations of lymphatic insufficiency and 
dysfunction is the development of LE. LE is characterised as abnormal, 
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severe swelling, and subsequent disfigurement, of peripheral areas of the 
body, most often in limbs (Grada and Phillips, 2017). Overt LE develops 
when venous capillary filtration and extravasation, resulting in formation of 
interstitial fluid, is greater than the capacity of the lymphatics to drain away 
the formed fluid, resulting in its aberrant retention. The resultant 
lymphostasis, in the local lymphatic architecture results in extravasation into 
surrounding interstitial spaces which contributes to a build-up of permanently 
retained/pooling of lymph (Carlson, 2014). The progressive aggregation of 
undrained lymph fluid results in continual swelling of the surrounding affected 
areas, while inflammation and resultant inflammatory cell infiltrates, with 
deposition of soluble inflammatory mediators, often observed in the static 
lymph fluid (Grada and Phillips, 2017), further exacerbate pathology. 
Additional contributions to swelling frequently occur post-establishment  of 
LE as the static fluid becomes prone to secondary opportunistic bacterial and 
fungal infections, resulting in painful inflammatory episodes (Myers, 2018) . 
In conclusion, whilst the pathophysiology of LE is still not fully understood, it 
is commonly agreed a break down in lymphatic function (lymphatic 
dysfunction) induces a state of lymphatic insufficiency, were net drainage is 
lower than net build-up of interstitial fluid. Chronic insufficiency is a trigger for 
numerous co-factors leading to the development of LE. 
1.5-Primary and secondary LE  
 
LE can be classified into primary (congenital) and secondary, (acquired) 
forms. The latter is induced when damage due to trauma, surgery or 
infection, results in the development of lymphatic dysfunction and oedema 
(Grada and Phillips, 2017). Primary LE is most often a result of genetic 
mutations that results in aberrant development of a functional lymphatic 
network, leading to poor lymphatic drainage and insufficiency (Adamczyk et 
al., 2016). Lymphoedema distichiasis syndrome results in patients 
developing spontaneous LE often around puberty, usually in the limbs, due 
to mutations in the Fork-head box protein C2 (FOXC2) gene (Mellor et al., 
2011). Defective FOXC2 signalling has been demonstrated to result in 
abnormal development of lymphatic vessel valves, causing lymphatic 
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dysfunction, retrograde lymph travel and insufficiency that leads to LE 
(Petrova et al., 2004). Milroy disease results in overt LE from birth due to a 
severely dysfunctional, and poorly developed, lymphatic system (Brice et al., 
2005). Genetic studies have found high association between mutations in the 
Vascular Endothelial Growth Factor Receptor (VEGFR)3 gene and Milroy 
syndrome (Ferrell et al., 1998; Karkkainen et al., 2000; Ghalamkarpour et al., 
2006). Cell surface-expressed VEGFR3 signals upon binding to its ligands 
VEGF-C and VEGF-D. VEGF-C, in particular, has been demonstrated to be 
a key driver of pre- and post-natal lymphangiogenesis (Oh et al., 1997; 
Skobe et al., 2001) with defective signalling demonstrated to result in poorly 
developed lymphatics (Ghalamkarpour et al., 2006) 
Secondary LE is the more common cause of lymphoedema with estimates 
between 180-250 million cases worldwide (Rockson and Rivera, 2008). In 
high income countries, the most common cause of secondary LE is either 
cancer mediated lymphatic remodelling, or medical intervention for the 
treatment of cancer, such as surgical resection of cancerous and sentinel 
lymph nodes (DiSipio et al., 2013; Mortimer, 2013). Both results in significant 
injury, or changes, to the local lymphatic architecture which results in the 
development of lymphatic dysfunction and insufficiency (Mortimer and 
Rockson, 2014). The most common cause of all secondary LE, however, is 
as a result of LF, which is in turn referred to as filarial LE (Warren et al., 
2007; Pfarr et al., 2009). Filarial LE is often progressive and clinically graded 
by: severity of swelling / disfigurement, thickness of skin and degree of 
pitting/sclerosis in the skin of affected areas (Pani and Srividya, 1995). While 
there has been a degree of success in reversing milder, earlier gradings of 
LE, the later, more severe grading (also known as elephantiasis) is 
irreversible and highly debilitating (Shenoy, 2008; Nutman, 2013). 
1.6- Filarial LE, a neglected facet of a neglected tropical disease? 
 
Significant progress has been made in eliminating filarial infection worldwide, 
with programmes such as Global Programme for the Elimination of 
Lymphatic Filariasis (GPELF) making commendable progress towards the 
elimination of LF as a public health problem by the WHO’s original 2020 
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target. Such success has risen from a strategy which aims to prevent the 
transmission of LF, involving mass drug administration programmes (MDA) 
of anti-filarial drugs - displaying microfilaricidal activity (effective against mf) - 
along with overlapping mosquito vector control measures, typically through 
distribution of long-acting insecticide impregnated bednets (Gyapong et al., 
2005; Hoerauf, 2006). To date, of the 73 countries targeted for MDA and 
blocking of transmission, only 18 have completed interventions and 
subsequent surveillance to confirm elimination, including Korea and China 
(Cheun et al., 2009; De-Jian, Xu-Li and Ji-Hui, 2013). Although a further 22 
countries are forecast to achieve elimination by the 2020 milestone, having 
already delivered MDA in disease endemic areas, 33 countries have been 
unable to achieve 100% geographical coverage for MDA programmes. 
Worryingly, 10 countries are yet to start any MDA programmes or have been 
unable to provide evidence that MDA is not required (Alexander, 2015). That 
58% of the countries involved are failing to implement measures necessary 
for the blocking of filarial transmission, 4 years before the deadline paints a 
dim outlook for the success of the 2020 target for elimination. These figures 
confirm that, despite excellent progress, LF remains an enduring global 
health problem and at-risk populations continue to remain extremely 
vulnerable to the development of the highly disabling, life-long pathologies 
associated with filarial infection. 
Irrespective of the time-frame for successful elimination of LF parasitic 
infection, LF patients displaying pathology will endure often irreversible, life-
long disability. The progress in treatment for the estimated 40 million cohort 
who suffer with high morbidity has been far more disappointing than the 
demonstrable success in LF elimination. Current treatment strategies mainly 
involve management of the symptoms, namely intense physiotherapy, 
heating or cooling and analgesics to the affected swollen limbs (Addiss and 
Brady, 2007). Good hygiene practices to the affected limbs and use of 
prophylactic antibiotics have also seen partial success in reducing further 
acute inflammatory attacks associated with filarial LE (Ottesen, 2006). A 
recent emphasis has been given to the self-care and management of LE 
symptoms by the patient, namely remedial exercises and practicing good 
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hygiene to affected areas (Douglass, Graves and Gordon, 2016). Surgical 
intervention is an effective anti-morbidity intervention for hydrocoele 
(hydrocoelectomy) (Shenoy, 2008). Hydrocoelectomy is not, however, readily 
accessible in hard-to-reach areas where health resources are limiting 
(Stanton et al., 2015). 
There is currently a paucity of research into novel and affordable therapies 
that ameliorate filarial LE and elephantiasis. Recent work has demonstrated 
that chemical intervention, during early stages of infection and before clinical 
manifestations of pathology, can be effective in reversing changes in skin 
firmness and subclinical changes to the lymphatic architecture (termed 
“covert pathology”). The authors argue halting these sub clinical pathologies 
are useful in preventing the development of later clinical LE pathologies 
(Douglass et al., 2019) . Further, it has been demonstrated that doxycycline 
is able to halt and even reverse early stages of filarial LE, independent of its 
antibiotic or filaricidal mode of actions (Debrah et al., 2006, 2009; Mand et 
al., 2012). Promisingly, doxycycline has shown measurable anti-morbidity 
success in phase II clinical trials (Mand et al., 2012). The anti-morbidity 
mode of action of doxycycline, however, is poorly understood, while efficacy 
has only been demonstrated in patients with lower grade LE, with less 
success on more severe, higher LE grades. 
Vascular and Lymphatic remodelling is regarded as a key ‘hallmark’ along 
the pathway to LF pathology (Addiss and Brady, 2007) and as such may be 
considered as a viable LF anti-morbidity drug strategy. Unfortunately, 
vascular remodelling processes in LF remain poorly elucidated, partly due to 
a lack of adequate preclinical model systems to mechanistically study LF 
disease aetiology. Furthermore, there is conflicting evidence across 
secondary LE model systems as to whether lymphatic remodelling events 
are causal factors in the development of lymphoedematous pathology, are a 
part of host repair mechanism which prevents more severe disease and 
could be harnessed for therapeutic potential or are merely ‘epiphenomena’ 
which are not causal in pathology development. What is clear, especially in a 
‘post-elimination era’ is that there is a requirement for more effective anti-
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morbidity strategies that could alleviate filarial LE to improve the quality of life 
of those afflicted with life-long disability. 
1.7- In vitro, in vivo and clinical evidence of a role for lymphatic 
remodelling in filarial infection and pathology 
 
The events and mechanisms that lead to pathology and subsequent 
morbidity in LF remain poorly elucidated. There is some evidence to suggest 
worm inhabitation of the peripheral lymphatics and their so called ‘worm 
nests’ lead to progressive physical damage and blockage of the lymphatic 
architecture, which contributes to lymphatic dysfunction and LE (Dreyer et 
al., 2000; Nutman, 2013). In addition to direct worm mediated damage, 
emerging evidence suggests that inflammatory immune responses to dying 
or dead worms, or release of the endosymbiotic Wolbachia bacteria inside 
filarial worms results in indirect, off target or ‘collateral’ damage to the 
lymphatics leading to lymphatic dysfunction (Babu and Nutman, 2014). 
Nevertheless, these findings cannot reconcile the fact that both these events 
occur in all cases of filarial infection, yet only a subset of patients display 
clinical pathology. Key questions remain unanswered about the complex 
relationship between the parasitic worm, the lymphatic niche in which they 
inhabit and the immune microenvironment to which they are exposed. The 
events and crosstalk that occurs at this interface, and what determines an 
asymptomatic or pathological outcome remains an area of great scientific 
interest. 
Lymphatic remodelling is regarded to be a key event which facilitates the 
manifestation of pathology in LF. In vitro evidence has demonstrated that co-
culturing of live worms, or their soluble extracts and antigens, with LECs 
induced activation, proliferation and tube formation (Bennuru and Nutman, 
2009a).  Such evidence implicates filarial infection with the ability to induce 
lymphatic remodelling in the host. Interestingly, initial studies involving filarial 
E/S products and LECs failed to induce the direct activation or proliferation 
(Weinkopff and Lammie, 2011), although later work by the same group 
showed filarial E/S products were able to stimulate primary human  
monocytes (from peripheral blood mononuclear cells (PBMCs)) to produce 
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lymphangiogenic mediators in vitro, which when cultured with LECs 
stimulated proliferation and tube formation (Weinkopff et al., 2014). This 
perhaps reconciles findings in which plasma from LF infected patients were 
able to induce proliferation of LECs in culture (Bennuru and Nutman, 2009b; 
Bennuru et al., 2010). Importantly, these findings suggest a significant and 
complex interplay between filarial worms and the host immune system which 
results in lymphatic remodelling during LF. Studies have demonstrated that 
asparingyl Transfer RiboNucleic Acid (tRNA) synthase, a ‘physiocrine’ 
product released from worms, can directly induce proliferation in Human 
Umbilical Vascular Endothelial Cell (HUVEC) assays (Jothi et al., 2016) 
suggesting vascular remodelling is induced following infection and parasite 
mediated signalling. Further experiments that investigate the effect of this 
‘physiocrine’ on LEC cells may yield an additional effect on lymphatic 
remodelling. The aforementioned in vitro evidence is strengthened by data 
acquired from in vivo models. Experimental intra-lymphatic infections into 
inguinal lymphatic ducts demonstrated a significant increase in lymphatic 
dilation, in Severe Combined ImmunoDeficient (SCID) or athymic mouse 
models (Vincent et al., 1984; Nelson et al., 1991). Interestingly this dilation 
was not limited to the immediate ‘worm nest’, where the worms localised, but 
the entire length of infected ducts, while chemotherapeutic removal of the 
worms led to a reversal of dilation (Vickery et al., 1991). Such dilation seems 
to be a hallmark of filarial infection as similar observations have been made 
in Mongolian jirds (Ah and Thompson, 1973) and feline (Denham and 
Fletcher, 1987; Grenfell, Michael and Denham, 1991) infection models. Of 
particular note were studies demonstrating initial lymphatic remodelling (in 
forms of dilation), but absence of pathological manifestations in 
immunodeficient mice, which upon immune reconstitution with immune-
competent splenocytes resulted in significant fibrosis, lymphatic remodelling 
and manifest pathology (Vickery et al., 1991). This could suggest that while 
initial lymphatic remodelling could be directed by filarial signals or ‘toxins’, 
adaptive immune responses are necessary to initiate larger scale lymphatic 
remodelling or changes to the architecture that is concomitant with 
pathological manifestations. 
43 
 
Overt lymphatic remodelling has also been demonstrated as a feature of 
filarial infection from clinical observations. Research involving a small 
number (n=15) of filarial patients utilised histological methods on patient skin 
explants to demonstrate a significant increase in vasculitis, vascular fibrosis 
and vessel diameter in filarial infected patients (Case et al., 1991). 
Additionally, marked dilation of worm inhabiting lymphatic vessels was 
observed in LF patients (Freedman et al., 1994). Surprisingly, limb 
scintigraphy demonstrated that ‘asymptomatic’ filarial patients also display a 
degree of either remodelling of the normal lymphatic architecture or dilation 
of lymphatic vessels (Freedman et al., 1995; Noroes et al., 1996; Shenoy et 
al., 2008; Kar et al., 2017). Ultrasonographical analysis of filarial-infected 
hydrocoele patients have strengthened the association of active infection 
with lymphatic remodelling, with marked dilation and tortuosity observed in 
infected scrotal lymphatics (Amaral et al., 1994; Noroes et al., 1996). 
Additionally, excised infected lymph nodes that have undergone histological 
analysis lead to observations of marked lymphatic hyperplasia and dilation 
(Jungmann, Figueredo-Silva and Dreyer, 1991). Mechanistically, serum 
comparisons between endemic normal and both microfilaraemic and 
pathology displaying patient groups demonstrated significantly higher plasma 
levels of factors: VEGF-A, VEGF-C, VEGF-D sVEGFR3 and Ang1/2 in 
filarial-infected microfilaraemic and pathology cohorts (Alexander Yaw 
Debrah et al., 2007; Debrah et al., 2009; Bennuru et al., 2010). These 
identified factors are known to be key drivers of lymphangiogenesis that can 
lead to lymphatic remodelling events (Lohela et al., 2009). Higher circulating 
levels of these factors in infected patients would suggest potential for 
lymphangiogenic remodelling, stimulated either directly by the worms (i.e. 
induction of growth factors derived from parasitized lymphatic tissue), or 
indirectly through an immune response to worm infection. Supporting 
evidence has come from work undertaken by Debrah et al. who observed 
significantly higher serum levels of VEGF-A  in filarial infected patients 
suffering from hydrocele pathology than uninfected counterparts (A Y Debrah 
et al., 2007). Treatment of these patients with macrofilaricidal drugs, leading 
to worm clearance, positively correlated with significant reductions of serum 
VEGF-A, VEGF-C and sVEGFR3 post treatment (Debrah et al., 2009). 
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These studies perhaps provide more compelling and direct evidence that 
worm presence leads to an increase in lymph/angiogenic factors and 
subsequent angiogenic/lymphangiogenic remodelling.   
 
1.8-Filarial-associated lymphatic remodelling and implications for 
pathogenesis 
 
Whilst there is substantial evidence that lymphatic remodelling is a key 
‘hallmark’ that occurs following filarial infection, what is less understood, is 
the causality of this remodelling in progression from a ‘grade 0’ or 
asymptomatic state to overt lymphoedematous disease. The pervading 
theory states that lymphatic damage or perturbation initiates lymphatic 
remodelling and dilation, driven by filarial adult inhabitation. The 
accumulation of this damage and subsequent lymphatic remodelling 
contributes to a ‘pathway’ that leads to pathological manifestations (Dreyer et 
al., 2000; Chakraborty et al., 2013; Nutman, 2013). Studies that demonstrate 
significantly higher circulating plasma pro-lymphangiogenic VEGF-C and 
VEGF-A in LF patients compared to uninfected controls  (A Y Debrah et al., 
2007; Bennuru et al., 2010) would suggest that an association exists 
between increased stimulation of lymphatic remodelling and lymphatic 
dysfunction/pathology. Importantly, doxycycline treatment has demonstrated 
an ability to significantly reduce serum levels of these lymphangiogenic 
factors, which was associated with amelioration of severity of lymphoedema 
and morbidity (Debrah et al., 2006, 2009). In addition, this amelioration was 
observed in filarial LE patients in the absence of active filarial infection, 
suggesting the doxycycline mode-of-action was independent from its adult 
worm curative activity (Mand et al., 2012). Together, these studies would 
suggest that reducing lymphatic remodelling by targeting the drivers of 
lymphangiogenesis could be a novel strategy to ameliorate lymphatic 
insufficiency and dysfunction associated with filarial infection. Research in 
oncology has demonstrated that aberrant lymphatic remodelling, in the form 
of a tumour’s ability to ‘hijack’ lymphangiogenesis, is essential for tumour 
vascularisation, survival and metastasis (Skobe et al., 2001; Hanahan and 
Weinberg, 2011; Ran and Montgomery, 2012) 
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The evidence above associating severity of LE with pro-lymphangiogenic 
mediators and evidence of pronounced lymphatic remodelling would support 
that remodelling / lymphangiogensis is pathological in nature. This is in 
contrast, however, to the theory in other areas of LE research. Primary LE 
has been directly linked with genetic mutations in a host of pro-
lymphangiogenic signalling pathways, preventing either development, of the 
lymphatic architecture (Brice et al., 2005; Mellor et al., 2011), or appropriate 
functional lymphatic remodelling. These aberrant mutations often result in 
severe lymphatic insufficiency and dysfunction. It can, however be argued 
that primary LE reflects more initial failure to develop lymphatics, rather than 
lack of remodelling. Recent studies, however, have demonstrated that 
secondary LE, acquired following surgical excision of tumour tissue in breast 
cancer, can arise due to mutations which render the VEGFR3 gene 
dysfunctional thus severely reducing the ability to remodel lymphatics 
following the injury resulting in failure of restoration of lymphatic drainage 
(Newman et al., 2012). Additionally, exogenous VEGF-C administration in an 
established murine tail model of secondary LE significantly increased rates of 
lymphatic remodelling, resulting in amelioration of lymphoedematous 
pathology (Jin da et al., 2009; Visuri et al., 2015). Co-administration of an 
anti-VEGF-C neutralising antibody in the same model abrogated this 
improvement (Jin da et al., 2009). Elegant studies that overexpressed the 
VEGF-C gene in the same murine model of LE, also lead to significant 
amelioration (Yoon et al., 2003). Recent research following filarial infected 
patient cohorts have observed a significant increase in forkhead box protein 
C2 (foxc2) and fms-like tyrosine kinase 4 (flt4- also known as vascular 
endothelial growth factor receptor 3(vegfr3)) gene mutations in pathology 
displaying cohorts, when compared to asymptomatic and non-infected 
cohorts. Such genes have been implicated as important intermediaries in the 
correct regulation and mediation of lymphagiogenic/ angiogenic 
programmes. Sheik et al. suggests that pathology arises as a result of 
aberrant function of these genes, leading to improper or complete abrogation 
of lymphatic remodelling that would usually repair worm mediated damage of 
lymphatics following filarial infection (Sheik et al., 2015). Together, this would 
suggest that lymphatic remodelling, rather than contributing to filarial 
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pathology, may be a host compensatory mechanism to repair filarial damage 
of the lymphatics, thus acting in a therapeutic capacity. 
From the evidence presented above, it is clear that lymphatic remodelling is 
highly regulated and the context of its activation can result in both 
pathological and therapeutic outcomes. This perhaps is best demonstrated in 
a review suggesting the ‘double-edged sword’ effect of lymphatic remodelling 
(Kim, Kataru and Koh, 2014). Equally as clear, however is that lymphatic 
remodelling is an important event, that occurs following filarial infection. 
Although there is tentative evidence that infers a role for worms themselves 
as well as the host immune response in lymphatic remodelling events, the 
exact contributors and the regulatory mechanisms that govern this important 
event remains elusive. In addition, whether the observed lymphatic 
remodelling in LF is a contributor to future pathology, or compensatory in 
nature to prevent pathological development, is highly debated and poorly 
defined. Defining a ‘developmental timeline’ of lymphatic remodelling 
following infection and how it is regulated both in terms of cellular and 
molecular mechanisms will aid in understanding the contribution of 
remodelling to filarial pathology. However, this is extremely challenging in 
human infections both due to uncertainty of degree of prior exposure and for 
ethical considerations post-diagnosing active infection. A better 
understanding of the processes that lead to lymphatic remodelling as a key 
event of LF may yield novel therapeutic strategies, that could ultimately result 
in new treatments to alleviate LF morbidity.  
1.9- Project Aims and Objectives 
 
The overarching aim of my PhD project is to assess how filarial infection 
induces lymphatic remodelling and test whether lymphatic remodelling 
events are pathological, or a result of tissue repair pathways to prevent the 
development of lymphatic pathology. With better knowledge of how lymphatic 
remodelling relates to pathology, it is hoped that manipulation of this process 
could potentially yield future therapeutic strategies to combat LF associated-
morbidity. 
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My project will look to address the question outlined above, by dissecting the 
potential role of host innate and adaptive immune response mechanisms in 
lymphatic remodelling, both on a cellular and molecular level. Preliminary 
objectives will be as follows: 
• Develop a murine filarial leg infection model which allows longitudinal 
imaging of the lymphatics in vivo, thus allowing the tracking of 
changes to the lymphatic architecture following infection. 
• Evaluate the consequences of filarial-associated lymphatic 
remodelling by: 
o Using imaging techniques in the model to quantify changes to 
the lymphatic architecture and its effect on lymphatic 
drainage/performance. 
o Investigate gross histological and anatomical changes following 
lymphatic remodelling. 
o Evaluate whether remodelling leads to signs of pathology 
development. 
• Investigate how host immune responses may contribute to lymphatic 
remodelling following infection (immune-competent vs 
immunocompromised mice) 
• Investigate adaptive and innate immune mechanisms that may play a 
role in lymphatic remodelling. This will be achieved through 
investigating: 
o Systemic immune cytokine and angiogenic/lymphangiogenic 
profiles following infection. 
o Immuno-phenotyping of adaptive and innate immune cells in 
the lymphatic network proximal to infection sites. 
o Isolation of important immune cells in filarial infection for 
investigation of their angiogenic/lymphangiogenic expression 
profiles/ 
• Based on findings from objectives above, make use of murine-specific 
reagents and evaluate their effect on lymphatic remodelling. It is 
hoped lymphatic remodelling can be manipulated (increased or 
suppressed) as a therapeutic target for the alleviation of pathology in 
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LF. Some preliminary manipulations that could be investigated 
include: 
o Use of mouse knockout lines for important immune pathways. 
o Blocking antibodies or traps to manipulate host immune 
responses or lymphangiogenic networks that contribute to 
filarial associated lymphatic remodelling. 
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Chapter 2 
 
Characterisation of an inbred murine experimental model 
of filarial-induced lymphatic pathology 
 
Chapter abstract  
120 million people are estimated to be infected with Lymphatic filariasis (LF) 
globally, while a 40 million patient subset present with the severely disabling 
pathology of lymphoedema, contributing to high levels of LF related 
morbidity. Lymphatic remodelling is a well-documented hallmark of LF 
patients, yet what drives its induction, and its causal link with aetiology of 
disease, is poorly defined. An immune competent murine model of Brugia 
malayi filarial infection was developed and validated to allow investigation of 
the longitudinal development of lymphatic remodelling. In addition, the 
association between magnitude of lymphatic remodelling and lymphatic 
insufficiency was investigated. The model indicated that onset of lymphatic 
remodelling occurs rapidly (as little as 6 days) post-infection and is highly 
associative with the degree of lymphatic insufficiency. Lymphatic remodelling 
and insufficiency persisted long-term (16 weeks) in animals with no evidence 
of adult infection. Severity of remodelling and insufficiency was dependent on 
the murine strain utilised and was increased after challenge infection, 
suggesting host adaptive immune responses influenced pathology. 
Lymphatic remodelling, and related insufficiency, is a consistent event that 
rapidly occurs following infection with infective B.malayi L3 larvae. 
Furthermore, the developed model enables the future interrogation of 
molecular, cellular and immunological mechanisms driving filarial-associated 
lymphatic pathology, with the objective to yield new therapeutic strategies to 
ameliorate LF morbidity.  
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2.1 Introduction 
 
As discussed in chapter one, lymphatic remodelling is a well-documented, 
feature of patients infected with lymphatic filariasis (LF), observed in both 
individuals with overt LE (Dreyer et al., 2000; Figueredo-Silva et al., 2002; 
Chakraborty et al., 2013) as well as ‘latent stage ‘asymptomatic’ (Freedman 
et al., 1995; Kar et al., 2017) infected patients. With a mixed and variable 
history of exposure and complications such as annual MDA treatments 
and/or secondary microbial skin infections, it is not possible to accurately 
interrogate causal mechanisms of lymphatic remodelling in natural human 
infections. In addition, the presence of lymphatic remodelling in both patient 
cohorts raises the question as to whether remodelling is responsible for, or 
contributes to the more advanced lymphoedematous pathological 
manifestations of LF. 
While the causal mechanisms of lymphatic remodelling remains undefined, it 
has been hypothesised to be driven both by direct stimulation from active 
filarial secretions of invading parasites (Shenoy, 2008; Bennuru and Nutman, 
2009a; Weinkopff et al., 2014) as well as possible host responses against 
filarial infection (Babu and Nutman, 2012, 2014). A pervading theory in the 
field states that long term inhabitation of the lymphatic architecture by filarial 
worms ,and subsequent damage caused by their motility and moulting, leads 
to the accumulation of lymphatic remodelling events, that tips the balance 
towards a lymphoedematous pathological outcome (Bennuru and Nutman, 
2009a; Taylor, Hoerauf and Bockarie, 2010). Conversely, Dreyer and 
colleagues propose that the bridging link between almost universal lymphatic 
remodelling in symptomatic and asymptomatic cohorts, and subsequent 
development of pathology, is attributed to other co-factors including worm 
death events and the proceeding host inflammatory reaction to filarial 
antigenic release (Dreyer et al., 2000; Figueredo-Silva et al., 2002). 
In depth immunological studies have shown the strength and type of 
adaptive immune responses may be critical, with strengthened inflammatory 
Th-1 and Th-17 responses associated with LE pathology, while more 
“regulatory” or “modified” Th-2 responses dominate asymptomatic LF 
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outcomes (King et al., 1993; Taylor et al., 2005; Babu and Nutman, 2014). 
Pfarr and colleagues, meanwhile, hypothesise that the intracellular bacterial 
symbiont Wolbachia and inflammatory events against them may play an 
important role in remodelling and the driving of subsequent pathology (Bandi, 
Trees and Brattig, 2001; Mand et al., 2009). A general consensus in the field 
of filariasis, therefore, links active parasitism of the lymphatics with adult 
parasites and consequential host inflammation, with the triggering of 
remodelling that eventually contributes to the development of LE (Nutman, 
2013). In contrast, studies investigating the mechanisms of secondary LE , 
not induced by filarial infection, supports a role for increased lymphatic 
remodelling as a compensatory, wound healing mechanism to restore 
lymphatic function, following damage or injury to the lymphatic architecture 
(Jin da et al., 2009; Visuri et al., 2015). 
A major hurdle in researching the link between remodelling and pathology is 
that most research is based on clinical observations, that only occur long 
after initial infection events. Establishing when remodelling occurs on the 
‘pathway’ to pathology, therefore, is difficult to achieve. Several permissive 
animal models exist that may allow interrogation of this question, including 
gerbils (McCall et al., 1973; Figueredo-Silva et al., 2002), rats (Ahmed, 1967; 
Benjamin and Soulsby, 1976; Lawrence and Denham, 1993), ferrets (Hines 
et al., 1989; Jackson-Thompson et al., 2018) and lymphoepenic mouse 
strains (Vincent et al., 1984; Nelson et al., 1991; Vickery et al., 1991; 
Lawrence, 1996) yet significant drawbacks exist in all cases. In the case of 
gerbils, rats and ferrets, the lack of available reagents and ability to easily 
genetically manipulate these model organisms make it difficult to 
mechanistically interrogate filarial lymphatic remodelling. Conversely, the use 
of immunodeficient mouse strains removes facets of the host response which 
may play a vital role in the induction of lymphatic remodelling and possible 
pathology. A table summarising the advantages and disadvantages of the 
current animal models of Brugia malayi/ pahangi filarial infection are 
summarised in the table below. 
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Animal Model Advantages Disadvantages 
Gerbils -Permissive- can attain 
full life cycle 
-Large, expensive to house in 
experimental conditions 
-Lack of 
immunological/experimental  
reagents which are gerbil 
specific  
-Lack of established genetic 
knockout/knockin strains 
Ferrets -Permissive- can attain 
full life cycle 
-Filarial LE pathology 
can be experimentally 
emulated 
-Large, expensive to house in 
experimental conditions 
-Lack of immunological/ 
experimental reagents which 
are ferret specific 
-Lack of established genetic 
knockout/knockin strains 
Rats -Partially permissive- 
larvae develop to adult 
worms 
-Not fully permissive, 
microfilariae are not released 
by adult worms into circulation 
-Large, expensive to house in 
experimental conditions 
-Not as comprehensive range 
of immunological reagents or 
knockouts in rats 
Immunodeficient 
mice strains 
-Partiall permissive- 
can attain full life cycle 
in ~50% of animals 
-Can emulate early 
lymphatic pathology 
(lymphatic vessel 
dilation) 
-Loss of components of host 
immune response to LF 
Table 2.1: Advantages and disadvantages associated with using 
current animal models of filarial infection 
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With the discussed lack of an optimal animal model, development of a 
murine immunocompetent mouse model facilitating the longitudinal 
interrogation of filarial associated lymphatic remodelling, would be of 
potential utility to investigate the relationship between lymphatic remodelling 
and pathological consequences in terms of lymphatic function. Such a model 
would allow for improved interrogation of the cellular and molecular 
mechanisms regulating filarial associated lymphatic remodelling. The 
utilisation of: well established genetic knock-in or knock-out lines, and well 
characterised murine antibody reagents could facilitate thorough 
characterisation of lymphatic remodelling and their role in filarial infection. 
Ultimately, clarifying the link between lymphatic remodelling and pathology, 
and utilisation to explore host mechanisms regulating lymphatic pathology, 
may yield novel therapeutic strategies to combat filarial disease. 
2.1.1- Research Aims and Objectives 
 
The aims of this research chapter, therefore, will be to develop a novel 
inbred, immunocompetent, murine pathology model of B. malayi filarial 
infection (BmL3) that allows longitudinal tracking of potential changes to the 
lymphatic architecture. The model will be utilised to interrogate: 
1. Whether there is evidence of host lymphatic remodelling post BmL3 
infection and, if so, determine the dynamics of pathology induction 
and resolution post-infection. 
2. If there is evidence to support that lymphatic remodelling is associated 
with lymphatic insufficiency 
3. How challenge infection or host genetic variation, in the form of 
varying inbred strains of mice, impacts on the development and 
severity of lymphatic remodelling  
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2.2- Methods 
 
2.2.1- Mouse Maintenance 
 
All procedures involving the use of laboratory animals were performed in a 
pathogen free facility at The Biomedical Services Unit (BSU), University of 
Liverpool. All animal procedures were approved by the Animal Welfare 
Committee of University of Liverpool and The Animal Welfare and Ethics 
Review Board of Liverpool School of Tropical Medicine (LSTM), and were 
carried out in accordance with The Use of Animals in Scientific Procedures 
Act (UK Home Office). 
Male Immuno-competent C57BL/6J Prox-1GFP transgenic mice were bred in 
house for B. malayi infection experiments and were created using out-bred 
Prox1-GFP FVB/N:CD1 cross mouse breeding pairs (A kind gift from the 
Hong lab, UCLA (Choi et al., 2011)) back-crossed onto C57BL/6J mice for 
six generations. Following six generations of back-crossing, resultant 
homozygous Prox-1GFP offspring were selected for future breeding pairs. 
Male BALB/c and C57BL/6J mice were purchased from Charles River 
(Margate,UK); all were 6-12 weeks at the start of each experiment. Male 
Mongolian gerbils were purchased from Charles River (Margate,UK) and 
were typically 8-12 weeks old at point of infection.  
2.2.2- Parasite Life Cycle and Maintenance 
 
The life cycle of B. malayi (Bm) was maintained in mosquitoes and 
Mongolian gerbils. Mongolian gerbils were initially infected intraperitoneally 
(i.p) with 400 B. malayi infective L3 larvae (BmiL3) and left for 12 weeks to 
establish fecund adult infection. Microfilariae (mf) were collected from 
infected Mongolian gerbils via catheterisation involving anaesthetisation with 
isoflurane followed by peritoneal washes with Roswell Park Memorial 
Institute (RPMI) 1640 media (ThermoFisher Scientific) to harvest Mf. Mf were 
subsequently purified, using PD10 column size exclusion chromatography 
(Amersham), enumerated by microscopy and mixed with heparinised human 
blood to a final concentration of 15–20,000 mf/ml. Mf spiked human blood 
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was then fed to female Aedes aegypti mosquitoes through an artificial 
membrane feeder (Hemotek) and reared for 14 days with daily sugar-water 
feeding to allow development of mf to the infective BmiL3 stage. Following 
14-day incubation BmiL3 were collected from infected mosquitoes by 
physical crushing of infected mosquitoes following immobilisation by chilling 
at 4C for 10 minutes, followed by concentration using a Baermann’s 
apparatus and RPMI media. BmiL3 were utilised for either downstream 
experiments or used to infect naïve Gerbils to maintain the life cycle 
2.2.3- Leg pathology model experimental infection 
 
Mice were sedated using isofluorane general anaesthetic and 100 B. malayi 
L3 larvae (BmL3) per mouse divided over two injection sites in a volume not 
exceeding 50µl/injection. 50 BmL3, were injected subcutaneously (sc.), using 
a 35-gauge needle (Sigma, Dorset) attached to a 1ml capacity syringe (BD 
Biosciences, UK) into the left hind leg of mice on top of the foot and 50 sc. 
caudal to the left knee joint. Sham-infected control mice received equal 
volumes of sterile Roswell Park Memorial Institute 1640 (RPMI) at both sc. 
injection sites. Mice were left for varying time points from 6 days to 16 weeks 
before sacrifice via schedule one method of rising concentration of CO2 (3 
minutes 0-100% CO2 followed by 2 minute 100% cycle) and subsequent 
exsanguination through standard cardiac puncture technique, prior to 
dissection and tissue sampling. Figure 2.1A shows a diagrammatic 
representation of the developed model. 
2.2.4-Intravital Near-Infrared (NIR) Imaging of lymphatic flow 
 
Mice infected as described above were maintained under isofluorane 
anaesthetic to allow equal volume (20l) s.c. injections of a prepared 1mg/ml 
solution in ddH2O of clinical-grade angiographic contrast agent indocyanine 
green (ICG; ‘cardio-green’) (Sigma, Dorset UK) into the dorsal area of both 
left and right hind feet. As the ICG is drained away from injection site through 
the lymphatics, a Photo Dynamic Eye (PDE) near infra-red (NIR) optical 
imaging device (Hamamatsu Photonics, Hertfordshire) was used to observe 
in real time the near infrared fluorescent signal emitted from the ICG. Mice 
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were imaged from above and placed in 4 different viewpoints: Dorsal 
(mouse’s back pointing upwards), ventral (mouse’s stomach pointing 
upwards), left (mouse placed on side with left hind leg pointing upwards) and 
right (mouse placed on side with left hind leg pointing upwards) (Figure 
2.1B). A digital moving image of approximately 3 minutes per mouse was 
recorded, using an EasyCap DC60 USB Video Capture Card Adapter 
(Softonic, Bacelona) that converted footage from the PDE imaging device 
directly to ImageJ software (NIH, USA) via the IJwebcam plugin. A resolution 
setting of 720 x 480 at 60 fps was utilised, encompassing all 4 viewpoints 
described and completed movies saved directly into .Tiff file format. The 
imaging method was applied either at single time points or longitudinally, 
where indicated ranging from 6 days to 16 weeks pi. 
2.2.5-Quantification of lymphatic remodelling and lymphatic insufficiency  
 
High resolution (720 x 480) still images from all 4 viewpoints per mouse were 
obtained from the imaging movies by pausing the digital moving image on 
the most representative example of all 4 viewpoints as described above. 
Downstream analysis was undertaken directly in ImageJ (NIH, USA) 
(described below), while representative images for figures were screen 
captured by using Snipping Tool (Windows, USA) and saved as a .Jpeg 
image at native 720 x 480 resolution. To avoid bias in analysis, images were 
blinded using the Filename Randomiser ImageJ macro. Briefly, Tiff moving 
image files were masked to assigned random letter/number sequences and a 
“key” file generated to allow deciphering of relevant files post analysis. 
Atypical ‘aberrant’ lymphatic patterns (not present in naïve mice) were 
quantified by tracing from the images obtained in all 4 viewpoints using 
ImageJ software (NIH, USA) (Figure 2.1C). Traced lymphatics were reported 
as a length measurement (arbitrary units- Pixels)- with higher lengths 
reporting higher quantities of aberrant lymphatic channels. Measurements 
from all four view-points were plotted into separate dot-plot graphs using 
GraphPad Prism Version 5 Software (GraphPad Software, La Jolla USA) 
For lymphatic insufficiency measurements, paused representative stills from 
the ventral viewpoint (see figure 2.1D) were analysed in ImageJ (NIH, USA). 
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A polygon selection region of interest (ROI) was used to trace round the left- 
and right-hindfoot, from below the popliteal lymph node (pLN) down to above 
the injection site (Figure 2.1D) and the “mean pixel fluorescent intensity 
measurement” obtained using the standard “measure> mean grey value” tool 
from ImageJ (NIH, USA). ImageJ calculates this measurement by assigning 
pixels in the ROI a “brightness” value between 0-255 and reporting the mean 
value from total number of pixels. Because ICG dye emits NIR fluorescence 
which is registered onf the PDE imaging device, an increased “mean pixel 
intensity”, equates to more ICG retention in the ROI. The intensities were 
reported as a ratio of the right (uninfected) hind lower limb : left (infected) 
hind lower limb, the equations used to calculate the Right/Left leg ratio is 
described below: 
𝑅𝑎𝑡𝑖𝑜 𝑉𝑎𝑙𝑢𝑒 =
𝑀𝑒𝑎𝑛 𝑅𝑂𝐼 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑡 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑅𝐼𝐺𝐻𝑇 𝐿𝐼𝑀𝐵
𝑀𝑒𝑎𝑛 𝑅𝑂𝐼 𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑡 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝐿𝐸𝐹𝑇 𝐿𝐼𝑀𝐵
  
 
A ratio value less than one (0.999-0) is indicative of ICG retention in the left 
(infected limb) while ratio values above one (>1) suggest retention of ICG in 
the right (uninfected foot) 
2.2.6-Evan’s Blue dermal retention assay (modified Miles Assay) 
 
A modified Miles Assay (Radu and Chernoff, 2013) was utilised whereby 
mice infected for 14 days, following BmL3 or sham infection as described 
previously, were maintained under isofluorane anaesthetic and a sc. injection 
of 10l (using a NanoFil 100l sub-microlitre injection syringe (World 
Precision Instruments, USA) for precise delivery) of 1% Evan’s Blue (Sigma, 
Dorset UK) w/v in sterile dulbecco’s Phosphate Buffered Media (dPBS) 
(Sigma, UK) administered in the dorsal foot pocket of the left hind leg. 
Following a 20-minute draining period, mice were euthanized using schedule 
one method of a rising concentration of CO2 followed by confirmation of 
death. The skin of the left hind leg between the knee and ankle joint was 
carefully excised and transferred to 1ml of dPBS (Sigma, UK) for an 
incubation period of 20 minutes before removal. A 100l sample of the PBS 
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from the incubated skin section was then transferred to a flat bottom 96 well 
plate (Starlab, Milton Keynes) and absorbance read on a VarioSkan 
(Thermofisher, UK) plate reader at 620nm. 
2.2.7-Epifluorescence Microscopy and quantitation of Lymphatic vessel width 
 
The C57BL/6J Prox-1GFP transgenic mice utilised in the pathology model 
results in any Prox-1 expression being visible due to Bacterial Artificial 
Chromomosome (BAC) transgenic knock-in of a GFP fluorescent tag to the 
promoter region of the prox-1 gene. Prox-1 is a master transcription factor for 
the lymphatic endothelium lineage and results in visualisation of the mouse’s 
lymphatic architecture when visualising GFP epifluorescence by 
fluorescence microscopy.  
Following various time points of the pathology model, mice were euthanised 
using schedule one method of a rising concentration of CO2 followed by 
confirmation of death. Skin samples were removed at areas of aberrant 
lymphatics (with equivalent areas used in sham control mice) and mounted 
onto a wooden board. Epifluorescence was then visualised using a 
fluorescent stereo-dissecting microscope (Leica Microsystems, Milton 
Keynes). Between 15 and 30 images were taken per mouse in these areas 
and saved as .BMP image files before blinding, utilising the same Filename 
Randomiser Macro in ImageJ as described above. Lymphatic channels 
representative of the captured individual image were then measured for 
lymphatic channel aperture using the ‘straight line’ measuring tool in ImageJ 
(NIH, USA). All image measurements across the 15-30 images per mouse 
were then pooled to allow calculation of an average lymphatic width of these 
measurements to be reported. 
In other experiments the popliteal lymph node (pLN, Iliac (iLN) and sub-iliac 
(siLN) lymph nodes from sham and 14dpi infected mice where dissected and 
placed on petri dishes ready for epifluorescence microscopy using a 
fluorescent stereo-dissecting microscope (Leica Microsystems, Milton 
Keynes). An image of the lymph node was taken in the GFP channel and an 
area measurement obtained in ImageJ using the Prox-1 fluorescence as a 
guideline for the perimeter of the lymph nodes. 
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2.2.8-Epifluorescence tracking of BmL3 migration 
 
BmL3 larvae were harvested and separated into 200 BmL3 aliquots. Aliquots 
were washed in RPMI 1640 (Sigma, Dorset) followed by staining in a 150µM 
solution of Alexa Fluor™ 546 NHS Ester (Succinimidyl Ester) (Thermofisher, 
UK) in Fluorobrite DMEM (Thermofisher, UK) for 2 hours. Following staining, 
BmL3 larvae were washed once in RPMI 1640 (Sigma, Dorset) before 
resuspension in approximately 50µl of RPMI 1640 (Sigma, Dorset) and 
drawing up into 35-gauge needle (Sigma, Dorset) 1ml capacity syringes (BD 
Biosciences, UK). 
C57BL/6J Prox-1GFP transgenic mice were injected sc with 400 BmL3 across 
two sites- 200 into the dorsal pocket of the foot and 200 in a pocket caudal to 
the left knee joint. Mice were left for 3 hours, 24 hours, 48 hours or 6 days pi 
followed by euthanisation using schedule one method of a rising 
concentration of CO2 and confirmation of death. Epifluorescence microscopy 
was undertaken, utilising a fluorescent stereo-dissecting microscope (Leica 
Microsystems, Milton Keynes), to locate BmL3 in the ‘dsRed’ filter channel. 
Fluorescent BmL3 were checked for location in relation to initial inoculation 
sites and common areas of lymphatic remodelling as visualised under PDE 
ICG imaging. Fluorescent BmL3  were also checked for co-localisation with 
Prox-1GFP expressing lymphatic channels. Where colocalization was found, 
images were taken or a time-course of images obtained to create moving 
images using manufacturer’s software. 
2.2.9-Lymph node and cardiac blood sampling  
 
At varying time points following the pathology model described above, mice 
were sacrificed utilising schedule 1 method of rising CO2 overdose and was 
immediately followed by blood collection, using standard cardiac puncture 
techniques, into heparinised collection tubes (Starstedt, Germany). Following 
cardiac punctures, left (infected) side popliteal, iliac and sub-iliac lymph 
nodes were dissected and a single cell suspension created by teasing apart 
of nodes on top of a 40 m cell sieve (Sigma, Dorset) followed by maceration 
of remaining lymph node tissue through the sieve using the handle of 2ml 
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syringes (Sigma, Dorset). The resultant single cell suspension was then 
centrifuged and resuspended in PBS (Sigma, Dorset) + 5% Foetal Bovine 
Serum + 2mM EDTA and aliquoted into equal cell numbers ready for 
proceeding cell cytometry. A manual total viable cell count was undertaken 
on pooled lymph node single cell suspensions to gain a measurement of LN 
cellularity per mouse. This was done by mixing LN suspensions 1:1 0.1% 
trypan blue (Sigma, Dorset): cell suspension (for dead cell differentiation) 
followed by mounting onto Kova Glasstic slides (Sigma, UK) for counting 
under a x10 light microscope   
2.2.10-Statistical Analysis 
 
All statistical analysis was undertaken using Prism software (Graphpad 
software, San Diego). All continuous data was tested for normal distribution 
using the Kolgmoronov-Smirnoff test for equal variance. Where data was 
normally distributed, a two-tailed independent Student’s t-test was used to 
test for significant differences between two groups. Where data was found to 
be not normally distributed, a log transformation of the data was first 
attempted and data re-tested for normal distribution. If data continued to be 
not normally distributed after log transformation, a two-tailed non-parametric 
Mann-Whitney U test was used to test for significant differences between two 
groups. Where more than 2 groups were being compared, a One-way 
ANOVA was utilised with a Tukey’s post-hoc comparisons test to measure 
differences in parametric data, while a Kruskal-Wallis test was used for non-
parametric data with Dunn’s post-hoc multiple comparisons test. The mean 
along with the standard error of the mean (SEM) are reported in all data 
unless otherwise stated. Significance is indicated as *=P<0.05, **=<0.01, 
***=<0.001 in all figures unless stated otherwise. 
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Figure 2.1: Development of a filarial mouse pathology model 
A) Schematic of the developed mouse pathology model where mice were 
subcutaneously infected with 100 BmL3 into the dorsal pocket of the left hind 
foot (50 L3) and pocket caudal to left hind foot knee (50 L3) followed by 
incubation for various time points before PDE NIR intravital imaging. B) 
Diagrammatic representation of the 4 viewpoints used to image mice hind 
legs. C) Illustration of the method used to quantify aberrant lymphatics 
across the 4 view-points. High quality still of the imaging movies are captured 
in all 4 view-points, normal lymphatic channels observed in naïve mice are 
highlighted in green and not traced/measured. Aberrant lymphatic vessels 
observed- defined as not present normally in naïve mice- are highlighted in 
red and would be traced and reported as a length measurement (Arbitrary 
unit: pixels) using ImageJ. D) Illustration of lymphatic insufficiency 
measurement taken from the ventral viewpoint. A polygonal area selection is 
made in ImageJ from just below the popliteal lymph node down to just above 
the injection site in both hind legs. The average pixel intensity is measured in 
both and reported as a ratio of right uninfected leg: left infected leg. Numbers 
below one would suggest aggregation of ICG in the left infected limb, 
numbers above one would suggest aggregation of ICG in right uninfected 
limb. 
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2.3- Results 
 
2.3.1- Significant lymphatic remodelling and lymphatic insufficiency is evident 
post- infection with B. malayi  larvae  
To investigate whether lymphatic remodelling was induced post-infection with 
BmL3, lymphatics were imaged longitudinally in the hind legs of infected and 
naïve mouse groups between 6 days and 12 weeks post-infection (pi) 
utilising PDE NIR optical imaging of ICG lymphatic drainage. Additionally, 
lymphatic vessels were visualised using GFP epifluorescence at +14 days pi 
for measurement of lymphatic channel density and aperture. As an additional 
measure to investigate if infection lead to lymphatic insufficiency, an Evan’s 
Blue dermal retention assay was undertaken at 14 days pi.  
Novel, aberrant lymphatics were significantly higher in BmL3 infected mice 
groups, compared to sham infected counterparts, at both 6 and 14 days pi in 
dorsal (Sham: 2.5±1.9 A.U. vs 6 day: 331.4±43.2, P<0.001, vs 14 day: 
79.3±25.2 P<0.001), ventral (Sham: 10.4 ± 8.232 A.U: vs 6 day: 546.3 ± 64.9 
A.U P<0.0001, vs 14 day: 252.0 ± 31.00 A.U P<0.001)  and left viewpoints 
(Sham: 2.2 ± 2.2 A.U: vs 6 day: 602.2 ± 87.3 A.U P<0.0001, vs 14 day: 374.5 
± 57.7 A.U P<0.0001) , (Figure 2.2A&B.). Six day infections displayed 
significantly higher novel aberrant lymphatics than 14 day infections in 
ventral (6 day: 546.3 ± 64.9 A.U vs 14 day: 252.0 ± 31.0 A.U P<0.0001) and 
left  (6 day: 602.2 ± 87.3 A.U vs 14 day: 374.5 ± 57.7 A.U P<0.001) 
viewpoints (Figure 2.2A&B). Additionally, the ratio of ICG fluorescence in 
right versus left limbs were significantly lower in BmL3 infected mice, 
compared to sham infected controls at both 6 (Sham: 0.9±0.1 R/L ratio vs 6 
days: 0.3±0.1 R/L ratio P<0.001) and 14 days pi. (Sham: 0.9 ± 0.06 R/L ratio 
vs 14 days: 0.6 ± 0.06 R/L ratio P<0.01)(Figure 2.2C.). At 14 days pi, a 
significant accumulation of Evan’s Blue was apparent in limb dermal tissues 
in BmL3 infected mice, compared to sham infected controls (Sham: 
0.06±0.01 O.D. 620nm vs BmL3: 0.1±0.02 P<0.001, Figure 2.3C&D). 
Following previously established qualitative classification of pathologies 
indicative of dermal backflow and lymphatic insufficiency (Yamamoto et al., 
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2011), all three grades: ‘splash’ ‘stardust’ and ‘diffuse’ were consistently 
observed in BmL3 infected mouse cohorts as early as 14dpi (Figure 2.2D) 
Apertures of Prox1-GFP+ dermal lymphatic channels were significantly larger 
in BmL3 infected mice compared to sham-infected controls at 14 days pi, 
(Figure 2.3A&B; Sham: 43.3±3.7 μm vs BmL3: 96.8±4.9μm, P<0.001 ). 
Further, epifluorescent visualisation of Prox1-GFP+ dermal lymphatic 
channels consistently demonstrated the presence of tortuous collateral 
lymphatics in BmL3 infected mice, which were absent in sham infected 
counterparts (Figure 2.3E) 
2.3.2- BmL3 migrate into pre-collector lymphatic channels, proximal to areas 
of lymphatic remodelling, as early as 3 hours following inoculation 
To investigate the time-course of BmL3 migration, confirm presence of BmL3 
in the lymphatic channels and in which lymphatic areas they reside, BmL3 
were protein labelled with AlexaFluor546 amine-reactive dye and inoculated 
into the left hind-limb of CB57/6J Prox-1GFP mice and their locations tracked 3 
hour and 24 hours after infection, using epifluorescence microscopy 
(Schematic shown in figure 2.4A). 
Highly motile BmL3 were observed inside host lymphatic pre-collector and 
collector channels as early as 3 hours pi. and resided in areas proximal to 
confirmed zones of common lymphatic remodelling as imaged by PDE NIR 
optical imaging of ICG lymphatic drainage (Figure 2.4B&C).  The highest 
number of intra-lymphatic larvae were observed 24 hours pi, with numbers 
dropping following this time point (Laboratory observation, data not shown). 
Motile worms were observed as late as 6 days following infection, although 
numbers of observed intra-lymphatic larvae declined rapidly following 48 
hours. The numbers of motile larvae visualised at both injection sites, with 
localisation outside of lymphatic vessels, were highest 3 hours pi. 
,decreasing in number up to 48 hours pi. No larvae could be visualised 4dpi 
or 6dpi at injection sites (Laboratory observation, data not shown). 
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Figure 2.2: lymphatic remodelling and insufficiency are significantly 
increased following B. malayi infection 
A) Representative images taken from PDE imaging and analysed for 
aberrant lymphatics and lymphatic insufficiency B) Quantification of aberrant 
lymphatics in dorsal, ventral, left leg and right leg or C) ventral backflow at 
indicated time-points post-infection with 100 BmiL3 compared to sham 
infection controls D) Representative examples of all three observed 
qualitative grade pathologies, defined in previous ICG studies as measures 
of lymphatic insufficiency   Data plotted is the number of ICG positive pixel 
arbitrary units within aberrant lymphatic channels (B) or the ratio of ICG 
positive pixel arbitrary units between right and left limbs in a ROI above the 
injection site and below the pLN per mouse (C). Horizontal bars indicate 
mean ±SEM per group. Data was pooled from either two or three individual 
experiments. Significance is indicated *=P<0.05, **=P<0.01, ***=P<0.001, 
One Way ANOVA with Tukey’s multiple comparisons tests. 
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Figure 2.3: Lymphatic insufficiency and dilation are significantly 
increased, while evidence of tortuous collateral lymphatics are 
manifest 14d post-infection compared to sham control 
A) Representative images of Prox-1 GFP epifluorescence in zones of dermis 
corresponding with ICG remodelling at 14 dpi with 100 BmL3 or 
corresponding zones in sham infected animals. B) Lymphatic aperture 
measurements of Prox-1 GFP epifluorescence in zones of dermis 
corresponding with ICG remodelling at 14 dpi with 100 BmL3 or 
corresponding zones in sham-infected animals. C) Representative image of 
limb lymphatic backflow in an infected and uninfected limb, 14 dpi with 100 
BmL3, visualised by modified Mile’s Assay were 10µl of Evan’s Blue was 
injected subcutaneously into the left hindlimb of experimental mice, followed 
by a timed drainage period of 20 minutes. Subsequent necropsy to excise 
the left hind-limb skin from ankle to below knee joint was then undertaken. D) 
Quantification of Evan’s Blue dermal backflow in excised lower hind-limb 
skin, 14 days post-infection with 100 BmL3, versus sham infection controls. 
Data is optical density at 620nm following extraction of dye in PBS per 
mouse. E) Representative example of tortuous collateral lymphatics as 
observed in BmL3 infected mice utilising epifluorescence microscopy 14dpi. 
Scale bars (yellow bars) represent 200μm. Horizontal bars represent mean 
±SEM were data is pooled from 2 individual experiments (D) or derived from 
a single experiment (B). Significance is indicated ***P<0.001, determined by 
student two tailed t-test 
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Figure 2.4: BmL3 migrate to lymphatic pre-collector channels proximal 
to areas of subsequent lymphatic remodelling 3-24 hours post 
infectionError! Bookmark not defined. 
A) Schematic of experiment timeline. B) NIR intravital imaging of ICG 
lymphatic drainage with yellow boxes demonstrating areas examined for 
BmL3 infection. C) Prox-1 GFP lymphatic channels and AF546 stained 
epifluorescence. Representative images of BmL3 located inside lymphatic 
pre-collector channels (arrows indicate BmL3 location). 
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2.3.3- Challenge filarial infection significantly increases lymphatic 
remodelling and lymphatic insufficiency compared to single infection. 
Following characterisation that lymphatic remodelling occurred as soon as 6 
days post-filarial infection, the impact of re-infection was evaluated. 
Following an initial infection (as described above), a further inoculation of 
BmL3 larvae was administered after a 2-week interval. PDE imaging was 
undertaken two weeks later (Schematic shown in figure 2.5A). 
Challenge infections (BmL3x2) significantly increased the extent of lymphatic 
remodelling, defined by increased incidence of aberrant lymphatics, in dorsal 
(BmL3: 79.3±25.2 A.U vs BmL3x2: 435.9±68 A.U P<0.001, left (BmL3: 
374.5±57.7 A.U vs BmL3x2: 790.1±82.1 A.U P<0.001) and ventral (BmL3: 
252±31.0 A.U  vs BmL3x2: 758.5±157.7 A.U P<0.001) viewpoints compared 
with single infection alone (Figure 2.5B&C). Left Leg / Right leg ROI ICG 
fluorescence, measured by PDE NIR imaging, between a single and 
challenge infection was not significantly different, although both single and 
double infections mediated a significant biased accumulation of ICG in the 
infected limb compared to sham infected controls (Figure 2.5D; BmL3: 
0.55±0.06 and BmL3x2 0.45±0.04 R/L ratio vs sham: 0.88±0.06, P<0.001 
and P<0.0001, respectively.) 
2.3.4- Aberrant lymphatics and lymphatic insufficiency persist 12 weeks 
following infection with B. malayi L3. 
 
To investigate whether the acute lymphatic remodelling and lymphatic 
insufficiency phenotype post-BmL3 infection was a transient and resolving 
event or led to long-lasting alterations, infected and sham infected mice were 
allowed to reach 12 week pi before subsequent PDE imaging (Schematic 
shown in figure 2.6A). In susceptible animal models, including immuno-
deficient mice and Mongolian gerbils, adult B. malayi develop to patent adult 
infections before 12 weeks. Mice that had been inoculated with BmL3 were 
checked for infection status through blood thick smears and all mice were 
confirmed as microfilmariae (mf) negative (6 mice) at 12wpi. Further careful 
examination of hind-limb lymphatics confirmed an absence of active intra-
lymphatic infection at 12 wpi (laboratory observations, data not shown). 
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Despite the infection negative status at 12 wpi (laboratory observation 
following thick blood smears of cardiac punctures from appropriate mice), 
mice that had been inoculated with BmL3 displayed significantly higher 
aberrant lymphatics compared to sham counterparts in dorsal (Figure 
2.6B&C; 12 weeks: 190.6±81.8 A.U vs sham: 0.2±0.2 A.U P<0.05) ventral 
(12 weeks: 830.5±162.6 A.U vs sham: 0.2±0.2 A.U P<0.0001) and left 
viewpoints (12 weeks: 682.5±165.4 A.U vs sham: 0.2±0.2 A.U P<0.001). 
Further, there were no significant differences in dorsal, ventral or left 
viewpoints between mouse groups who had received prior inoculations either 
at 2 or 12 weeks (Figure 2.6B&C). In addition, left leg fluorescence/right leg 
fluorescence (R/L leg ratio) was significantly lower in the 12 week pi mouse 
group compared to sham controls and no significant differences in R/L leg 
ratio were apparent in 2 week versus 12 week pi mouse groups (Figure 2.6D; 
12 week: 0.4±0.05 R/L ratio vs Sham: 0.9±0.06, P<0.0001). 
2.3.5- BmL3 infection is associated with a significant lymphadenopathy and 
increased cellularity of local draining lymph nodes. 
Fourteen days post-infection with 100 BmiL3 or sham inoculates, skin 
draining lymph nodes (sdLN) of the infected left leg (pLN, iLN, and siLN) 
were excised and total sdLN area determined utilising Prox-1GFP 
epifluorescence as a guide. A pooled, single cell suspension of sdLN per 
mouse was then prepared and quantified by cell counting.  
At 14 dpi the areas of the pLN, iLN, and siLN proximal to the inoculation site 
were significantly increased compared to sham infection controls (Figure 
2.7A&B; pLN :  BmL3 2.9±0.15 mm2 vs Sham 0.9±0.15 mm2 P<0.01, iLN: 
BmL3 7.5±0.89 mm2 vs Sham 2.0± 0.09 mm2 P<0.01, siLN: 3.5±0.4 mm2 vs 
sham: 0.69±0.08 mm2 P<0.0001). Furthermore, cellularity of the pooled sdLN 
were significantly increase in infected mice, compared to sham controls 
(Figure 2.7C; BmL3: 1.9x107 ± 5.0x106  vs 6.1x106 ± 2.4x105 cells, P<0.05).  
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Figure 2.5: Challenge filarial infection significantly increases lymphatic 
remodelling and insufficiency 
A) Schematic of experimental time-line. Sham infections followed BmL3 
timeline. B) Representative images from PDE analysis. C) Quantification of 
aberrant lymphatics in dorsal, ventral, left leg and right leg or, D) dermal 
backflow from primary (BmL3) vs challenge infection (BmL3x2) compared to 
sham infection controls. Data plotted is the total ICG positive pixel arbitrary 
units defining aberrant lymphatic channels (C) or the ratio of ICG positive 
pixel arbitrary units between right and left limbs in a ROI above the injection 
site and below the pLN per mouse (D). Horizontal bars indicate mean±SEM 
per group. Data was pooled from either three individual experiments (primary 
infection and sham data reused from figure 2.2B-C) or a single experiment 
(challenge). Significance is indicated *=P<0.05, **=P<0.01, ***=P<0.001 
derived from 1 Way ANOVA with Tukey’s multiple comparisons tests. 
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Figure 2.6: Lymphatic remodelling and insufficiency persist 12 weeks 
following infection with BmL3. 
A) Schematic of experimental time line. B) Representative PDE images PDE 
analysis. C) Quantification of aberrant lymphatics in dorsal, ventral, left leg 
and right leg or, D) dermal backflow from 2 weeks vs 12 weeks compared to 
sham infection controls. Data was pooled from 2 (2+12 weeks) or 3 (sham) 
individual experiments. Horizontal bars represent mean ±SEM. Significance 
is indicated as *=P<0.05, **=P<0.01, ***=P<0.001 derived from One Way 
ANOVA with Tukey’s multiple comparisons tests. 
 
 
  
77 
 
2.3.6- C57BL/6J mice demonstrate significantly elevated severities of 
lymphatic remodelling and insufficiency versus BALB/c mice following filarial 
infection  
Potential host strain variation in filarial-associated lymphatic remodelling and 
insufficiency was explored by comparing pathologies 14 dpi between 
commercially-supplied BALB/c and C57BL/6J mouse cohorts.  
C57BL/6J BmL3 infected mice were found to display significantly higher 
levels of aberrant lymphatics in dorsal (BALB/c BmL3: 27.9±16.3 A.U vs 
C57BL/6J BmL3: 284.0±72.3 A.U P<0.001), ventral (BALB/c BmL3: 
231.6±33.0 A.U vs C57BL/6J BmL3: 611.6±101.6 A.U P<0.001) and left leg 
(BALB/c BmL3: 150.8±44.4 A.U vs C57BL/6J BmL3: 656.7±109.8 A.U 
P<0.001) viewpoints of PDE imaging, when compared to BALB/c infected 
mice (Figure 2.8A&B). Both C57BL/6J and BALB/c BmL3 infected mice 
demonstrated a significant change in the ratio of R/L leg ICG accumulation 
(Figure 2.8C; BALB/c Sham: 1.080±0.08 R/L ratio vs BALB/c BmL3: 
0.44±0.09, P<0.001, CB57/6J Sham: 0.99±0.03 R/L ratio vs CB57/6J BmL3: 
0.57±0.09, P<0.001), however C57/6J BmL3 infected mice retained 
significantly higher levels of Evan’s Blue in the dermis of infected limbs 
compared to BALB/c infected mice (Figure 2.8D; BALB/c BmL3: 0.11±0.01 
OD620 vs CB57/6J BmL3: 0.17±0.03, P<0.05 ) 
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Figure 2.7: BmL3 infection results in lymphadenopathy and significant 
increases in sdLN cellularity 
A) Representative Prox-1GFP images of sdLNs (pLN, iLN, siLN) between 
infected and BmL3 infected counterparts. B) Area measurements of sham vs 
BmL3 pLN,iLN and siLN  (n=3 per group) C) Cellularity measurements of 
pooled sdLNs (n=8-9 per group). Data is from a single experiment (A+B) or 3 
individual experiments (C) Horizontal bars represent the mean ±SEM with 
significance indicated as *=P<0.05, **=P<0.01 ***=P<0.001 derived from 
student’s two tailed t-test. 
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Figure 2.8: C57BL/6J mice are predisposed to more extensive 
lymphatic remodelling and insufficiency compared with BALB/c mice 
following B. malayi infection. 
A) Representative images of mouse groups from PDE imaging B) 
quantification of aberrant lymphatics in dorsal, ventral and left leg viewpoints 
or C) dermal backflow from 14 days post-infection comparing BmL3. infected 
BALB/C vs C57BL/6J groups D) Quantification of Evan’s Blue dermal 
backflow in excised lower hind-limb skin. Horizontal bars represent the mean 
±SEM, data shown is pooled from 3 independent experiments. Significance 
is indicated as *=P<0.05 **=P<0.01  ***=P<0.001 derived from one-way 
ANOVA with Tukey’s multiple comparisons post-hoc test. 
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2.4- Discussion 
Lymphatic remodelling, encompassing lymphatic vessel dilation, lymphatic 
neovascularisation, lymphadenitis and the presence of tortuous collateral 
lymphatics, is a key hallmark observed in patients suffering from filarial 
infection (Figueredo-Silva et al., 2002; Baluk et al., 2005; Shenoy, 2008; 
Nutman, 2013). The pervasive theory in the field hypothesises that changes 
to the lymphatic architecture are a result of progressive damage to existing 
lymphatics, as a consequence chronic inhabitation of live fecund adult filarial 
worms (Nutman, 2013). Dreyer and colleagues speculate that these 
lymphatic remodelling events also require death events of pre-established 
adult infections, either natural or drug-induced, that cause bolus release of 
toxic and antigenic material and consequent immune responses to drive 
pathological manifestations observed in LF (Dreyer et al., 2000).  Currently, it 
is impossible to accurately delineate the relative impact of each of the 
different filarial life cycle stages on the ensuing lymphatic remodelling and 
pathologies evident in naturally infected human populations. The introduction 
described an inadequacy of current animal models to interrogate the 
temporal induction of lymphatic remodelling, the role of remodelling in 
lymphatic dysfunction, and immune-dependent mechanisms that potentially 
drive remodelling processes  
The first objective of the thesis was to assess the initial impact of filarial 
larval invasion on lymphatic remodelling and possible pathology in a novel, 
immunocompetent murine model of infection. The data collected indicates 
that significant alterations to the lymphatic architecture are manifest as early 
as 6 days following infection. Homeostatic hind-limb lymphatic drainage 
consistently shows linear, single channel flow from the foot injection site, 
firstly to the popliteal lymph node followed by subsequent flow via another 
single efferent collector channel to the iliac lymph node (Example shown in 
sham infection representative image in figure 2.2A). The linear patterns of 
‘normal lymphatic flow’ observed are replicated in human studies, reporting 
similar ‘linear flow patterns’ in ‘normal’ subjects imaged using similar 
methods of NIR intravital imaging (Yamamoto et al., 2011; Narushima et al., 
2015). In contrast, filarial infection resulted in overt changes with many 
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“micro-channels” becoming visible at 6 and 14 days pi (Figure 2.2A). These 
channels create areas of “webbing” across the dorsal and ventral hind limb 
that did not appear to connect to existing draining lymph nodes. Devised 
quantification methods of intravital imaging enabled thorough 
characterisation of infection-associated lymphatic remodelling. This 
quantification showed significant increases in aberrant lymphatics compared 
to sham controls at both 6 days and 14 days. Aberrant lymphatics were 
observed in 100% of mice infected at this early time point. The pattern of 
aberrant lymphatics (Figure 2.2A, 2.3A) are similar to ‘tortuous collateral 
lymphatics’ observed in LF patients (Case et al., 1991, 1992; Freedman et 
al., 1994; Shenoy, 2008). Further, lymphatic patterns visualised in the 
C57BL/6J mouse model of filarial infection displayed resemblance to those 
reported in non-LF LE patients, utilising the same imaging techniques of ICG 
lymphangiography (Mihara et al., 2012). The common ‘lymphatic backflow 
patterning’s’ putatively named  ‘splash’ and ‘starburst’, both of which 
positively correlated with grades of lymphatic insufficiency, were consistently 
observed in the filarial mouse model (Yamamoto et al., 2011; Narushima et 
al., 2015). This would suggest that the lymphatic remodelling observed are 
pathological in nature, contributing to lymphatic insufficiency rather than 
suggested ‘compensatory’ therapeutic remodelling hypothesised to ‘repair’ 
lymphatic insufficiency in models of surgically-induced LE (Haiko et al., 2008; 
Alitalo, 2011; Lähteenvuo et al., 2011) .The apparent lack of connection of 
these novel lymphatics to any existing draining lymphatics would suggest 
that rather than diverted lymphatic drainage into pre-existing proximal 
lymphatic channels, caused by an infection-mediated occlusion of normal 
lymphatic flow, the aberrant lymphatic channels are potentially novel 
neovascularisation events stimulated by the invasion of BmL3 into the 
lymphatic architecture. No significant increases in aberrant lymphatics were 
observed in the control right hind-limb in infected mice, nor in sham 
counterparts (Figure 2.2B) signifying that filarial infection induces very focal 
changes to the lymphatic architecture and associated lymphatic function, 
localised to sites of initial parasitism. Significantly higher levels of aberrant 
lymphatics were observed at the earlier 6-day time point, compared to 
mouse cohorts imaged at 14 days pi (Figure 2.2B). While, initially, this would 
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suggest a pattern of resolution of lymphatic remodelling, further investigation 
of imaging (Figure 2A) would suggest a higher degree of dilation of lymphatic 
channels at the 14 day time point. This results in a larger spread of ICG 
fluorescence which masks adjacent lymphatic channels, resulting in a falsely 
low level of aberrant lymphatics being reported, particularly in lower parts of 
the hind limb. Potentially, this masking reveals a sensitivity issue of the PDE 
imager, where the higher fluorescence overtakes the resolution limit, thus 
yielding artificially lower levels of aberrant lymphatics at 14 days, compared 
to 6. Regardless, the observations of sustained remodelling in long-term 
infection experiments indicates a failure to resolve aberrant lymphatic 
formation or insufficiency post-14 days. 
The use of the Prox-1GFP reporter mouse on the C57BL/6J background 
strain provided a useful tool to visualise, via epifluorescence, the lymphatic 
micro-architecture, as Prox-1 is a common transcription factor exclusive to 
the lymphatic endothelial cell lineage (Partanen and Paavonen, 2001; da 
Cunha Castro and Galambos, 2009). Visualisation of the common areas in 
which these aberrant lymphatic channels allowed clear visualisation of the 
aberrant lymphatics channels which were consistently observed to be pre-
collector lymphatic vessels, sometimes termed “lymphangions”, adjoined by 
lymphatic valves, located in the subcutaneous tissues (laboratory 
observation, representative examples shown in figure 2.3A&E). In contrast, 
fewer abnormalities were observed either in the blind-ended dermal 
lymphatic capillary beds prior to the pre-collecting ducts, or the larger 
collector vessels to which the pre-collector vessels supply (laboratory 
observation, data not shown). These aberrant channels were highly 
abnormal and bore similarity to described ‘tortuous collateral lymphatic 
channels’ in histological studies of patients suffering from filarial LE. The 
aberrant channels consistently displayed areas of gross dilation, followed by 
areas of irregular constriction, and is in stark contrast to the uniform, linear 
channels observed in uninfected mice (shown in figure 2.3E). Additionally, 
quantifying the aperture of channels in areas of most pronounced ICG 
lymphatic remodelling confirmed a ~2-fold average dilation of the sub-
cutaneous lymphatics in areas proximal to the initial filarial infection.  
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With evidence suggesting early onset lymphatic remodelling, it was important 
to investigate if remodelling was significantly associated with physical 
inhabitation of BmL3 in the affected local lymphatic architecture. Utilisation of 
the Prox-1GFP reporter mouse on the C57BL/6J to visualise lymphatic 
channels and the staining of live BmL3 before inoculation allowed the 
tracking of migrating larvae from the initial infection site shortly after 
inoculation. These experiments demonstrated BmL3 rapidly migrate from 
subcutaneous dermal tissues into lymphatic channels as early as 3-hours pi 
(figure 2.4C. Previous findings from Brugia pahangi infections in gerbils 
demonstrate rapid migration from skin tissue injection sites into lymphatic 
vessels, but more commonly to the popliteal or sub-iliac lymph nodes 
themselves (Ah and Thompson, 1973; Chirgwin et al., 2006), around 3 days 
post infection. Further, both studies demonstrate migration away from initial 
injection site as little as 3 hours post infection (Chirgwin et al., 2006). The 
data described is generally in concordance with these studies, although 
faster migration of larvae, more commonly to lymphatic vessels proximal to 
sdLN’s (as little as 3 hours) rather than sdLNs themselves were observed. 
BmL3 proximal to sdLNs were consistently found to inhabit lymphatic 
channels proximal to areas of observed lymphatic remodelling, inferring 
remodelling is rapidly initiated upon invasion of BmL3 into lymphatic 
channels. Furthermore, microscopy revealed evidence of remodelling in 
uninhabited lymphatic architecture, proximal to BmL3 resident lymphatic 
channels. 
The rapid onset of all three aforementioned ‘hallmarks’ of lymphatic 
remodelling, as little as 6 days pi, while corroborating the hypothesis that 
remodelling, notably lymphangiectasia, is a consequence of filarial 
inhabitation of lymphatic vessels, contradicts the pervading theory that 
inhabitation and resultant damage occurs over a longer time period 
(Jungmann, Figueredo-Silva and Dreyer, 1991; Noroes et al., 1996; Dreyer 
et al., 2000). Whilst no overt rupturing, or obvious damage to the lymphatic 
architecture, in areas of lymphatic remodelling were observable, it is possible 
that the initial L3 invasion into and subsequent migration within pre-collectors 
may induce lymphatic tissue damage. Parasite-mediated damage could 
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trigger a disproportionate ‘runaway’ wound healing response leading to 
remodelling. Further, or in addition, lymphatic remodelling could be induced 
directly by filarial signals, such as excretory/secretory proteins with 
lymphangiogenic potential, as has been previously reported (Shenoy et al., 
2008; Weinkopff et al., 2014). Finally, the host anti-filarial immune response 
could trigger inflammatory-associated lymphangiogenesis (IAL) that is a well-
known ‘hallmark’ documented in a range of inflammatory conditions including 
infection (Flister et al., 2010; Abouelkheir, Upchurch and Rutkowski, 2017).  
The data together would suggest that remodelled lymphatics, in contrast to 
being a consequence of long term damage due to adult inhabitation, is a very 
early “seeding event”, actively initiated either by larvae themselves or host 
immune responses, on a ‘timeline’ to pathology. A pertinent question to 
investigate would therefore be what are the divergent events following the 
ubiquitous initial lymphatic remodelling and early pathology, between hosts 
that later develop pathology and more asymptomatic groups that appear to 
tolerate active infections without overt LE. (Freedman et al., 1994, 1995; Kar 
et al., 2017) 
A key objective upon observation of rapid and significant lymphatic 
remodelling, post filarial infection, was to investigate the consequences of 
such overt remodelling and whether it may contribute to lymphatic 
dysfunction. Overt LE is the major pathology associated with LF, while LE 
itself is often one of the final stages of a varied group of sub-pathologies 
(Pani and Srividya, 1995; Nutman, 2013). LE is clinically described as the 
extravasation of lymphatic fluid into the interstitial spaces surrounding 
lymphatic vessels (Grada and Phillips, 2017). The accumulating factors 
leading to this end stage can be complex, but it is generally agreed a 
disruption of normal lymph flow and resultant perturbation of homeostatic 
lymphatic flow- leads to aberrant accumulation of lymph in lymphatic 
channels (lymphostasis) (Brouillard, Boon and Vikkula, 2014; Carlson, 2014). 
One of the largest contributing factors to lymphostasis is lymphatic vessel 
dysfunction. Dysfunction can occur due to: damage to the lymphatic vessel 
valves that direct lymph flow, leading to valvular insufficiency and lymph 
backflow(Petrova et al., 2004), hyperplasia/aplasia/dilation of lymphatic 
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endothelial cells comprising lymphatic vessels (Kesler et al., 2013), 
obliteration or blockages to the lymphatic architecture, dysfunction in 
lymphatic vessel contractility (Zawieja et al., 2012) and, breakdown in the 
integrity of lymphatic channels that results in a ‘leaky phenotype’ allowing 
lymph extravasation. Lymphoedema often develops over a “timeline of 
pathology” and initiates following events which cause lymphatic dysfunction- 
even if associated dysfunction does not immediately manifest as clinical 
lymphoedema. Onset of lymphatic dysfunction in the presence of rapidly 
remodelled lymphatics in the murine model following B. malayi infections 
would suggest, rather than being a compensatory repair mechanism, the 
remodelling observed may be a pathological contributor to later LF related 
pathology. 
PDE imaging 6 and 14 days following filarial infection demonstrated a clear 
retention or “pooling” of the fluorescent dye in the lower left infected hind-
limb, which was completely absent in the healthy uninfected right leg. 
Additionally, this retention was not observed in sham infected mouse 
cohorts. Investigators of human, non-filarial LE patients, using similar 
intravital imaging methods, observed aggregations of ICG dye which was 
indicative of the dye escaping into interstitial spaces after irregular 
lymphostasis and lymphatic dysfunction in these channels (Narushima et al., 
2015). Further a positive correlation between severity of dye aggregation 
with higher grades of LE and lymphatic dysfunction was determined 
(Yamamoto et al., 2011). A method was devised to allow quantification of the 
retention of ICG dye at or above the injection site which demonstrated a 
significantly higher aggregation of dye in the left infected leg in infected 
mouse cohorts (as shown by a significantly lower R/L fluorescence leg ratio) 
compared to sham controls at both 6 and 14 days pi. This suggests the rapid 
initiation of lymphatic remodelling following filarial infection is highly 
coincident with the onset of significantly impeded lymphatic drainage. Further 
strengthening of these assertions came from Evan’s Blue dermal retention 
assays which quantitatively measured the volume of Evan’s Blue that 
persisted in the lower limb skin (knee to ankle joint) following injection into 
the foot. At 14 days post-filarial infection, significantly larger quantities of 
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Evan’s blue aggregated within the lower hind-limb of infected mice than 
sham controls cohorts . Thus two measures of lymphatic function in the 
model indicate that normal homeostatic lymphatic drainage of the lower limb 
is perturbed following filarial infection, indicative of lymphatic dysfunction. 
Further the observed dysfunction is highly associated with significant levels 
of lymphatic remodelling these assertions are strengthened by recent work 
which demonstrate similar findings of mechanical damage, associated with 
both filarial entry, and movement through the lymphatics in a litomosoides 
rodent model (Kilarski et al., 2019)). These were frequently observed in pre-
collector vessel areas, matching with where the majority of observed 
lymphatic remodelling is observed in the developed brugian leg pathology 
model 
Taken together, filarial infection not only results in rapid onset lymphatic 
remodelling, but is coincident with development of early lymphatic 
insufficiency, disrupting homeostatic lymph drainage. It can be postulated 
that rapid, novel remodelling of lymphatic channels impedes normal lymph 
clearance, with nascent, immature vessels lacking the proper structure or 
smooth muscle cells required for efficient pumping and lymphatic transport of 
lymph fluid. Additionally, remodelling of local lymphatic channels into a more 
dilated phenotype is coincident with significantly elevated Evan’s Blue fluid 
retention in the dermis, This might indicate that remodelled, dilated 
lymphatics become more ‘leaky’, allowing lymph to escape channels into 
surrounding interstitial spaces. Whilst insufficiency and ‘leakiness’ occured 
very early following infection and persisted for 12 weeks (the longest time-
point scrutinised), pathology remained ‘sub-clinical’, in so much as overt 
swelling of the affected limb (ie LE) was not apparent in the first 12 weeks 
after infection.  
Almost all BmL3 infected BALB/c and C57BL/6 mice (>95%) displayed 
significant lymphatic alterations and associative pathological insufficiency. 
Extrapolating to human infection, this suggests that rapid onset of lymphatic 
remodelling may occur early and in a large proportion of filarial infected 
subjects. Therefore, many filarial infected individuals (especially younger LF 
patients who are less infection-experienced) may still exhibit “covert”, 
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subclinical pathology manifest as lymphatic insufficiency/ lowered lymphatic 
draining efficiency. This is supported by clinical findings which demonstrated 
filarial antigen positive, asymptomatic patients, display profound lymphatic 
alterations (Amaral et al., 1994; Freedman et al., 1994, 1995; Noroes et al., 
1996; R K Shenoy et al., 2007). Further, so called “covert pathology”, in 
terms of subtle changes to fluid retention and skin elasticity has been 
characterised in asymptomatic filarial infected cohorts (Douglass et al., 
2017). This raises the possibility that identifying both early filarial infection (ie 
pre-patent infections) and individuals with covert lymphatic insufficiency and 
interventions aimed at blocking progression at the “covert pathology” stage 
may be a promising therapeutic strategy to prevent future development of 
pathological manifestations. Recent work adds strength to this prospect in 
which chemotherapeutic treatment at these early stages ameliorated filarial 
“covert pathology” (Douglass et al., 2019)     
Emerging evidence suggests that the lymphatic architecture is highly 
dynamic with post-natal lymphangiogenesis occurring in response to 
inflammatory stimuli (Vranova and Halin, 2014; Abouelkheir, Upchurch and 
Rutkowski, 2017). It is thought inflammatory responses induce the increases 
in lymphatic flow in areas of infection, either through dilation or extranodal 
lymphatic vessel or neo-lymphangiogenesis, primarily to increase trafficking 
of immune effector cells to areas of need, coordinating an appropriate and 
robust immune response (Kim, Kataru and Koh, 2014). Additionally, 
evidence suggests inflammatory-induced lymphatic remodelling aids in the 
increase of trafficking of antigens or antigen presenting cells to local lymph 
nodes, thus acting as a bridging arm mediating innate and adaptive immune 
responses to infection, shaping the most appropriate immune response 
(Soderberg et al., 2005; Qi, Kastenmüller and Germain, 2014). Finally, 
inflammatory associated lymphangiogenesis (IAL) can increase lymphatic 
flow both through lymph nodes ,thus optimising antigen presentation and 
appropriate immune responses (Liao et al., 2015)-,and through infection sites 
thus clearing antigens and cellular debris/damage in the resolution phase of 
infection (Abouelkheir, Upchurch and Rutkowski, 2017). It is clear, therefore, 
that IAL is a necessary component of inflammation and the correct host 
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immunological response yet, significantly, resolves resulting in restoration of 
normal lymphatic flow and architecture, as part of return to homeostasis.  
Long term infections utilising the established model were undertaken to 
interrogate whether the rapid onset of lymphatic remodelling, and associated 
lymphatic insufficiency, following filarial infection was a transient mechanism 
involved with homeostatic IAL. Such remodelling would presumably enter a 
resolution phase upon clearance of infection and therefore be a separate 
mechanism to filarial induced lymphatic remodelling. Immunocompetent 
CB57/6J and BALB/c mouse strains are known to be resistant to filarial 
infection, and whilst CB57/6J mice clear larval infections at an earlier time-
point compared with BALB/c mice, the BALB/c background still remains 
resistant to long-term, fecund infections (Lawrence, 1996). Permissiveness 
to fecund infection requires the ablation of adaptive immune responses, as 
observed in athymic nude or Severe Combined Immuno-Deficient (SCID) 
mice, where successful establishment of microfilariae (mf) producing fecund 
adult infections occurs in approximately 90% of infected cohorts (Nelson et 
al., 1991). Twelve week infections in the CB57/6J mouse strain is therefore 
an appropriate time frame by which filarial infection would be effectively 
cleared and resolution of IAL achieved, while mice who have not effectively 
cleared infection at this time point will have established a fecund infection 
and begin to release detectable mf into the bloodstream as well as large, 
5cm adult B. malayi worm nests apparent in infected lymphatics (Vincent, 
Sodeman and Winters, 1980; Vincent et al., 1984). Cardiac punctures and 
subsequent thick blood smears revealed that all mice were mf negative, with 
no evidence of adult worm intra-lymphatic infections suggesting all mice in 
the 12-week cohort had effectively cleared filarial infection at this late time 
point. PDE imaging of 12 week infected mice, while demonstrating a 
significantly higher amount of lymphatic remodelling compared to sham 
counterparts, showed no significant difference in aberrant lymphatics 
between 2-week and 12-week infected mouse cohorts. Additionally, the 
retention of ICG dye in the infected foot, analysed by PDE imaging and 
quantification of R/L leg fluorescence, remained significantly higher in 12-
week infected mice compared to sham controls, with no significant difference 
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observed between 2-week and 12-week infections. Taken together these 
data suggests, in contrast to acute IAL, both the observed filarial induced 
lymphatic remodelling and associated insufficiency persists long term and 
does not resolve, even in the absence of active filarial infection.  
With only approximately 30-40% of LF patients suffering LE pathology, a key 
unanswered question is what diverging mechanisms occur which pushes 
filarial infection from asymptomatic, altered lymphatics and “covert 
pathology”, to symptomatic overt LE. It is highly likely, in endemic areas of 
filarial infection, that individuals would be subjected to multiple infection 
events across their lifetime. With the data suggesting strong persistence of 
altered lymphatics, post-clearance of filarial infection, thus the impact of 
multiple infections on severity of lymphatic remodelling and dysfunction was 
investigated. Experiments involving sequential BmL3 inoculations suggested 
that mice groups subjected to two individual BmL3 (BmL3x2) infection events 
developed significantly higher levels of aberrant lymphatics compared to 
mice subjected to a single inoculation alone (BmL3). Scrutiny of larger 
sample sizes may resolve this trend, while the addition of an Evan’s Blue 
dermal retention assay for challenge infections may further elucidate whether 
multiple infection events worsens lymphatic insufficiency. Taken together, the 
data provides evidence that additional BmL3 infections result in progressively 
higher remodelling of local lymphatics, potentially worsening the level of 
lymphatic dysfunction in the infected area. Considering the data, the 
accumulation of ever more remodelled and dysfunctional lymphatic 
architecture could pave the way to a critical ‘tipping-point’ that results in more 
profound collapse of lymphatic drainage and subsequent symptomatic LE. 
Endemic patients, however, live in areas at high risk of infection throughout 
their lifetimes with the chance of reinfection in most patients relatively high, 
including non-pathology displaying ‘asymptomatic’ groups. Furthermore, 
there are reported cases of non-endemic patients suffering from filarial LE 
and pathology often after historic travel to endemic countries and becoming 
infected (Jones, 2014). Therefore, while continuous infections may 
significantly contribute to later pathology and lymphatic dysfunction through 
higher levels of lymphatic remodelling, it cannot by itself be the sole driving 
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mechanism to the development of filarial LE. Instead, immunological, 
molecular, cellular or genetic mechanisms in addition to lymphatic 
remodelling events must play a significant role in determining later 
manifestation of pathology as also postulated in Dreyer’s model for filarial 
pathogenesis (Dreyer et al., 2000).  
To begin to understand the possible immune component to the observed 
lymphatic pathology, experiments were undertaken to investigate changes to 
the local immunological environment, following filarial challenge at the early 
2-week time point. Filarial infection into the two sites in the left hind-limb 
results in marked lymphadenopathy to all 3 draining: popliteal, iliac and sub-
iliac lymph nodes (LNs), demonstrated by the significant increases in LN 
area in BmL3 infected mice, compared to sham controls, 2 weeks following 
infection. This was further corroborated when all draining lymph nodes were 
pooled and a single cell suspension created, showing a significant increase 
in cellularity of the LN’s in BmL3 infected mice compared to sham controls. 
These results would suggest that filarial infection is either inducing significant 
cellular migration to/from, trafficking to/from or proliferation in the three LN’s 
local to the infection site. LN’s act as sentinels in the host immune system, 
playing a key role in immune surveillance to possible pathogenic threat, by 
scanning for antigens in lymphatic fluid that flows through them (Liao and 
Padera, 2013). More pertinently, draining LN’s play a key role in coordinating 
early immune responses to possible threat, helping to shape innate and 
adaptive immune responses to the most appropriate type against the 
pathogen encountered (Chang and Turley, 2015). Rapid increases in LN size 
and cellularity following filarial challenge would suggest significant activation 
of a robust host immune response at this early time-point. For 
lymphadenopathy to occur, it is often necessary for the lymphatic vessels, 
supporting LN architecture and intranodal functions, to rapidly remodel and 
vascularise in order to sustain higher influx of cells, antigens and debris 
flowing through them (Angeli et al., 2006). While such lymphatic remodelling 
is associated with a normal immune response and IAL, it is further evidence 
of filarial infection inducing a significant change to the pre-existing lymphatic 
architecture very shortly after infection. 
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A final objective in this chapter was to investigate if the severity of lymphatic 
remodelling, and associated lymphatic insufficiency significantly varies in the 
murine model depending on genetic background of inbred mice. Experiments 
utilising the established model were undertaken to evaluate differences 
between purchased C57BL/6J and BALB/c mice strains in relation to severity 
of early onset lymphatic remodelling and degree of associated pathology 
related lymphatic insufficiency. BmL3 infected, commercially purchased and 
therefore outsourced, C57BL/6J mice displayed similar levels of aberrant 
lymphatics to the BmL3 infected, bred in-house, Prox-1GFP C57BL/6J mouse 
cohorts previously used. This suggests the reproducibility of observed 
aberrant lymphatics and insufficiency following BmL3 infection, across 
varying sources of CB57/6J mice, ruling out the possibility that the observed 
differences are a result of the genetic manipulation of the in-house colony. 
This assertion was further strengthened by the data demonstrating 
significantly increased aberrant lymphatics, PDE imaged aggregation of dye 
in inoculated hind limb and increased Evan’s Blue dermal retention in BmL3 
infected BALB/c mice compared to sham control BALB/c counterparts, 
suggesting filarial induced lymphatic remodelling and pathological lymphatic 
insufficiency is repeatable across differing genetic mouse strain 
backgrounds. Interestingly, BmL3-infected CB57/6J mice displayed 
significantly higher levels of PDE imaged aberrant lymphatics and increased 
Evan’s Blue dermal retention than BmL3 infected BALB/c counterparts. This 
infers that the C57BL/6J mouse strain develop a more severe filarial 
associated lymphatic pathology phenotype compared to BALB/c counterparts 
following BmL3 infection, as demonstrated by higher levels of lymphatic 
remodelling and insufficiency.  
The strain-dependent difference in filarial lymphatic pathology is suggestive 
that severity of remodelling and insufficiency is significantly influenced by 
host responses to filarial infection. Previous literature advocates quite 
marked phenotypic variation, particularly in relation to host anti-filarial 
immunological responses, between the two mouse strains utilised. Early 
work from Lawrence and colleagues noted a lack of surviving larvae post-
infection on the CB57/6J murine background compared to other inbred 
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strains (Lawrence et al., 1995).  In studies comparing the kinetics of filarial 
clearance between BALB/c and CB57/6J mice, Rajan and colleagues 
described significantly faster clearance of B. malayi filarial infection in 
CB57/6J mice than BALB/c counterparts, owing to the more ‘vigorous’ host 
immunological response in CB57/6J cohorts (Shenoy et al., 1998). Further 
observations from the same group showed differences in susceptibility to 
infection on the two backgrounds, even in adaptive immune deficient SCID 
variants of the strains, suggesting differences in innate immune responses 
also exist between the two strains (Rajan et al., 1999). Work examining 
susceptibility to B. pahangi infection in varying inbred mouse strains 
demonstrated higher parasite recovery in BALB/c mice, compared to B.6 
backgrounds, with authors speculating genetic differences in T-cell 
responses being a key component (Howells et al., 1983). In Litomosoides 
sigmodontis, a rodent filarial parasite used as a laboratory model of human 
filarial parasites, C57BL/6J mice are considered refractory- with the parasite 
unable to establish fecund infection while BALB/c mice are considered 
relatively permissive, establishing fecund infection and release of circulating 
microfilariae in >50% of infections (Graham et al., 2005). The C57BL/6J 
strain becomes susceptible to fecund filarial infection in L. sigmodontis upon 
ablation of IL-4 cytokine responses- a key driver of CD4+ T cell helper 2 
“Th2” adaptive immunity (Le Goff et al., 2002). Further, manipulation of IFN- 
(a prototypic “Th1” cytokine) also renders mice more susceptible to 
experimental L. sigmodontis infection (Gentil, Hoerauf and Pearlman, 2012). 
This indicates both arms of the adaptive immune response are initiated 
following filarial infection leading to a state of non-permissiveness. This may 
also be explained by variation in regulatory adaptive immune responses 
between BALB/c and C57BL/6J strains. For instance, regulatory CD4+ T 
cells “T-regs” are elevated in BALB/c mice following L. sigmodontis infection 
and their specific ablation leads to increased Th2 adaptive immunity and 
control of infection (Taylor JI, 2005). Further, recruitment of ‘regulatory’ 
monocytes/macrophages in BALB/c mice, rather than the  local in situ 
proliferation of resident ‘Th2-activated’ macrophages in C57BL/6J mice are 
hypothesised to influence the degree of immunological resistance to 
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experimental L. sigmodontis infection (Campbell et al., 2018). Taken 
together, there is clear evidence of marked immunological dichotomies that 
consequently shape immunity/susceptibility to filarial parasitic infection 
between the two strains. The significant differences in lymphatic remodelling 
and resultant insufficiency observed between BALB/c and C57BL/6J strains, 
suggests initial host adaptive immune responses may also play a key role in 
dictating severity of lymphatic pathology following larval filarial infection.  
2.5- Concluding remarks 
Despite remodelling of the lymphatic architecture remaining a clear 
“hallmark” of LF infection, its role in pathological development remains 
elusive, primarily due to a lack of adequate animal models that can 
longitudinally interrogate lymphatic remodelling events and possible 
associations with pathology. The successful development of a novel murine 
infection model in this chapter demonstrated that rapid and profound 
changes to the lymphatic architecture occur as early as 6-days post infection, 
and in response to the L3 larval stage of filarial infection. This not only 
contrasts a long-standing pervading theory that lymphatic remodelling is a 
long-term consequence of adult infections, but robust evidence presented 
demonstrates clear early associations between observed lymphatic 
alterations and development of pathological lymphatic insufficiency and 
dysfunction. The consistency in which lymphatic alterations and insufficiency 
was observed suggests, regardless of symptomatic or asymptomatic 
outcome, a degree of “covert pathology” exists in all filarial infected patients. 
In addition, the data presented demonstrates that the severity of this 
pathological remodelling and insufficiency is variable; challenge infections 
significantly worsens filarial lymphatic pathology, while significant differences 
in severity of lymphatic pathology and insufficiency exist between inbred 
murine strains. Together these findings demonstrate differences in host 
genetics and immune responses to BmL3 infections determine, not only 
degree of lymphatic remodelling, but the severity of ensuing pathological 
lymphatic insufficiency. 
Proceeding chapters will utilise the developed tractable limb pathology model 
to investigate the cellular, molecular and immunological drivers of BmL3 
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associated lymphatic pathology. Interrogation of the inducers of lymphatic 
remodelling could ultimately yield novel, promising therapeutic strategies 
aiming to target early lymphatic remodelling events, to attempt to prevent, 
ameliorate, or even reverse future pathological manifestations of LF 
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Chapter 3 
Investigating the molecular mechanisms of filarial 
inflammatory associated lymphatic pathology. 
 
In Chapter two, a development of a novel murine limb infection model was 
established indicating infection with Brugia malayi filarial L3 (BmL3) infective 
stage larvae rapidly induce lymphatic remodelling and lymphatic 
insufficiency. The rapid induction of lymphatic pathology in response to 
BmL3 infection and the molecular mechanisms that mediate it remain poorly 
understood. Utilising the novel murine BmL3 infection model, multiplex 
analysis was undertaken to investigate associations between induction of 
filarial-associated lymphatic pathology and alterations in circulating levels of 
angiogenic/lymphangiogenic molecules. BmL3 infection rapidly induced the 
upregulation of a milieu of lymphangiogenic mediators. Further, specific 
angiogenic/lymphangiogenic molecules: VEGF-C, members of the TGF-β 
superfamily and prolactin were further increased following multiple infections, 
or preferentially elevated in C57BL/6J versus BALB/c mice, coincident with 
increased patterns of pathology. Administration of an adenoviral VEGF-C 
expression vector to locally upregulate VEGF-C was, on its own, sufficient to 
induce significant levels of lymphatic remodelling and pathological 
insufficiency in the hind limb and to levels comparable to BmL3 infection. 
Taken together, these data identify a milieu of lymphangiogenic molecules 
that are important in the mediation of filarial associated lymphatic 
remodelling and insufficiency, providing new insights into the molecular 
mechanisms driving pathology.  Targeted manipulation of these signalling 
pathways to inhibit the induction of lymphatic remodelling and insufficiency, 
following BmL3 infection, may represent a novel therapeutic strategy to 
prevent the onset of future pathological manifestations of lymphatic filariasis.   
98 
 
3.1- Introduction 
 
Clinical studies on lymphatic filariasis (LF) infected patient cohorts have 
identified associations between filarial infection and significant elevation of a 
number of circulating growth factors, known to induce lymphatic remodelling 
including: Vascular Endothelial Growth Factors A, C & D (VEGF-A,C,D), 
soluble VEGF Receptor-3 (VEGFR-3), Fibroblast Growth Factor-2 (FGF-2), 
Angiopoietins 1 and 2 (Ang-1/2) and Placental growth factors (PIGF) (Debrah 
et al., 2006, 2009; A Y Debrah et al., 2007; Bennuru et al., 2010; Babu et al., 
2012). Six-week doxycycline antibiotic treatment is associated with reduced 
elevated serum VEGF-C/VEGFR-3 at a time-point preceding clinical 
improvements in LF pathology (Debrah et al., 2006, 2009). These studies 
identify a potential causal role for increased lymphangiogenic molecules in 
inducing filarial-associated pathological lymphatic remodelling. The direct 
targeting of these factors may represent a therapeutic strategy to ameliorate 
LF related pathology. 
Work to date, however, is based on the premise that filarial-induced 
lymphatic remodelling occurs within a chronic time-frame, primarily as a 
result of adult inhabitation, death and chronic inflammatory events within 
lymphatic vessels (Chakraborty et al., 2013; Nutman, 2013). Clinical studies 
have only investigated growth factor changes following detection of patent 
adult filarial infection, or long after the manifestation of often irreversible 
symptomatic LF pathology (hydrocele / elephantiasis). Chapter two 
demonstrated that rapid onset of lymphatic remodelling, concurrent with 
pathological lymphatic dysfunction, is manifest following infection with the 
infective L3 larval stage of Brugia malayi (BmL3). Similarly, lymphatic 
alterations and lymphatic insufficiency are manifest in LF-infected children 
some of whom are ‘asymptomatic’ at the level of clinical presentation of 
lymphoedema (LE) (Kar et al., 2017). The prevention, or reversal, of this 
early ‘seeding’ lymphatic remodelling could present a novel therapeutic 
strategy to potentially block development of later pathological manifestations 
of lymphatic filariasis (LF). A knowledge gap, therefore, exists in defining the 
molecular signalling events that drives the induction and maintenance of 
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filarial inflammatory-associated lymphatic pathology following initial larval-
stage infections.  
The overarching aim of the research detailed within this chapter was to utilise 
the developed filarial lymphatic pathology model (defined in chapter two) to 
evaluate potential molecular mechanisms driving induction of filarial-
associated lymphatic pathology. Specific objectives were: 
• To identify circulating lymphangiogenic molecules that are altered 
following induction of early filarial-associated lymphatic pathology. 
• To evaluate whether differences in filarial-associated pathology 
apparent between mouse genetic backgrounds, or following larval re-
infections, are associated with magnitude of circulating 
lymphangiogenic molecules. 
• To experimentally reduce or enhance identified specific-
lymphangiogenic molecules to evaluate their effect on filarial-
associated lymphatic remodelling and pathology.  
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3.2- Methods 
 
3.2.1-Murine hind-limb infection model and associated pathological readouts 
 
The murine experimental model of filarial-induced lymphatic was utilised 
throughout this chapter, methods can be accessed from chapter 2.2.1-2.2.7  
3.2.2-Cardiac blood sampling and harvesting of plasma 
 
14 days post infection (or other time points as specified) in the previously 
described pathology model, mice were sacrificed utilising Schedule 1 method 
of rising CO2 overdose. Blood withdrawal was undertaken immediately 
following confirmation of cessation of life, using standard cardiac puncture 
techniques, into heparinised anti-coagulent collection tubes (Starstedt, 
Germany) and placed on ice until centrifugation. 
Collected blood was centrifuged at 2000rpm for 10 minutes, the serum above 
pelleted blood cells was then harvested into clean 1ml Eppendorf tubes 
(Sigma, Dorset) and stored at -80ºC for later multiplex analysis. 
3.2.3-Multiplex Analysis of circulating angiogenic/lymphangioenic molecules 
 
Harvested plasma was thawed slowly and kept on ice throughout. A 
multiplex immunoassay for 25 growth factor analytes (MILLIPLEX MAP 
Mouse Angiogenesis/Growth Factor Magnetic Bead Panel, Merck, Germany) 
was undertaken following manufacturer’s protocol.  
The prepared multiplex immunoassay was read on a Bioplex 200 suspension 
array system (Biorad, Watfrod, UK). Data was analysed in real time using 
Luminex XPONENT software (Luminexcorp, Netherlands). Analyte 
concentrations were either reported as a fold change from the mean serum 
concentration of relevant sham control groups or analyte concentration levels 
depending on experiment.  
3.2.4- Analysis of TGF-β and BMP-9/10 by Enzyme Linked Immunosorbent 
Assay (ELISA) 
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Thawed plasma was either analysed directly (BMP-9/10) or first activated 
(TFG-β) by addition of 1M Hydrochloric Acid (HCL) (Sigma, Dorset) for 5 
minutes immediately followed by addition of 1.2M Sodium Hydroxide 
(NaOH)/0.5M (Sigma, Dorset). Circulating concentrations of TGF-β and 
BMP-9/10 were analysed by utilising relevant Duo-set ELISAs (RnD 
systems, Abingdon) as per manufacturer’s instructions. 
3.2.5-VEGF-C Adenoviral infection experiments 
 
Adenoviral vectors (ad) encoding full length VEGF-C (adVEGF-C) or full 
length GFP (adGFP) were constructed by Vector Development Lab, Texas. 
adVEGF-C and adGFP were reconstituted in Dulbecco’s Phosphate Buffered 
saline (dPBS) (Sigma, Dorset) and further diluted when required to create 
final viral dosages of 5x1010 , 5x109 or 1x108 viral particles/injection. 
C57BL/6J mouse cohorts were administered bi-daily viral doses or sham 
control (dPBS (Sigma, Dorset) of an equal volume utilised in adenoviral 
injections), subcutaneously into the left hind limb as previously described 
(Chapter 2). 6 days after initial injection, mice underwent PDE intravital 
imaging as previously described (chapter 2), followed by an Evan’s Blue 
dermal retention assay (described in chapter 2). 
3.2.6-Sunitinib intervention experiments 
 
Sunitinib malate (Selleckchem, Munich) was reconstituted in a liquid 
suspension of: 0.5%Carboxy-MethylCellulose (CMC; Sigma, Dorset), 0.4% 
Benzyl Alcohol (Sigma, Dorset), 0.5% Tween80 (Sigma, Dorset), 0.5% 
Sodium Chloride (NaCl; Sigma, Dorset) in double distilled water (ddH2O). 
C57BL/6J mice were placed into sham control, BmL3 infected + Sunitinib 
and BmL3 infected + Vehicle control groups followed by SC injection of 100 
BmL3 larvae or sham RPMI into the left hind limb of relevant groups as 
previously described in chapter 2.  
On the same day as BmL3/sham infection, Sunitinib malate at 40mg/kg, or 
0.5% CMC, 0.4% Benzyl Alcohol, 0.5% Tween80 0.5% NaCl only vehicle 
control was  administered by oral gavage to relevant mice and continued 
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daily for the length of the experiment. 14 days following infection, all mouse 
groups were PDE imaged as described in chapter 2, followed by Schedule 1 
for lymph node harvest and other experimental end point readouts as 
detailed in chapter 2. A schematic of the experiment plan can be seen in 
Figure 3.5A.  
3.2.7-VEGFR-3-Fc and ALK-1-Fc chimera intervention experiments 
 
Recombinant Mouse VEGFR-3/Flt-4-Fc chimera (RnD systems, Abingdon, 
Cat #:743-R3-100) and Recombinant Mouse ALK-1-Fc chimera (RnD 
systems, Abingdon, Cat #:770-MA-100) were resuspended in sterile dPBS 
(Sigma, Dorset). C57BL/6J mice were randomised into sham control, BmL3 
infected + vehicle control (dPBS), BmL3 + VEGFR-3-Fc chimera and BmL3 + 
ALK-1-Fc follow by relevant SC injection with 100 BmL3 larvae, or sham 
RPMI into the left hind limb as previously described in chapter 2.  
On the same day as infection, 65µg of VEGFR-3-Fc chimera or ALK-1-Fc 
chimera, or equal volumes of dPBS only were injected to relevant groups 
subcutaneously using the same injection sites utilised for BmL3 infection (as 
previously described in Chapter 2). Injections were continued bi-daily for the 
length of the experiment. 6 days post infection, all mouse groups were PDE 
imaged followed by undertaking of an Evan’s Blue dermal retention assay as 
previously described in chapter 2. Cardiac blood sampling was also 
undertaken for analysis of circulating serum sALK-1 and VEGF-C levels. A 
schematic of the experiment plan can be seen in Figure 3.6A 
3.2.8-Statistical Analysis 
 
All continuous data was tested for normal distribution using the 
Kolgmoronov-Smirnoff test for equal variance. Where data was normally 
distributed, a two-tailed independent Student’s t-test was used to test for 
significant differences between two groups. Were data was found to be not 
normally distributed, a log transformation was first performed and normality 
retested. Data that remained not normally distributed following log 
transformation underwent non-parametric Mann-Whitney U tests to test for 
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significant differences between two groups. Where more than 2 groups were 
being compared, a One-way ANOVA was utilised with a Tukey’s post-hoc 
comparisons test to measure differences in parametric data, while a Kruskal-
Wallis test was used for non-parametric data with Dunn’s post-hoc multiple 
comparisons test. The mean along with the standard error of the mean 
(SEM) are reported in all data unless otherwise stated. Significance is 
indicated as *=P<0.05, **=0.01, ***=0.001 in all figures unless stated 
otherwise. 
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3.3- Results 
 
3.3.1- BmL3 infection is associated with rapid upregulation of multiple 
circulating lymphangiogenic molecules 
 
Fourteen days following infection, BmL3 infected cohorts displayed 
significant increases in circulating : VEGF-C (2.5±1.3-4.4 median fold-
increase±IQR, P<0.001), sALK-1 (1.5±0.9-2.9, P<0.05), Prolactin (1.6±0.8-
3.2, P<0.05), Follistatin (1.3±0.9-2.4, P<0.05), Angiopoietin-2 (1.2 ±1-1.6, 
P<0.05) and TNF-α (1.4±1.1-2.1, P<0.05) compared to sham controls (Figure 
3.1A&B). Additionally, BmL3 infected cohorts displayed significantly 
decreased circulating endoglin (Figure 3.1A-B; 0.83±0.50-0.96, P<0.05). 
3.3.2- Sequential BmL3 re-infection results in further upregulation of 
circulating lymphangiogenic molecules compared to primary BmL3 infection 
 
Fourteen days following final inoculation of primary infected (BmL3x1) or re-
infected (BmL3x2) mice, circulating levels of sALK-1 (5.5±2.6-15 vs 1.5±0.9-
1.3 , P<0.05), prolactin (6.3±3.1-9.3 vs 1.6±0.83-3.2, P<0.05) and HGF 
(2.2±1.9-7.3 vs 0.7±0.4-, P<0.01) were significantly upregulated in BmL3x2 
versus BmL3x1 infection groups, normalised to infection controls (Figure 
3.2B&C). In addition, BmL3x2 infected mice had significantly decreased 
levels of CXCL3 (0.48±0.3-0.6 vs 1±0.7-1.6, P<0.05). Circulating levels of: 
sALK-1 (6.3±3.1-9.3, P<0.01) and HGF (2.2±1.9-7.3, P<0.01) were all 
significantly increased from sham infection control mice (Figure 3.2B&C). 
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Figure 3.1- BmL3 infection results in significant upregulation of 
multiple circulating lymphangiogenic molecules. 
A) Heatmap displaying mean fold-change of circulating growth factors 14 dpi 
with 100 BmL3 in C57BL/6J mice compared with sham infection controls. 
Red indicates increases while blue expresses decreases compared to 
controls. B) Individual analytes attaining statistical significance are displayed, 
plotting fold change from mean sham control concentration. Data is pooled 
from 3 individual experiments. Horizontal bars plot median ± interquartile 
range (IQR). Statistical significance is noted as *=P<0.05, ***=P<0.01 
derived from Mann-Whitney tests. 
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3.3.3- Increased filarial lymphatic pathology in C57BL/6J mice, compared to 
BALB/c mice, is associated with variation in circulating lymphangiogenic 
mediators. 
 
To further investigate the role of identified lymphangiogenic molecules in the 
induction of filarial associated lymphatic pathology, C57BL/6J, which 
demonstrate a higher severity of lymphatic pathology (Chapter 2), and 
BALB/c mouse strains were compared. 
BmL3 infected C57BL/6J mice had significantly higher upregulation of: 
VEGF-C (2.5 ±1.3-4.4 vs 0.6±0.5-1.6, P<0.01), sALK-1 (2.4±0.86-2.8.6 vs 
1.3±1-1.7, P<0.05), SDF-1 (1.1±0.8-1.5 vs 0.6±0.4-0.9, P<0.001) and 
Angiopoietin-2 (1.2±1-1.45 vs 0.9±0.7-1.1, P<0.01) compared to BmL3 
infected BALB/c mice (Figure 3.3A&B). In addition, compared to BmL3 
BALB/c mice, BmL3 C57BL/6J mice displayed significantly lower 
downregulation of Endoglin (Figure 3.3A&B; 0.83±0.5-1 vs 1±0.7-1.3, 
P<0.05). 
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Figure 3.2- BmL3 re-infection results in further upregulation of 
circulating lymphangiogenic molecules. 
A) Schematic of experimental plan. B) Heatmap displaying mean fold 
change of circulating mediator level in re-infected (BmL3x2) mice compared 
to primary infected (BmL3x1) mice normalised to sham control mean analyte 
concentration. Red indicates increases while blue indicates decreases 
compared to infection controls C) Individual data of analytes attaining 
statistical significance. Plots are fold-change from mean concentration of 
sham control. Data is pooled from 3 individual experiments (sham and L3x1) 
or a single experiment (L3x2). Horizontal bars represent median value ± 
interquartile range (IQR). Statistical significance is indicated as *=P<0.05, 
**=P<0.01, ***=P<0.001 derived from Kruskal Wallis test followed by Dunn’s 
multiple comparisons test between specified groups. 
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3.3.4- Local upregulation of VEGF-C is sufficient to induce significant levels 
of lymphatic remodelling and pathological lymphatic insufficiency 
 
VEGF-C is a well-defined lymphangiogenic mediator and was one of the 
most consistently systemically upregulated factors examined in C57BL/6J 
mice following larval infection. To investigate impact of localised upregulation 
of VEGF-C in limb lymphatics and lymphoid tissues, varying titres of 
adenovirus particles expressing VEGF-C (adVEGF-C), an adenovirus that 
induces overexpression of VEGF-C upon infection of cells (Enholm et al., 
2001; Lähteenvuo et al., 2011), were inoculated into the left hind limb of 
naive C57BL/6J mice. A schematic of xperiment can be seen in figure 3.4A 
No significant difference was observed in aberrant lymphatics, in any plane 
of view, between mice inoculated with high titre (5x1010) control adenovirus 
expressing GFP  (adGFP) and sham-infection controls (Figure 3.4B&C). 
Compared to adGFP controls, mice inoculated with 5x1010 adVEGF-C had 
significantly increased aberrant lymphatics in dorsal, ventral and left 
viewpoints (dorsal: 299.5±65.1 vs 3.4±3.4 A.U,  p<0.05; ventral: 257.7±46 vs 
48.00±40 A.U., p<0.05; left: 329.1±78.4 vs 29.1±29.1 A.U, p<0.01), 
determined by PDE imaging (Figure 3.4B&C). 5x109  particle adVEGF-C 
mice also displayed significantly higher aberrant lymphatics, compared to 
5x1010 adGFP controls, in dorsal, ventral and left viewpoints (dorsal: 
94.9±24.2 A.U,  p<0.05; Ventral: 264.3±52.7 A.U, p<0.01; Left: 281.7±59.6 
A.U, p<0.01 ). 1x108 adVEGF-C inoculated cohorts displayed significantly 
higher aberrant lymphatics than adGFP inoculated controls viewed ventrally 
(193.4±49.8 A.U, p<0.05). Magnitude of lymphatic remodelling was VEGF-C 
dose-dependent with 5x109  adVEGF-C inoculated mice displaying 
significantly lower aberrant lymphatics than 5x1010  adVEGF-C inoculated 
mice in the dorsal aspect (94.9±24.2 vs 299.5±65.1 A.U, P<0.01), whilst 
1x108 adVEGF-C inoculated mice displayed significantly lower aberrant 
lymphatics compared to 5x109  adVEGF-C inoculated animals in dorsal and 
Left PDE imaged planes of view (dorsal: 11.4±11.4 vs 94.9±24.2 A.U., 
P<0.05; Left: 56.2±26.1 vs 281.7±59.6 A.U, P<0.01) (Figure 3.4C). 
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 Figure 3.3- BmL3 infection is associated with altered circulating levels 
of lymphangiogenic mediators in ‘high pathology’ C57BL/6J versus 
‘low pathology’ BALB/c mouse strains.  
A) Heatmap depicting upregulation/downregulation of circulating 
lymphangiogenic mediators from BALB/c and C57BL/6J mice 2 weeks 
following subcutaneous infection with 100 BmL3. Mean fold-change 
increases (red) and decreases (blue) are shown normalised to sham-infected 
control groups. B)  Individual analytes achieving statistical significance 
plotted as fold-changes from corresponding sham infected controls.  Data is 
pooled from three individual experiments with horizontal bars representing 
the median value ± IQR. Statistical significance is represented as *=P<0.05, 
**=P<0.01, ***=P<0.001 derived from Mann-Whitney tests. 
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Figure 3.4- Local upregulation of VEGF-C alone is sufficient to induce 
significant lymphatic remodelling and associated pathological 
lymphatic dysfunction. 
A) Schematic of experimental plan. C57BL/6J mice (n=3-6) were 
administered bi-daily subcutaneous injections of: 5x1010 viral units of adGFP, 
5x1010, 5x109 or 1x108 viral units of adVEGF-C, or sham-injections. B) 
Representative images from near infrared intravital PDE imaging of the 
dorsal, ventral and left viewpoints, C) quantitation of aberrant lymphatics in 
all groups derived from PDE imaging analysis across the 3 imaged 
viewpoints, D) quantified lymphatic insufficiency measurements taken from 
PDE imaging of the ventral viewpoint, E) Evan’s Blue lower limb retention, as 
measured from Evan’s Blue dermal retention assay and, F) Examples of 
lymphoedematous pathological manifestations (black arrows: injected left 
hind limb, orange arrows: sham injected right hind limb) 6 days post-
inoculation. Data is pooled from 2 individual experiments (B-D) or a single 
experiment (E) from groups of 3 mice. Graph horizontal bars plot mean ± 
SEM and statistical significance represented as: *=P<0.05, **=P<0.01 
derived from a Kruskall Wallis test followed by Dunn’s multiple comparisons 
post-hoc test between specified groups. 
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PDE lymphatic ventral backflow measurements revealed no significant 
difference between adGFP- and sham-inoculated mice (Figure 3.4D). 
Contrastingly, ICG accumulation in injected hindlimbs were significantly 
lower in 5x1010 and 5x109 adVEGF-C groups, compared to 5x1010 adGFP 
controls (Figure 3.4D; 5x1010 adVEGF-C: 0.2±0.04 and 5x109 adVEGF-C: 
0.38±0.08 vs 5x1010 adGFP: 0.94±0.03 R/L ratio, both P<0.001). However, 
5x1010 and 5x109 adVEGF-C inoculations induced significant retention of ICG 
in infected hindlimbs compared to 1x108 adVEGF-C inoculated mice (Figure 
3.4D; 5x1010 adVEGF-C: 0.2±0.04 and 5x109 adVEGF-C: 0.38±0.08 vs 1x108 
adVEGF-C: 0.77±0.07 R/L ratio, P<0.001 and P<0.01, respectively). No 
significant difference was observed in ratio of ICG accumulations in right 
versus left hindlimbs between 1x108 adVEGF-C and 5x1010 adGFP 
inoculated mice. The Evan’s Blue (EB) dermal retention assay revealed no 
significant difference in EB accumulations between sham and 5x1010 adGFP 
groups, while significantly higher OD620 EB retention was observed in 5x109 
adVEGF-C inoculated mice compared to 5x1010 adGFP inoculated controls 
(Figure 3.4E; 0.38±0.11 vs 0.07±0.01 OD620, P<0.05). Significant oedema 
was manifest in the injected left hind limb of mice receiving 5x1010 adVEGF-
C doses, while no physical differences in limb swelling or size could be 
detected at lower adVEGF-C particle titres (Figure 3.4F). 
3.3.5- Sunitinib treatment is insufficient to modify filarial-associated lymphatic 
pathology or circulating VEGF growth factors. 
 
To investigate if inhibition of VEGF signalling would result in significant 
changes to filarial associated lymphatic remodelling and insufficiency, 
Sunitinib, a small molecule receptor tyrosine kinase inhibitor that inhibits 
downstream signalling of all three VEGF receptors (VEGFR1-3) (Roskoski, 
2007), was administered following BmL3 infection (Schematic of experiment 
shown in figure 3.5A). 
At 14dpi, PDE imaging indicated that irrespective of sunitinib treatment, 
BmL3 infected mouse groups had significantly higher aberrant lymphatics in 
dorsal, ventral and left viewpoints compared to sham infected controls 
(Figure 3.5B&C). No significant difference in aberrant lymphatics were 
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observed between L3+Vehicle and L3+Sunitinib treated mice (Figure 
3.5B&C). In addition, L3+Veh and L3+Sun groups displayed higher ICG dye 
retention in the left (infected) limb than sham infection controls (Figure 3.5D; 
0.58±0.11 and 0.54±0.07 vs 0.98±0.07 R/L leg ratio, both P<0.001). No 
significant difference in ICG dye retention in the left limb was observed 
between L3+Veh and L3+Sun groups (Figure 3.5D). In addition, at 14dpi, 
circulating VEGF-C was elevated in both L3+Veh and L3+Sun groups. 
VEGF-A, VEGF-C and VEGF-D in circulation was not modified by sunitinib 
treatment compared to L3+Veh groups (Figure 3.5E). 
3.3.6- In vivo administration of a sVEGFR3-Fc ‘trap’ failed to significantly 
modify  circulating VEGF-C following BmL3 infection.  
 
In an attempt to specifically reduce bioavailable VEGF-C following BmL3 
infection, a Mouse VEGFR3-Fc chimera was administered in the infection 
model followed by imaging of pathological readouts at 6dpi. The VEGFR-3-
Fc chimera is an extracellular domain portion of Mouse VEGF Receptor 3- 
the receptor for the ligand VEGF-C (Lohela et al., 2009)- fused to the Fc 
chain of mouse IgG1, that sequesters VEGF-C, preventing VEGF-C/VEGFR-
3 interactions and thus downstream VEGF-C signalling (Takahashi, 2011). 
At 6dpi, a non significant elevation of circulating VEGF-C was observed in 
BmL3 infected groups, compared to sham controls, while no significant 
difference in VEGF-C serum concentrations were observed between BmL3 
infected and BmL3 + VEGFR3-Fc mouse cohorts (Figure 3.6F). PDE 
imaging demonstrated BmL3 infected cohorts administered: vehicle control 
(BmL3) and BmL3 administered VEGFR3-Fc (BmL3+sVEGFR3-Fc) 
displayed similar significantly increased aberrant lymphatics compared with 
sham infected controls, with no significant differences in aberrant lymphatics 
observed between BmL3 and BmL3+sVEGFR3-Fc cohorts (Figure 3.6B&C). 
BmL3 and BmL3+sVEGFR3-Fc mice also displayed similar limb ICG 
retention (Figure 3.6D). Additionally, the Evan’s blue dermal retention assay 
demonstrated that BmL3 and BmL3+sVEGFR3-Fc mice displayed a similar 
elevated retention of EB dye compared to sham infection controls (Figure 
3.6E) 
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3.3.7- Administration of an ALK-1-Fc ‘trap’ did not significantly impact on 
filarial associated lymphatic remodelling and insufficiency, following BmL3 
infection. 
To investigate if increased concentrations of sALK-1 could affect filarial 
associated pathology following BmL3 infection, a ALK-1-Fc chimera was 
administered to a mouse cohort following BmL3 infection and PDE imaging 
and associated pathological readouts undertaken 6dpi. The ALK-1-Fc 
chimera is the extracellular domain of ALK-1 fused to the Fc chain of mouse 
IgG1 which will sequester ALK-1 ligands: Bone Morphogenic Protein- 9 
(BMP-9), Bone Morphogenic Protein- 10 (BMP-10), and Transforming 
Growth Factor-β (TGF-β), thus reducing receptor ligand interaction and 
inhibiting downstream signalling. 
BmL3 infected mice, administered with ALK-1-Fc (BmL3+sALK-1-Fc), 
displayed significantly higher circulating serum levels of sALK-1 than BmL3 
infected mice alone (Figure 3.6G; 2589 ± 927 vs 105 ± 12 pg/ml, P<0.001). 
While no significant difference was observed in circulating ALK-1 ligands: 
TGF-β and BMP-9 between sALK-1-Fc and vehicle treated infected groups 
(Figure 3.6G). BmL3+sALK-1-Fc treated mice displayed significantly reduced 
circulating BMP-10 compared to vehicle treated infected counterparts (Figure 
3.6G; 50 ± 22 vs 7 ± 3.pg/ml, P<0.05) . PDE imaging demonstrated that both 
BmL3 and BmL3+sALK-1-Fc mice displayed significantly higher aberrant 
lymphatics compared to infection controls, while no significant difference was 
observed between BmL3+sALK-1-Fc and BmL3 or BmL3+sVEGFR3-Fc 
groups (Figure 3.6B&C). Additionally, both BmL3 and BmL3+sALK-1-Fc mice 
displayed higher infected limb ICG retentions compared with infection 
controls, with no significant differences apparent between BmL3 and 
BmL3+sALK-1-Fc groups (Figure 3.6D). Similarly, the Evan’s blue dermal 
retention assay demonstrated that both BmL3 and BmL3+sALK-1-Fc groups 
displayed a similar increased EB dye dermal retention than sham infection 
controls (Figure 3.6E). 
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 Figure 3.5- Sunitinib treatment does not modify filarial associated 
lymphatic pathology or reduce circulating VEGF-A-D. 
A) Schematic representation of experimental plan. B) Representative images 
from near infrared intravital PDE imaging of the dorsal, ventral and left 
viewpoints of relevant treatment groups C) Quantitation of aberrant 
lymphatics in all groups derived from PDE imaging analysis across the 3 
imaged viewpoints D) Quantified lymphatic insufficiency measurement of all 
groups taken from PDE imaging of ventral viewpoint. Data is from a single 
experiment. E) Serum VEGF-A,C and D levels of all groups quantified by 
multiplex analysis and expressed as fold change from sham infection control 
group. Graph horizontal bars are mean±SEM with statistical significance 
represented as: *=P<0.05, **=P<0.01, ***=P<0.001 derived from a one-way 
ANOVA with Tukey’s multiple comparison post-hoc test. 
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Figure 3.6- Administration of VEGFR-3 or ALK-1 –Fc traps do not 
significantly alter filarial lymphatic pathology. 
A) Schematic representation of experimental plan. B) Representative images 
from near infrared intravital PDE imaging of the dorsal, ventral and left 
viewpoints of relevant treatment groups C) Quantitation of aberrant 
lymphatics in all groups derived from PDE imaging analysis across the 3 
imaged viewpoints D) Quantified lymphatic insufficiency measurement of all 
groups taken from PDE imaging of ventral viewpoint E) Quantified dermal 
retention of Evan’s blue following dermal retention assay F) Quantified 
circulating concentrations of VEGF-C following sVEGFR-3-Fc chimera 
treatment. G) Quantified circulating concentrations of sALK-1 and it’s ligands 
following sALK-1-Fc treatment Data is pooled from two individual 
experiments. Horizontal bars are mean±SEM with statistical significance 
represented as: *=P<0.05, **=P<0.01, ***=P<0.001 derived from a one-way 
ANOVA with Tukey’s multiple comparisons post-hoc test. 
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3.4- Discussion 
 
Chapter two demonstrated that BmL3 infection induces rapid lymphatic 
remodelling, resulting in significant pathological lymphatic dysfunction, 
possibly forming the basis for the development of later lymphoedematous 
pathology. Therefore, a key research question investigated here was to 
interrogate the molecular mechanisms that mediate the rapid induction of 
lymphatic remodelling and dysfunction following filarial larval infection. As 
discussed in detail in Chapter 1, the molecular regulation of post-natal 
lymphangiogenesis and lymphatic remodelling is highly complex which, 
despite increasing research interest in the field, remains to be fully 
elucidated. Induction of lymphangiogenesis, and changes to the lymphatic 
architecture, is  highly regulated with dynamic interplay between pro-
lymphangiogenic signals and the downregulation of ‘regulatory’ inhibitory 
signals of lymphangiogenesis (Coso, Bovay and Petrova, 2014). Further, 
induction of lymphangiogenesis appears to be highly context dependent, with 
combinations of several identified lymphangiogenic cues required to induce: 
lymphatic endothelial cell proliferation, lymphatic vessel sprouting and 
lymphatic patterning, occurring to specific stimuli and the surrounding 
microenvironment (Linares and Gisbert, 2010; Tammela and Alitalo, 2010). 
In filariasis, clinical studies have demonstrated that significant changes in 
circulating concentrations of several known lymphangiogenic factors 
between uninfected healthy individuals and filariasis patients presenting with 
forms of lymphoedema or changes to the lymphatic architecture (A Y Debrah 
et al., 2007; Debrah et al., 2009; Bennuru et al., 2010; Anuradha et al., 2012; 
Babu et al., 2012; Jensen et al., 2015). However it is not known whether any 
of these mediators are functionally important in induction or progression of 
filarial LE. 
The novel murine limb pathology model developed in chapter two provides a 
tractable in vivo model to begin to interrogate molecular mediators of 
lymphatic pathology following filarial infection. Longitudinally tracking 
changes of circulating levels of lymphangiogenic molecules after BmL3 
infection, and how these changes correlate with observed lymphatic 
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remodelling and dysfunction enables associative evidence to be ascertained 
between pathology and potential host lymphangiogenic factors that mediate 
them, following early filarial infection.  
Following 14 days post BmL3 infection, utilising a focused protein array of 
known angiogenic/lymphangiogenic growth factors, significant upregulation 
of circulating: Vascular Endothelial Growth Factor-C (VEGF-C), soluble 
Activin Like Kinase 1 (sALK-1), Prolactin, Follistatin, Angiopoietin 2, and 
Tumour Necrosis Factor-α (TNF-α) were observed compared to sham-
infected controls. The significant upregulation of this milieu of factors, 
concurrent with the described lymphatic remodelling, dysfunction and 
pathology in the B. malayi larval lymphatic infection model (chapter 2), 
promotes a role for these molecules in induction of filarial pathology.   
From re-infection experiments, further increases in sALK-1 and prolactin in 
circulation were apparent, concomitant with increased lymphatic remodelling, 
compared to primary infections. The association between higher lymphatic 
remodelling/insufficiency and higher levels of sALK-1 and prolactin may 
suggest a dose-dependent effect in the induction of pathological lymphatic 
remodelling. This strengthens the evidence for the functional importance of 
these molecules in the mediation lymphatic remodelling and insufficiency.  
Comparing circulating levels of lymphangiogenic factors between ‘high 
pathology’ C57BL/6J mice and ‘low pathology’ BALB/c mice post-B. malayi 
L3 infection, weaker upregulation of VEGF-C, sALK-1 and Angiopioetin-2 in 
BALB/c mice was evident. Additionally, a trend toward lower levels of 
prolactin in BALB/c mice was identified (seen in figure 3.3A). Taken together, 
the data further demonstrates a possible concentration-dependent effect of 
these molecules, where increased concentrations result in the induction of 
higher magnitudes of lymphatic remodelling and dysfunction.  
VEGF-C, a member of the VEGF superfamily, is a ligand that when bound to 
its primary receptor, VEGFR-3, induces lymphangiogenesis (Lohela et al., 
2009). In humans, mutations in VEGF-C or VEGFR3 genes results in 
congenital primary lymphoedematous pathologies linked to poorly developed 
lymphatic networks (Evans et al., 2003; Ghalamkarpour et al., 2006; Gordon 
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et al., 2013; Nadarajah et al., 2018), while VEGF-C overexpression in murine 
models demonstrate aberrantly increased lymphatic vessel density and 
lymphatic hyperplasia (Goldman et al., 2005). VEGFR-3 is highly expressed 
on lymphatic endothelial cells (LECs), which upon ligation of VEGF-C 
induces: LEC proliferation (Veikkola et al., 2003), migration (Ochi et al., 
2007) and sprouting from existing lymphatic vessels (Karkkainen et al., 2004; 
Xu et al., 2010), allowing remodelling of the existing lymphatic architecture 
as well as induce the formation of new channels. Further it has been 
demonstrated that endothelial cells upregulate production of VEGF’s in 
response to VEGFR ligation (Lee et al., 2007). There is a well-established 
role for VEGF-C in post-natal lymphatic remodelling and lymphangiogenesis, 
as part of homeostatic mechanisms particularly in the context of wound 
healing (Saaristo et al., 2006; Bao et al., 2009; Zhao et al., 2014) and 
inflammatory-associated lymphangiogenesis, as a necessary stage of 
inflammation (Kubo et al., 2002; Kataru et al., 2009) . Importantly, there is 
evidence implicating VEGF-C signalling in pathological lymphangiogenesis 
and remodelling, such as in organ transplant rejections (Hajrasouliha et al., 
2012; Mertlitz et al., 2017), metastasis of tumours (Skobe et al., 2001; Su et 
al., 2007), psoriasis (Kunstfeld et al., 2004; Liew et al., 2012) and rheumatoid 
arthritis (Paavonen et al., 2002; Wauke et al., 2002; Zhang et al., 2007). The 
pleiotropic nature of VEGF-C, therefore may imply that its role in induction of 
lymphatic remodelling and lymphangiogenesis is a double-edged sword, 
where depending on context, it can both ameliorate or contribute to 
pathology (Kim, Kataru and Koh, 2014). 
Studies specific to LF have demonstrated significantly increased serum 
VEGF-C concentrations in both symptomatic and ‘asymptomatic’ LF patients 
(with assumed covert manifestations of aberrant remodelling), compared to 
endemic control group (A Y Debrah et al., 2007; Bennuru et al., 2010). The 
data presented is in concordance with these studies, with significantly 
increased serum VEGF-C observed. Importantly, however, the data suggests 
that significantly increased VEGF-C secretion occurs rapidly, and in 
response to much the earlier life cycle stage BmL3 larval infection. Further, 
VEGF-C upregulation was concurrent with significant levels of lymphatic 
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remodelling and dysfunction, suggestive of a role for VEGF-C in the 
induction of these pathological processes. This data corroborates earlier 
studies demonstrating reversal of lower grade LF related lymphoedema 
following doxycycline administration associated with reversal of elevated 
serum VEGF-C levels (Debrah et al., 2006, 2009; Mand et al., 2012). 
The subcutaneous infection of a VEGF-C overexpressing adenoviral vector 
(adVEGF-C) in identical infection sites utilised for BmL3 infection delivers 
VEGF-C protein secretions (Saaristo et al., 2002) targeted to similar 
anatomical areas exposed to migrating infective BmL3 larvae. In these 
experiments, a maximal dose of a GFP-overexpressing adenoviral vector 
(adGFP) was utilised as a control, accounting for potential lymphatic 
remodelling or insufficiency that may occur due inflammatory host responses 
and possible inflammatory-associated lymphangiogenesis to adenoviral 
infection. However, AdGFP cohorts displayed no significant changes in 
aberrant lymphatics or aberrant retention of ICG dye compared to sham 
inoculations, demonstrating that adenoviral infection alone does not induce 
any measurable lymphatic remodelling or insufficiency. In contrast, adVEGF-
C infected cohorts displayed significantly increased levels of both lymphatic 
remodelling and pathological insufficiency. Further, administration of 
increased concentrations of adVEGF-C viral units resulted in correspondingly 
higher levels of aberrant lymphatics, with most the severe level of remodelled 
lymphatics observed in cohorts administered the maximal 5x1010 PFU dose. 
Therefore, upregulation of local VEGF-C signalling alone can sufficiently 
drive pathological lymphatic remodelling and dysfunction in a dose-
dependent manner. Maximal doses of adVEGF-C administration resulted in 
manifestation of overt lymphoedema in the infected limb at the early 6 day 
time point, while ‘mid’ doses recapitulated levels of lymphatic remodelling 
and insufficiency similar to that observed in filarial infected mice at the same 
time point. In contrast to this data, previous research has demonstrated 
VEGF-C administration ameliorates, and even reverses, lymphoedematous 
pathology in an acquired lymphoedema murine tail model (Chavez-Rueda et 
al., 2005; Jin da et al., 2009) as well as in a pig lymph node excision LE 
model (Lähteenvuo et al., 2011). A contrasting study, however, 
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demonstrated worsening of lymphoedema following VEGF-C administration 
in the same tail lymphoedema model (Gousopoulos et al., 2017), better 
aligning with the data described. Notably, the exogenous administration of 
VEGF-C in the aforementioned studies was preceded by an injury event 
resulting in disruption to the lymphatic network which results in lymphatic 
insufficiency and eventual development of lymphoedema. This differs 
substantially to administration of VEGF-C to un-manipulated ‘healthy 
lymphatics’. The dichotomy in therapeutic outcome could therefore be 
explained by the ‘type’ of secondary lymphoedema in which administration of 
VEGF-C is delivered. In a situation where augmented lymphangiogenesis 
would be desirable, to ‘reconnect’ or ‘repair’ the existing lymphatic network 
following overt injury, increased VEGF-C levels mediating 
lymphangiogenesis and remodelling would be beneficial. In contrast, 
unregulated, aberrantly increased VEGF-C signalling in healthy subjects- a 
situation more akin to what is encountered following BmL3 infection- ,would 
result in aberrantly increased lymphatic remodelling in the absence of overt 
lymphatic injury, disrupting normal lymphatic homeostasis and driving 
lymphatic insufficiency. Experiments undertaken by Saaristo et al (2002) 
strengthens this concept, reporting pathological changes to blood 
vasculature following adenoviral administration of VEGF-C to healthy mouse 
subjects. 
With local upregulation of VEGF-C signalling alone demonstrated to induce 
remodelling and pathological insufficiency, it was hypothesised that 
perturbing VEGF-C and/or its downstream signalling cascade during early 
BmL3 infection may be a valid therapeutic target to inhibit filarial associated 
lymphatic remodelling, therefore ameliorating development of pathology. 
Studies in oncology have previously assessed a strategy involving the 
blockade of VEGF signalling. Such blockade has shown to be highly effective 
in reducing both blood and lymphatic vascularisation of tumours as well as 
inhibiting metastasis (Ellis and Hicklin, 2008). The result is the clinical 
development of several classes of biological and small molecule drugs as 
anti-cancer therapies indicated for a diverse range of tumours from renal 
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cancers to neuroblastomas (Ferrara, Hillan and Novotny, 2005; Cardones 
and Banez, 2006). 
The startling success of these ‘anti-angiogenic and anti-lymphangiogenic’ 
drugs provides a rationale for the use of these drugs to block VEGF-C 
signalling, therefore inhibiting lymphatic remodelling and insufficiency 
following filarial infection. Sunitinib, a receptor tyrosine kinase (rtki) inhibitor 
is a small molecule that has shown efficacy as a pan-VEGF inhibitor (Chow 
and Eckhardt, 2007). This is achieved by inhibiting downstream signalling of 
all three VEGF receptors thus blocking VEGF signalling which mediates 
angiogenesis and lymphangiogenesis (Roskoski, 2007; Takahashi, 2011). 
With VEGF-C known to be the main ligand for VEGFR-3, effective sunitinib 
treatment would inhibit downstream VEGF-C signalling, which would be 
hypothesised to inhibit filarial associated lymphatic remodelling. A number of 
monoclonal antibodies, designed to block ligation of the VEGF ligands to the 
appropriate VEGFR receptor have also reached the clinic; bevacizumab, a 
monoclonal antibody against VEGF-A has shown success in blocking tumour 
vascularisation (Ferrara, Hillan and Novotny, 2005). A strategy to sequester 
the released pool of VEGF molecules, resulting in vastly decreased VEGF 
signalling, has been successful. Aflibercept was created by ligating the 
extracellular binding domain of VEGF receptors 1 and 2 to the Fc region of 
human IgG1 (Byrne et al., 2013), this results in a decoy receptor that binds 
any released VEGF-A, and to a lesser extent C, preventing signalling with 
functional VEGFR1-2 receptors resulting in the inhibition of angiogenesis and 
lymphangiogenesis (Takahashi, 2011). More specific targeting of VEGF-C in 
anti-lymphangiogenic therapies has been achieved by a similar sequestration 
strategy, involving the fusing of VEGFR-3 (the main receptor for VEGF-C) to 
an Fc region (Wang, Zhang and Groopman, 2004; Emami-Naeini et al., 
2014). 
Both Sunitinib and a VEGFR-3 -Fc chimera were utilised as a potential 
therapeutic intervention to prevent filarial lymphatic pathology in the 
developed BmL3 pathology model. Disappointingly, neither administration of 
Sunitinib or the VEGFR-3-Fc chimera had any significant effect on the 
severity of lymphatic remodelling or pathological insufficiency following BmL3 
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infection, when compared to BmL3 infected vehicle controls. Further, 
surprisingly, neither intervention disrupted the circulating levels of the target 
VEGF-C molecule. It is therefore likely that both Sunitinib and VEGFR-3-Fc 
chimera treatments failed to adequately block, or alter VEGF-C signalling in 
the experimental model, therefore making inferences from the data 
unreliable. Future experiments to confirm, or validate, that inhibitor reagents 
used bind to their relevant ligands, or mediate their relevant biological effect 
may help to determine the failure of both these intervention experiments 
While efficacy of sunitinib to block VEGF mediated LEC proliferation was 
validated in vitro (data not shown, undertaken by colleagues), the expense of 
the VEGFR3-Fc chimera resulted in only sufficient amounts for the in vivo 
experiments could be purchased, resulting in a lack of validation in vitro. 
Nevertheless, relatively high dosages of both were utilised in the study, and 
in line with dosages utilised in previous studies that demonstrate in vivo 
efficacy (O’Farrell et al., 2003; Benedito et al., 2012). Further work to 
optimise, and then validate, a treatment concentration and administration 
regime that demonstrates efficacy in blocking VEGF-C signalling in the 
model will be required before results from any experimental repeat prove 
reliable. Use of the adVEGFC in vivo lymphoedema model should assist in 
assessing effective VEGF-C-based antiangiogenic treatment approaches. 
Alternatively, a strategy utilising mouse strains with conditional knockout of 
VEGF-C (VEGF-Cflox/flox -(Aspelund et al., 2014) or VEGFR-3 (VEGFR-3flox/flox 
- (Haiko et al., 2008) ) signalling may prove a better strategy to better control 
of VEGF-C signalling following BmL3 infection, thus providing proof of 
concept that VEGF-C blockade could significantly lower filarial associated 
lymphatic remodelling and pathology. 
ALK-1 is a member of the Transforming Growth Factor-β (TGF-β) receptor 
superfamily (Graham and Peng, 2006), with conflicting evidence for its role in 
lymphangiogenesis and lymphatic remodelling. Recent studies suggest 
ligation of endothelial cells expressing the receptor ALK-1 with its primary 
ligand, Bone Morphogenic Protein-9 (BMP-9) results in signalling that inhibits 
lymphatic vessel formation, LEC proliferation and reduction of Prox-1 
expression- the major transcription factor of lymphatic endothelial cell lineage 
129 
 
(Yoshimatsu et al., 2013.). Conversely, BMP-9/ALK-1 signalling has been 
shown to be important for normal lymphatic vessel patterning and function.  
BMP-9 knockout mice demonstrate marked lymphatic drainage insufficiency, 
due to aberrant lymphatic vessel patterning and loss of lymphatic vessel 
maturation, with visible valvular defects (Levet et al., 2013). BMP-9/ALK-1 
signalling has also been demonstrated to be important for early postnatal 
lymphatic patterning, with interruption of ALK-1 signalling, utilising an ALK-1 
Fc chimera that binds ALK-1 ligands and prevents downstream signalling, 
resulting in abnormalities in the lymphatic architecture of the retina and tail 
(Niessen et al., 2010). Finally, it has been proposed that LEC ALK-1 receptor 
ligation with TGF-β itself may be required for sprouting lymphangiogenesis 
and functional dermal lymphatic patterning, both of which are severely 
disrupted following TGF-β blockade (James, Nalbandian and Mukouyama, 
2013). Contrasting studies, however, have demonstrated that TGF-β 
signalling inhibits LEC proliferation and results in loss of lymphatic 
endothelial cell identity (Kasten et al., 2009). Upregulation of circulating 
soluble ALK-1 (sALK-1) co-incident with induction of filarial lymphatic 
pathology may suggest a functional role of this soluble receptor in filarial-
induced lymphatic remodelling, yet further work is required to understand the 
relevance of this circulating soluble version of ALK-1. Most research to date 
focuses on the membrane bound receptor form of ALK-1 and resultantly, the 
biological role for sALK-1 remains poorly understood. As has been shown 
with various soluble version of receptors, such as sVEGFR3 (Singh et al., 
2013; Emami-Naeini et al., 2014), sALK-1 may act as a decoy receptor, 
reducing downstream ALK-1 signalling by binding to, and thus sequestering 
circulating ligands (such as BMP-9/BMP-10 and TGF-β) which have 
demonstrable roles in the induction of lymphangiogenesis. Alternatively, the 
increased levels of circulating sALK-1 may reflect an upregulation of 
membrane-bound ALK-1 expression, following engagement with ALK ligands 
and ALK-1 signalling. The contrasting role of ALK-1 in lymphangiogenesis 
described in the literature may suggest a temporal aspect for ALK-1 
signalling, were the regulated timing and strength of ALK-1 signalling, at 
varying stages of lymphangiogenesis dictate the development of functional 
lymphatic channels.  
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Similar to VEGF-C blockade, ALK-1 inhibitors are currently the focus of 
clinical trials as a novel anti-angiogenic/lymphangiogenic therapy for cancer 
(Jimeno et al., 2016; Burger et al., 2018).  The ALK-1 trap, comparable to 
VEGFR-Fc chimeras, aims to sequester ALK-1 ligands; BMP-9 and BMP-10 
which are strong stimulators for both angiogenesis and lymphangiogenesis 
(Niessen et al., 2010; Levet et al., 2013). This served as a rationale for 
administration of an ALK-1-Fc chimera as an intervention in the established 
infection model. ALK-1-Fc chimera administration to BmL3 infected mice 
resulted in further significantly increased levels of circulating serum sALK-1, 
compared to BmL3 infected mice alone. Due to associations between 
increased sALK-1 level and higher magnitudes of lymphatic remodelling and 
insufficiency, it was hypothesised that sALK-1-Fc administration may result in 
enhanced severity of observed lymphatic remodelling and insufficiency. 
Despite the successful delivery of the chimera following infection, no 
significant effect on filarial associated lymphatic remodelling, or insufficiency 
was observed compared to BmL3 infected + vehicle treated mice. The 
associated costs of the ALK-1-Fc chimera, similar to the VEGFR-3-Fc 
chimera, resulted in purchasing of only a limited quantity, sufficient for a 
single in vivo experiment only. As a result, the lack of validation of the 
purchased ALK-1Fc to bind to its targets means a failure of the reagent 
cannot be discounted, with further in vitro experiments to prove binding 
activity to ALK-1 ligands: BMP-9, BMP-10 and TGF-β advisable. 
Nevertheless, comparable doses to those utilised in previous in vivo studies 
with success were utilised (Mitchell et al., 2010; Ricard et al., 2012). While 
circulating TGF-β levels were not significantly altered in this study, it is 
postulated that the increased sALK-1 concentrations following infection may 
act to sequester an increased systemic release of its secondary ligand, TGF-
β. With TGF-β demonstrated to act as a significant inhibitor of 
lymphangiogenesis (Kasten et al., 2009), increased sALK-1 may remove the 
‘inhibitory breaks’ of lymphangiogenesis, enabling lymphatic remodelling to 
occur. This may, however be dose-dependant and while the two-fold 
increase observed following infection may be optimal to remove TGF-β 
mediated inhibition, the ten-fold increase observed following sALK-1-Fc 
administration may, in addition to TGF-β sequestration, also strongly 
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sequester lymphangiogenic ligands BMP-9 and BMP-10. The resultant 
removal of not only inhibitory signals, but also stimulatory ligands could result 
in no net change to remodelling, as was observed. Possible evidence of this 
is demonstrated by the significantly lower circulating BMP-10 and a non-
significant trend suggesting lower BMP-9 in sALK-1-Fc treated infected 
animals compared to vehicle treated infected counterparts. With circulating 
lymphangiogenic BMP-10 demonstrating a non-significant trend suggesting 
increased levels following BmL3 infection, and the administered trap 
successful in significantly lowering circulating BMP-10..Alternatively, as the 
sAlk-1-Fc administration failed to effect filarial lymphatic pathology, this may 
be evidence of redundancy of BMP9/10 lymphangiogenic signalling 
pathways in induction of filarial associated lymphatic remodelling pathology. 
Conversely, it is possible the high BmL3 numbers used in the inoculations 
provided too strong a stimulus for lymphatic remodelling and pathology (with 
resultant strong upregulation of the milieu lymphangiogenic signals 
discussed in this chapter) to be overcome by blockade of one pathway alone. 
Further intervention experiments utilising lower BmL3 inoculations, or using 
the “low pathology” BALB/c background instead of the “high pathology” 
C57BL/6J strain used in these experiments may result in significantly altered 
filarial lymphatic pathology following treatment. Further, the failure to affect 
filarial associated lymphatic pathology with an intervention targeting a single 
lymphangiogenic pathway suggests a combinatorial approach, with therapies 
designed to inhibit several of the identified lymphangiogenic pathways may 
be more effective in reducing lymphatic pathology following BmL3 infection. 
A potential more effective and achievable therapeutic approach might be to 
target the upstream inflammatory processes driving secretions of pro-
lymphangiogenic factors (discussed in chapters 4 & 5). 
While little research has been undertaken to investigate the role of prolactin 
in lymphangiogenesis, a role for prolactin on the induction of angiogenesis 
has been demonstrated. Genetic deletion of the prolactin receptor in mice 
resulted in vascular defects and lack of normal angiogenesis of the corpus 
luteum (Grosdemouge et al., 2003), while over expression of prolactin, 
utilising intramuscular injection of prolactin cDNA fused with a 
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cytomegalovirus promoter, resulted in significant vascular development in the 
testes of mice (Ko, Ahn and Cho, 2003). Prolactin injection in an in vivo chick 
chorioallantoic membrane resulted in markedly higher lymphangiogenesis 
and endothelial cell migration, which was prevented with addition of a 
prolactin inhibitor (Reuwer et al., 2012). Importantly, prolactin has been 
shown to indirectly induce angiogenesis by stimulating the release of growth 
factors such as VEGF-A (observed to be upregulated following BmL3 
infection, albeit not with statistical significance) on a multitude of cells 
including the epithelium and macrophages (Malaguarnera et al., 2004). With 
VEGF ligands often showing affinity for multiple VEGFR receptors, it is 
possible prolactin indirectly stimulates lymphangiogenesis through a 
prolactin/VEGF/VEGFR3 signalling pathway, contributing to BmL3 induced 
lymphatic remodelling. Additionally, VEGF-A has been demonstrated to 
indirectly induce lymphangiogenesis in the cornea through chemotactic 
recruitment of macrophages that appear necessary for corneal lymphatic 
remodelling (Cursiefen et al., 2004). Prolactin stimulated release of VEGF-A 
may be important for recruitment of cellular drivers of lymphatic remodelling, 
while prolactin may be necessary itself to correctly programme monocytes 
and macrophages into phenotypes of lymphangiogenic potential 
(Malaguarnera et al., 2004). It is clear, however, that the role of prolactin in 
filarial lymphatic pathology needs further investigation, as proteolytically 
cleaved 16K fragments of prolactin have demonstrated potent anti-
lymphangiogenic potential in vitro and in vivo (Kinet et al., 2011). 
Additionally, prolactin has been implicated in regulation of immune 
responses, promoting the survival of T-cells (Carreño et al., 2005) and 
differentially modulating CD4+ T-cell responses depending on concentration 
(Chavez-Rueda et al., 2005; Legorreta-Haquet et al., 2012). It is therefore 
possible that observed upregulation of prolactin is a consequence of a role in 
the immune response to early filarial infection, rather than mediation of 
lymphatic remodelling, with further work required to delineate the two.  
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3.5- Chapter concluding remarks 
 
With prior studies demonstrating a causal link between increased 
lymphangiogenic mediators and filarial associated lymphatic remodelling, a 
key objective within this chapter was to better elucidate the driving molecular 
mechanisms involved in mediating lymphangiogenesis and lymphatic 
remodelling, observed to rapidly occur following filarial larval infection. The 
developed model in chapter two provided a tractable system to longitudinally 
track changes to the lymphatic architecture following filarial infection, thus 
allowing investigation of whether the observed rapid induction of lymphatic 
remodelling and dysfunction was associated with significant alterations to 
circulating lymphangiogenic molecules. The data described in the chapter 
successfully identified a milieu of lymphangiogenic factors which were 
differentially expressed following BmL3 infection. Further, changes to these 
lymphangiogenic factors were significantly associated with alterations to the 
lymphatic architecture and pathological lymphatic insufficiency. 
VEGF-C, a well characterised inducer of lymphangiogenesis was observed 
to consistently be significantly upregulated, concurrent with the onset of 
lymphatic remodelling and pathology, while experimentally induced local 
upregulation of VEGF-C in absence of BmL3 infection was enough to 
recapitulate similar levels of lymphatic remodelling and pathology observed 
in filarial infected mice. Of interest, a host of less well characterised 
molecules such as prolactin, TGF-β family members (such as sALK-1) and 
Follistatin were all demonstrated to be significantly changed following 
infection, highlighting the complexity of the potential regulating molecular 
mechanisms that mediate filarial associated lymphatic remodelling. While 
targeted manipulation of the two most consistently upregulated molecules, 
VEGF-C and sALK-1, failed to significantly alter remodelling or pathology in 
BmL3 infected cohorts, experimental difficulties encountered does not rule 
these molecules out as functional mediators of filarial associated lymphatic 
pathology and distinct experimental approaches will be required in the future 
to investigate their functional roles.  
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The data together reveals a host of molecules that potentially play a key role 
in mediating filarial associated lymphatic remodelling. Specifically targeting of 
these molecules, to prevent development of lymphatic remodelling and 
associated insufficiency following filarial infection, highlights a potential novel 
therapeutic strategy to stop later pathological manifestations of LF. Further 
work, however, will be required to fully understand the contribution of 
identified molecules in the lymphangiogenic processes that drives the 
observed post-natal lymphatic remodelling. Better knowledge of how the 
identified molecules affect: LEC proliferation, migration as well as lymphatic 
patterning and vessel maturation following filarial infection may yield a more 
focused list of candidate molecules as therapeutic targets. 
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Chapter 4 
Cellular mediators of filarial inflammatory-associated 
lymphatic pathology  
 
Prior work has defined rapid onset of lymphatic remodelling and associated 
lymphatic insufficiency, following B.malayi larval L3 (BmL3) infection (chapter 
2), while upregulation of multiple lymphangiogenic mediators implicated in 
filarial associated lymphatic remodelling were defined in chapter 3. In this 
chapter, the murine B. malayi lymphatic pathology model was utilised to 
interrogate inflammatory cell population dynamics following BmL3 infection, 
while purifications of inflammatory cell populations were undertaken to 
characterise their secretion of lymphangiogenic mediators. BmL3 infection 
resulted in significant expansion of Cd11b+Ly6C+CCR2+ monocytes in skin 
draining Lymph nodes (sdLNs), proximal to infection, which were 
demonstrated to secrete significant concentrations of lymphangiogenic 
molecules associated with the initiation of lymphatic pathology. C57BL/6J 
mice, predisposed to a more extensive filarial-infection associated lymphatic 
pathology, displayed significantly increased expansions of monocyte and 
macrophage populations than ‘low-pathology’ BALB/c mice following BmL3 
inoculations. Subsequently, clodronate and anti-CCR2 ablation experiments 
were undertaken to investigate the impact of monocyte/macrophage lineage 
cells and CCR2+ inflammatory monocytes on development of filarial-
associated lymphatic pathology. Ablation of macrophage and/or CCR2+ 
monocyte populations in proximal lymphatic channels and sdLNs local to 
BmL3 inoculation resulted in significant amelioration of lymphatic dilation and 
insufficiency. Together, the data demonstrates a novel role for recruited 
monocytes and macrophages in contributing to lymphatic pathology. 
Targeting the recruitment or differentiation of these monocyte/macrophage 
populations may yield a novel therapeutic approach to inhibit development of 
filarial associated pathology.    
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4.1- Introduction 
 
Chapter two detailed the development of a novel murine filarial infection 
model which enabled robust interrogation of the early stages of lymphatic 
pathology following filarial larval invasion. The model demonstrated rapid 
onset remodelling of the lymphatic architecture, coinciding with significant 
lymphatic dysfunction, as early as 6 days following filarial infection. Chapter 
three detailed investigations into the molecular mechanisms mediating 
lymphangiogenic events that contribute to filarial infection associated 
lymphatic pathology. This resulted in the characterisation of lymphangiogenic 
mediators and pathways demonstrated to be implicated in the initiation of 
lymphatic remodelling and associated insufficiency following filarial infection. 
With the data suggesting significant increases of a milieu of growth factors, 
hormones and cytokines associated with lymphangiogenesis, a key objective 
in this chapter was to investigate the cellular sources of these molecules.  
Cellular mediators have been identified in other settings of 
lymphangiogenesis resulting in post-natal lymphatic remodelling including: 
‘wound healing’ macrophages (Krzyszczyk et al., 2018), other cells of 
myeloid origin (Zumsteg and Christofori, 2012) and B-cells (Angeli et al., 
2006). Despite this, the cellular mechanisms implicated in filarial infection-
associated lymphatic remodelling remain poorly defined. It is postulated that 
filarial adult excretory/secretory products (E/S products) may include 
molecules with direct angiogenic / lymphangiogenic potential and may 
directly mediate ‘early’ dilation through direct signalling with lymphatic 
endothelial cells (LECs) lining lymphatic vessels (Higazi et al., 2003). 
Additionally, studies have demonstrated the ability of B. malayi parasite 
homogenates to directly activate LECs, thus inducing lymphangiogenesis 
and remodelling (Bennuru and Nutman, 2009a). Conversely, more recent 
studies dispute this finding, showing no evidence for LEC activation with 
excretory secretory products of filarial parasites (Weinkopff and Lammie, 
2011). Instead, data from the same lab argues a crucial role for monocytes, 
where adult B. malayi ES products stimulated primary human monocytes 
(PBMCs) to produce lymphangiogenic mediators in concentrations that 
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stimulated LEC proliferation in vitro (Weinkopff et al., 2014). This would 
perhaps suggest an underappreciated role for host immune cells in being a 
causal driver of lymphatic remodelling following filarial infection, that is 
postulated to increase the risk of lymphatic filariasis (LF) related pathology. 
An evident role for inflammatory immune cells (particularly of leukocyte 
origin) in driving the remodelling of the lymphatic architecture following 
experimental bacterial infection already exists (Kataru et al., 2009). 
Clinical studies enrolling patients suffering with chronic LF can only 
adequately interrogate associations between lymphatic remodelling and 
inflammatory cell recruitment at the point of adult parasitism, long after initial 
filarial L3 larval infection. The developed model (chapter 2), however, clearly 
demonstrates rapid alterations to the lymphatic architecture, in response to 
BmL3 larval invasion to lymphatics proximal to infection site. The early local 
cellular events which may contribute to the observed early lymphatic 
pathology remain uncharacterised. 
In chapter 3, systemic upregulation of a number of pro-lymphangiogenic host 
mediators were demonstrated following inoculation with BmL3. With 
lymphadenopathy apparent in the sdLN proximal to parasitized and 
remodelled lymphatics, host immune cells are a potential major source of 
these growth factors. Investigation into molecular/cellular signalling axes 
driving filarial-infection associated lymphatic pathology could yield novel 
cellular therapeutic targets. 
The objectives of this chapter were to: 
• Investigate early changes to lymphoid and myeloid leukocyte cell 
populations proximal to areas of BmL3 lymphatic infection, utilising the 
established murine experimental pathology model. 
• Compare whether there are differences in the magnitude of lymphoid 
and myeloid leukocyte cell populations post-infection in C57BL/6J 
‘high pathology’ versus BALB/c ‘low pathology’ mouse strains  
• Interrogate if specific leukocyte cell types secrete significant quantities 
of lymphangiogenic molecules implicated in the development of 
pathology 
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• Determine a direct role for specific leukocyte populations in filarial 
lymphatic remodelling, by investigating the ability of filarial-stimulated 
cell populations to mediate proliferation of lymphatic endothelial cells 
(LEC). 
• Investigate if ablations of specific leukocyte cell populations, proximal 
to BmL3 infection, influences the development of filarial infection 
associated lymphatic pathology  
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4.2- Methods 
 
4.2.1-Murine hind-limb infection model and associated pathological readouts 
 
The murine experimental model of filarial-induced lymphatic pathology was 
utilised throughout this chapter, methods can be accessed from chapter 
2.2.1-2.2.7  
4.2.2-Lymphoid/ lymphatic and blood tissue harvest and single cell 
preparation 
 
Following inoculation of 100 BmL3 and at time points varying from 6 days 
post infection (dpi)-14dpi, mice were sacrificed using Sch1 method of rising 
concentration of CO2 followed by confirmation of kill. Inoculated limb skin 
draining lymph nodes (sdLNs) i.e..  popliteal (pLN), iliac (iLN) and sub-iliac 
(siLN) were carefully excised from mice along with their relevant afferent and 
efferent lymphatic channels. A single cell suspension was created by teasing 
apart sdLN’s and channels on top of a 40 m cell sieve (Sigma, Dorset) 
followed by physical maceration of remaining lymph node tissue through the 
sieve, using the handle of sterile, 2ml syringes (Sigma, Dorset). The resultant 
single cell suspension was re-suspended in Dulbecco’s Phosphate Buffered 
Saline (dPBS) (Sigma, Dorset) + 5% Foetal Bovine Serum (FBS) + 2mM 
EDTA and aliquoted into equal cell numbers, ready for proceeding cell 
cytometry or FACs. A measurement of total cellularity was obtained by a 
manual cell count on sdLN single cell suspensions, using a haemocytometer 
in a 1:1 cell sample:2% w/v Trypan Blue (Sigma, Dorset) solution for 
Live/Dead cell differentiation.. 
In experiments were blood immunophenotyping was undertaken, blood 
samples, acquired utilising cardiac puncture at necropsy, was first depleted 
of red blood cells (RBCs), utilising RBC lysis buffer (Biolegend, London) as 
per manufacturer’s protocol. Following depletion, blood samples were 
resuspended in Dulbecco’s Phosphate Buffered Saline (dPBS) (Sigma, 
Dorset) + 5% Foetal Bovine Serum (FBS) + 2mM EDTA and aliquoted into 
equal volumes of 100μl, ready for proceeding cell cytometry. 
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4.2.3-Flow cytometry 
 
Cell suspension samples, prepared as above, were placed on ice throughout 
the proceeding staining steps. Blocking of Fc regions was undertaken by a 
20 minute incubation with rat anti-mouse Cluster of Differentiation(CD)16/32 
CD16/32 Fc-block (eBioscience, Hatfield UK) followed by a subsequent 30 
minute incubation of samples with efluor 450 fixable viability dye 
(eBioscience, Hatfield UK) for live/dead cell differentiation. Subsequent cell 
surface staining was undertaken for 30 minutes using the following rat 
monoclonal antibodies: Ly6G Phycoerythrin(PE) (ebioscience, Hatfield), 
Ly6C PerCyP5.5  (eBioscience, Hatfield), Rat IgG1 Allophycocyanine APC 
Isotype control (eBioscience, Hatfield), Rat IgG1 Fluorescein (FITC) Isotype 
control (eBioscience, Hatfield), CD4 APC (eBioscience, Hatfield), Chemokine 
receptor-2 (CCR2) Phycoerythrin-Cyanine7 (PE-Cy7) or CCR2 AlexaFluor 
700 (AF700) (eBioscience, Hatfield), CD11b AlexaFluor 488 (AF488) or  
CD11b PerCyP5.5  (eBioscience, Hatfield), B220 APC (eBioscience, 
Hatfield), CD3 PE (Biolegend, London), F/480 Brilliant Violet 711 (BV711) 
(Biolegend, UK), MHCII APC (eBioscience, Hatfield), Tim-4 PE-Cy7 
(eBioscience, Hatfield). Surface-antibody labelled cell suspension samples 
were then fixed for 40 minutes using the Forkhead box P3 (FoxP3) 
Fixation/Permeabilisation Kit (eBioscience, Hatfield), followed by immediate 
acquisition undertaken on a Becton Dickinson (BD) LSRII Flow cytometer 
(BD Biosciences, Berkshire, UK). Data was analysed using Flowjo software 
(BD Biosciences, Berkshire, UK). The gating strategy utilised is outlined in 
supplementary figure 4.1 below, while antibody clones are listed in appendix 
1. 
4.2.4-Fluorescent Antibody Cell Sorting (FACS) and subsequent cell 
secretion assays 
 
Following surface staining with specific antibodies, lymphatic/lymphoid cell 
suspensions from individual BmL3 or sham infected mice were cell sorted 
using a Becton Dickinson FACsAria II (BD Biosciences, Berkshire, UK) to 
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≥95% purity into ice cold dPBS (Sigma, Dorset) + 40% FBS Serum + 2mM 
EDTA to maintain maximum cell viability. The gating strategy used to sort 
cells into: Monocytes, B-cells, T-cells, and macrophages is outlined in Figure 
S4.1 below. Following cell sorting, cells were resuspended into RPMI 1640 
(Sigma, Dorset) supplemented with: 10% FBS (Sigma, Dorset), Penicillin / 
Streptomycin at 100 I.U./mL (Sigma, Dorset) and Amphotericin B 2.5mg/L 
(Sigma, Dorset). Purified B and T-cells were plated out at 1x106 cells in 
250µl, while monocytes and macrophages were plated out at 2.5x105 cells in 
100µl into flat-bottom 96 well plates (Starlab, Milton Keynes). Plated purified 
cell populations were incubated at 37ºC, 5% CO2 for 72 hours before plate 
centrifugation and harvesting of cell supernatants. Collected supernatants 
were frozen at -70ºC for future analysis. 
4.2.5-Multiplex Analysis 
 
Concentrations of a panel of angiogenic/lymphangiogenic analytes were 
probed for cell sorted culture supernatants (as described above) using the 
MAGMAP-24k milliplex full panel (Merck Millipore, East Midlands), as per 
manufacturer’s instructions, and analysed using a Bioplex 200 (Biorad, 
Hertfordshire). Analyte expression was normalised to analyte secretion/1x106 
cells after accounting for initial supernatant volume and cell concentrations. 
Data was then plotted by sorted cell population with between 3 and 5 
individual mouse cell sorted sdLN populations used as replicates. 
4.2.6-Cell culture 
 
Primary (adult) Dermal Lymphatic Human Micro-Vascular Endothelial Cells 
(HMVECdLy: LECs) were purchased from Lonza (Slough, UK) and were 
maintained and passaged in fully supplemented Endothelial Growth Medium-
2 Bullet kit (EGM-2)(Lonza, Slough UK). THP-1 monocytes were a kind gift 
from Professor Giancarlo Biagini (LSTM, UK) and passaged using Roswell 
Park Memorial Institute (RPMI) 1640 (Sigma, Dorset) supplemented with: 
10% FBS (Sigma, Dorset), Penicillin / Streptomycin 100 I.U./mL (Sigma, 
Dorset) and Amphotericin B 2.5mg/L (Sigma, Dorset)All cells were 
maintained at 37ºC, 5% CO2. 
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4.2.7-Production of Brugia malayi L3 larval extract (BmL3E) 
 
Batches of between 1000 and 2000 Brugia malayi L3 larval were washed 3 
times in dPBS (Sigma,Dorset) before re-suspension in between 200µl-500µl 
E-toxate ultra-pure water (Sigma,Dorset). Resuspended larvae were left in 
constant motion using a tube roller at 4 ºC overnight. The following day, 
samples were sonicated (using a Vibracell sonicator (Jencons)) for 5 
minutes, and repeated for 3 sonication  cycles to ensure full lysis of larvae 
and extraction of water-soluble macromolecules. BmL3E protein 
concentrations were quantified using a BCA assay (ThermoFisher, UK), as 
per manufacturer’s protocol, before being frozen at -20ºC until utilised in 
assays. 
4.2.8-Macrophage/ LEC co-culture survival/proliferation assay 
 
Thp-1 monocytes were plated into the cell inset of 6 well trans-well plates 
(Sigma, Dorset) at 1x106 cells/well and differentiated into adherent “M0” 
macrophages using 10ng/ml PMA (Sigma,Dorset) for 24 hours. Following 
differentiation, macrophage insets were washed in PBS before stimulation 
with either 10µg/ml of BmL3E, 10 live Brugia malayi L3 larvae (L3) or media 
only (M0) for 48 hours. On the intermediate day, LECs were seeded 
separately on the bottom of fresh 6 well trans-well plates at 8x104 cells/well. 
Following 48-hour stimulation, L3/BmL3E/M0-activated macrophage insets 
and LEC adherent layers were washed, before addition of the inserts onto 
the top of LEC wells, creating a LEC/Macrophage co-culture. A 20% EGM-2, 
80% Endothelial basal media (EGM-2 without addition of any growth 
supplements, +0.1% FBS only) mix was used as the culture media. LEC 
wells without macrophage inserts plated in: 80:20 media alone or full EGM-2 
were used as negative (negligible growth) and positive (maximal growth) 
controls respectively. All LEC/Macrophage co-culture wells and LEC control 
wells were incubated for 72 hours at 37ºC, 5% CO2. Following incubation, 
macrophage inserts were discarded and LEC cells dissociated from wells 
using 1x Trypsin/EDTA solution (Thermofisher, UK). All LEC samples were 
manually counted using a haemocytometer in a 1:1 cell sample: 2% Trypan 
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Blue (Sigma, Dorset) solution for Live/Dead cell differentiation. A schematic 
summary of the assay can be found in Figure 4.7A 
4.2.9- CCR2 and clodronate liposome monocyte/macrophage depletion 
experiments 
 
Following inoculation of 100 BmL3 into the left hind limb, infected mice were 
administered either: MC-21 rat anti-mouse CCR2 depleting antibody (a well 
characterised depleting antibody (Frade et al., 1997) and a kind gift from 
Professor Matthias Mack) intraperitoneally (i.p,) daily at an amount of 65µg 
per injection, or clodronate liposome suspensions (Liposoma, supplied by 
Professor Nico Van Rooijen, VU University Medical Centre, Netherlands) at a 
concentration of 5mg/ml further diluted 1:2 in dPBS (Sigma, Dorset), 
subcutaneously (s.c.) across the two infection sites (s.c. top of foot, s.c. 
caudal to knee joint) every three days. Both mouse groups, together with 
BmL3 infected only and sham infected groups were treated for 6 days 
followed by intravital PDE imaging and other end-point readouts as 
previously described (2.2.2-2.2.7) 
4.2.10-Statistical Analysis 
 
All continuous data was tested for normal distribution using the 
Kolgmoronov-Smirnoff test for equal variance. Where data was normally 
distributed, a two-tailed independent Student’s T-Test was used to test for 
significant differences between two groups. Where data was found to be not 
normally distributed, a log transformation was first attempted and data re-
tested for equal variance. If data remained non-parametric, a two-tailed 
Mann-Whitney U test was utilised to test for significant differences between 
two groups. Where more than 2 groups were being compared, a One-way 
ANOVA was utilised with a Tukey’s post-hoc comparisons test to measure 
differences in parametric data, while a Kruskal-Wallis test was used for non-
parametric data with Dunn’s post-hoc multiple comparisons test. The mean 
along with the standard error of the mean (SEM) are reported in all data 
unless otherwise stated. Significance is indicated as *=P<0.05, **=0.01, 
***=0.001 in all figures unless stated otherwise. 
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Supplementary Figure S4.1: Gating strategy from flow cytometric 
immunophenotyping for determination of cell populations in sham and 
BmL3 infected sdLNs and proximal lymphatic/lymphoid tissues 
Immune cell populations from sdLN and proximal lymphatic collecting 
channels of BmL3 and Sham infected mice underwent immunophenotyping 
utilising flow cytometry. The gating strategy utilised is displayed with % live 
cell populations shown representative of data acquired. Percentages are 
derived as percentage of total live cells from acquired sample. Percentages 
of individual cell populations were used to derive final cell numbers from 
manual live cell counts of total sdLN suspensions as described in methods. 
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4.3- Results 
 
4.3.1- B. malayi infection induces significant increases in multiple leukocyte 
populations within lymphatic / lymphoid tissues proximal to larval invasion. 
 
To explore a possible role of immune cells in mediating filarial-associated 
lymphatic pathology, the population dynamics of local leukocyte populations 
following BmL3 infection were investigated. sdLN’s (pLN, iLN, siLN) proximal 
to the infection site, along with connecting lymphatic vessels, were harvested 
and flow-cytometric immunophenotyping undertaken on BmL3 and sham 
control mouse cohorts 14 dpi. 
BmL3 infected mice were observed to have significantly increased: CD3+ T 
lymphocytes (1.8±1.9x107 vs 7.1± 0.6x106 cells, P<0.001), B220+ B 
lymphocytes (2.4±0.2x107 vs 2.2±5.1x106 cells, P<0.001), 
Cd11b+MHCII+F4/80+ macrophages (M) (2.8±0.5x106 vs 1.6±0.3x106 cells, 
P<0.05), CD11b+Ly6C+CCR2+ “inflammatory monocytes” (7.7±1.1x104 vs 
2.7±0.4x104 cells P<0.001) and SiglecF+SSChi eosinophils (4.9 ± 1.0x104 vs 
2 ± 0.47x103 cells P<0.001) and CD11b+Ly6G+Ly6G+ neutrophils 
(1.05±0.28x105 vs 2±0.23x104 cells P<0.05)  compared to sham control 
counterparts (Figure 4.1A).  
4.3.2- The contribution of ‘resident’ Tim-4+ M to the overall sdLN M 
compartment is significantly diminished following BmL3 infection. 
 
To investigate if the significant increase of total macrophage populations in 
sdLN and adjoining lymphatic tissue are due to in situ proliferation of resident 
macrophages or derived from recruited monocytes, Tim-4 macrophage 
expression, a marker of macrophage residency (Davies et al., 2011; Shaw et 
al., 2018), was compared. Following 14 day BmL3 infection, the percentage 
of macrophages that were Tim-4+ was significantly reduced, compared to 
sham infected counterparts (Figure 4.1B&C; 40.5 ± 6.2  vs 83.1 ± 2.5 % Tim-
4+ MФ , P<0.01). 
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4.3.3- C57BL/6J mice demonstrate more pronounced expansions of 
CD11b+Ly6C+CCR2+ inflammatory monocytes and Cd11b+MHCII+F/480+ M 
compared to BALB/c mice in lymphatic / lymphoid tissues proximal to B. 
malayi larval invasion  
 
To investigate if the predisposition to increased lymphatic pathology in 
C57BL/6J versus BALB/c mice was associated with differences in the 
quantity or quality of leukocyte increases in lymphatic / lymphoid tissues 
proximal to sites of initial B. malayi larval invasion, flow-cytometric immuno-
phenotyping of infected limb sdLN and lymphatic channels isolated at 14dpi 
were undertaken. 
BmL3-infected C57BL/6J and BALB/c mouse cohorts (C57BL/6J L3, BALB/c 
L3) both displayed significantly increased cellularity within sampled lymphatic 
/ lymphoid tissues compared with respective sham controls (Figure 4.2A; 
C57BL/6J: 5.5±0.6x107 vs 2.2±0.4x107 cells P<0.001, BALB/c: 5.0±0.8x107 
vs 1.5±0.2x107 cells, P<0.001). No significant differences in cellularity 
between BmL3 infected C57BL/6J and BALB/c mouse cohorts were 
observed (Figure 4.2A).  
C57BL/6J BmL3 infected mice demonstrated a significantly higher fold-
change increase (compared to sham controls) of CD11b+Ly6C+CCR2+ 
monocytes compared with BALB/c BmL3 infected animals (Figure 4.2B, 
C57BL/6J: 4.9±0.9 vs BALB/c: 2.2±0.5 fold change, P<0.05). A significantly 
higher fold-change in CD11b+MHCII+F4/80+ macrophages was also 
observed in C57BL/6J mice compared with BALB/c animals following BmL3 
infection (Figure 4.2B; C57BL/6J: 2.9±0.5 vs BALB/c: 1.2±0.4 fold change, 
P<0.05). Comparatively, there were no significant differences in fold-change 
of B220+ B cells or CD3+ T cells between C57BL/6J and BALB/c mouse 
groups following infection (Figure 4.2B). 
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Figure 4.1: Filarial Infection results in significant increases of multiple 
leukocyte populations in lymphatic / lymphoid tissues proximal to 
larval invasion. 
A) Quantification of immune cell populations from sdLN and proximal 
lymphatic collecting channels of BmL3 and Sham infected mice. B) Gating 
strategy utilised to determine Tim-4 expression on macrophages. % Shown 
are representative values and demonstrate percentage of macrophages that 
are Tim-4+ C) Quantified Tim-4+ macrophage expression. Horizontal bars 
represent the mean ±SEM. Data is pooled from 3 (monocytes) individual 
experiments (N=18 mice/group), 2 individual experiments (eosinophils and 
macrophages) (N=3 mice/group) or a single experiment (T-cells, B-cells, 
Neutrophils and Tim-4+ macrophage expression) (N=3-4 mice/group). 
Significance is indicated as **=P<0.01, ***=P<0.001 derived from a student 
two-tailed t-test (T+B-cells, Monocytes and Macrophages or a Mann Whitney 
Test (Eosinophils and Neutrophils). 
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4.3.4- CD11b+Ly6C+CCR2+ monocytes, CD11b+MHCII+F480+ MФ’s and 
CD3+ T-cells are significant sources of lymphangiogenic molecules 
associated with filarial lymphatic pathology. 
 
Localised cellular sources of circulating lymphangiogenic mediators following 
B. malayi infection (defined in chapter 3) were investigated. LN and 
lymphatic vessels, proximal to infection, were dissected from BmL3-infected 
or sham infected mice 14dpi and resultant suspensions were cell-sorted 
using Fluorescent Antibody Cell Sorting (FACS) into: CD11b+Ly6C+CCR2+ 
inflammatory monocytes, CD3+ T lymphocytes, B220+ B lymphocytes and 
CD11b+MHCII+F4/80+ macrophages. The purified immune cell populations 
were subsequently cultured for 72 hours ex vivo followed by Luminex 
analysis on culture supernatants to quantify secretions of a panel of known 
angiogenic/lymphangiogenic molecules. Diagrammatical representation of 
sorting experiments are shown in figure 4.3A 
At 14 dpi, isolated CD11b+Ly6C+CCR2+ monocytes secreted significantly 
higher concentrations of sALK-1 (140.2 IQR:102-182 vs 0 IQR:0-0.75 
pg/ml/106 cells P<0.05), prolactin (376.9 IQR: 221- 403 vs 8.8 IQR: 1.7- 16 
pg/ml/106 cells P<0.05), amphiregulin (35.3 IQR:30-39 vs 0 IQR: 0- 0.75 
pg/ml/106 cells P<0.001), IL-6 (17.2 IQR:6-43 vs 0 IQR- 0-0.75 pg/ml/106 
cells P<0.05) compared to sham-infected unsorted lymphatic / lymphoid cell 
suspensions (Figure 4.3B). Additionally, marginal non-significant increased 
secretions of: CXCL-1 were recorded when comparing CD11b+Ly6C+CCR2+ 
monocyte cultures from infected mice with sham-infected counterparts 
(Figure 4.3B). Purified CD3+ T cells secreted significantly higher: 
amphiregulin (16.8 IQR:14-191.3 vs 0 IQR:0-0.75 pg/ml/106 cells P<0.05), IL-
6 (25.4 IQR:13-53 vs 1.186 IQR:0.1-1.8 pg/ml/106 cells P<0.05), Prolactin 
(102.4 IQR:93-122 vs 17.2 IQR:3-23 pg/ml/106 cells P<0.05), sALK-1 (60.5 
IQR:36-64 vs 4.7 IQR:1-12 pg/ml/106 cells P<0.05) and CXCL-1 (36.3 
IQR:16-70 vs 0 IQR:0-3.7 pg/ml/106 cells P<0.05)  compared with sham-
infected purified CD3+ T-cell suspensions (Figure 4.3B). Purified B220+ B-
cells from infected mice secreted significantly higher: Amphiregulin (11.4 
IQR:7-12 vs 0 IQR:0-0.75 pg/ml/106 cells P<0.05), Prolactin (82.9 IQR:44-
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112 vs 14.4 IQR:7-17 pg/ml/106 cells P<0.05) and IL-6 (20.6 IQR:11-67 vs 0 
IQR:0-0.4 pg/ml/106 cells P<0.05) compared to purified sham infected cell 
counterparts. Finally, CD11b+MHCII+F480+ macrophages from BmL3 infected 
mice secreted significantly higher VEGF-C than sham infected counterparts 
(Figure 4.3B; 264.7 IQR:188-286 vs 154.8 IQR:122-162 pg/ml/106 cells 
P<0.05) 
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Figure 4.2: Local sdLN CD11b+Ly6C+CCR2+ monocytes and F/480+ MФ’s 
demonstrate more pronounced expansions in ‘high pathology’ 
C57BL/6J mice compared with ‘low pathology’  BALB/c mice. 
A) Quantification of inoculated limb sdLN pooled total cellularity (number of 
cells) and B) sdLN individual immune cell populations between 14dpi BALB/c 
and CB57/6J mouse strains inoculated with 100 BmL3. Fold change 
increases from relevant sham infected mouse groups are plotted for 
individual immune cell populations. Horizontal bars represent the mean 
±SEM with data pooled from two individual experiments. Significant 
differences are indicated as *=P<0.05 ***=P<0.001 derived from a One-way 
ANOVA with Tukey’s post-hoc test (B) or student two-tailed t-test (C)  
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Figure 4.3: Macrophages, monocytes and T-cells derived from 
lymphatic / lymphoid tissues proximal to lymphatic pathology are 
significant sources of lymphangiogenic mediators following B. malayi 
infection. 
A) Schematic representing workflow of cell sorted cells from mice inoculated 
with 100 BmL3 or sham control 14dpi B) Quantification of lymphangiogenic 
molecule secretion from purified cell populations (red) compared to relevant 
purified sham infected cell populations (blue). Secretions were normalised to 
secreted concentration of analyte in pg/ml per 1x106 cells ([analyte 
pg/ml]/1x106 cells). Bars represent the median ±Interquartile range, with 
significance indicated as *=P<0.05 **=P<0.01 ***=P<0.001 derived from 
Mann Whitney tests comparing purified infected cell populations to relevant 
purified sham control populations. 
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4.3.5-Depletion of phagocytic or CCR2+ cells significantly ameliorates B. 
malayi infection-associated lymphatic dilation and lymphatic insufficiency. 
 
To test whether local increases in either total phagocytic cells, including 
monocytes and M, or specific increases in CD11b+Ly6C+CCR2+ monocytes 
impacted on the extent of lymphatic remodelling and insufficiency following 
BmL3 infection, CB57/6J or CB57/6J Prox-1GFP mice were either 
administered: subcutaneous clodronate liposomes (CL) at initial inoculation 
site every three days or daily intraperitoneal anti-CCR2 depleting antibody. 
Treated mice were compared with BmL3 infection or sham infection controls. 
CCR2+ monocyte depletion was confirmed by flow cytometric immuno-
phenotyping of circulating blood, or lymphatic / lymphoid cell suspensions. 
Anti-CCR2 (α-CCR2) and CL treated BmL3 infected mice demonstrating a 
significant decrease in % CCR2+ monocytes in blood (Figure 4.4C; 0.51 ± 
0.1 and 1.2 ± 0.4 vs 2.7 ± 0.28 %WBC cells ) compared to BmL3 infected 
counterparts, while a significant decrease of total CCR2+ monocytes in 
lymphoid/lymphatic tissue proximal to BmL3 inoculation site was observed 
post anti-CCR2 antibody treatment (Figure 4.4B; 9.9x103±1940 vs 5.0x104 ± 
4417 CD11b+Ly6C+CCR2+ cells, P<0.05). 
Corroborating data detailed in chapter 2, BmL3-infected mouse cohorts 
displayed significantly increased aberrant lymphatics across dorsal, ventral 
and left limb PDE-imaged viewpoints compared to sham infected controls (all 
P<0.001, Figure 4.5A). Additionally, BmL3 infected mice demonstrated 
significantly higher retention of fluorescence in the infected left foot up to the 
pLN (significantly decreased Right/Left foot ratio) (Representative ICG 
examples 4.5B, P<0.001, Figure 4.5B&C), while significantly higher Evan’s 
Blue was measured in a dermal retention assay compared to sham control 
mouse groups (P<0.05, Figure 4.5D). Finally, via epifluorescence microscopy 
analysis, significantly larger apertures of lymphatic vessels, in areas of 
lymphatic remodelling, were apparent in BmL3 infected mice, compared with 
sham infection controls (Representative images 4.5E, P<0.01, Figure 
4.5E&F).  
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No changes were apparent in aberrant lymphatic patterns, discernible by 
PDE lymphangiography, between mice infected with BmL3 and treated with 
CL or CCR2-depleting antibody and infection controls (Figure 4.5A). Also, 
no significant difference in right leg/left leg ICG fluorescent ratio was 
observed between BmL3 and BmL3+CL mouse groups (Figure 4.5C), 
however, significantly less Evan’s Blue accumulation was apparent in 
BmL3+CL mice compared to BmL3 infection controls (Figure 4.5D; 0.1±0.04 
vs 0.3± 0.05, OD620, P<0.05). BmL3+CCR2 mouse cohorts displayed 
significantly less retention of ICG fluorescence in the ROI in the infected left 
foot up to below the pLN, compared with BmL3 infection controls (Figure 
4.5B&C; 0.6±0.1 vs 0.2±0.03 R/L leg ratio, P<0.05). Additionally, significantly 
less Evan’s Blue accumulated in the surrounding dermis in areas proximal to 
remodelled lymphatics in the BmL3+CCR2 mouse group compared to 
BmL3 infection controls (Figure 4.5D; 0.1± 0.02 vs BmL3: 0.3±0.05 OD620, 
P<0.001). No significant difference was apparent when comparing Evan’s 
Blue retention between BmL3+CCR2 infected mice and sham infection 
controls (Figure 4.5D).  
Via Prox-1GFP visualisation of lymphatic collecting vessels proximal to BmL3 
infection, a significant decrease in average lymphatic apertures was detected 
in areas where remodelling was apparent, in both L3+CL and L3+CCR2 
groups, compared to BmL3 infection controls (Representative images figure 
4.5E. figure 4.5F; average aperture BmL3 infections: 97.2±8.5 vs 77.1±4.8, 
or 75.2±4.4 µm BmL3+CL or  BmL3+CCR2, respectively, both P<0.05).  
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Figure 4.4: Anti-CCR2 treatment significantly reduces circulating and 
local sdLN Cd11b+Ly6C+CCR2+ monocyte populations in BmL3 infected 
mice while CL reduces circulating Cd11b+Ly6C+CCR2+ monocytes.  
Sham infected mice were compared with mice inoculated with 100 BmL3 and 
treated with either: anti-()CCR2 ablating antibody i.p. daily (L3+CCR2), 
clodronate liposomes (CL) s.c. every 3 days (L3+CL) or no further treatment 
(L3). 2dpi: A) Gating strategy used to phenotype both circulating blood and 
local sdLN Cd11b+Ly6C+CCR2+ monocytes along with representative flow 
plots demonstrating Cd11b+Ly6C+CCR2+  monocytes (CCR2+ expression 
was confirmed on the Cd11b+Ly6C+ gate) percentages shown demonstrate 
percentage of total live cells B) Quantified Cd11b+Ly6C+CCR2+ monocytes 
as total cell number in lymphoid and lymphatic tissues proximal to BmL3 
infection site C) Quantified Cd11b+Ly6C+CCR2+ monocytes as percentage 
of White blood cell (WBC) compartment of blood horizontal lines represent 
mean ±SEM while bars plot mean ±SEM Data is from a single experiment 
(N=3-4 mice/group) with statistical significance indicated as *=P<0.05 
**=P<0.01  ***=P<0.001 derived from a one-way ANOVA with Tukey’s 
multiple comparisons post-hoc test. 
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Figure 4.5: Depletion of phagocytes or CCR2+ monocytes significantly 
ameliorates filarial associated lymphatic insufficiency and local 
lymphatic vessel dilation post BmL3 infection. 
Sham infected mice were compared with mice inoculated with 100 BmL3 and 
treated with either: anti-()CCR2 ablating antibody i.p. daily (L3+CCR2), 
clodronate liposomes (CL) s.c. every 3 days (L3+CL) or no further treatment 
(L3). 6dpi: A) Quantification of aberrant lymphatics using PDE imaging in 
dorsal, ventral and left leg viewpoints B) Representative PDE images 
demonstrating lymphatic insufficiency- yellow box highlights differences in 
ICG retention between groups C) Quantification of lymphatic insufficiency 
using ICG fluorescence ratio of ROI from ankle to below pLN between 
mouse groups  D) Evan’s Blue Dermal retention assay quantifying Evan’s 
Blue retention in inoculated limb 6dpi E) Representative Prox-1GFP 
fluorescence microscopy images from all experimental groups demonstrating 
differences in lymphatic vessel aperture. Yellow scale bar is 100µm F) 
Lymphatic aperture measurements of Prox-1 GFP epifluorescence in zones 
of dermis corresponding with ICG remodelling or matched zones in sham-
infected animals. Horizontal lines of (A),(C) and (D) represent mean ±SEM 
while bars plot mean ±SEM in (F), Data is from a single experiment with 
statistical significance indicated as *=P<0.05 **=P<0.01  ***=P<0.001 derived 
from a one-way ANOVA with Tukey’s multiple comparison post-hoc test. 
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Figure 4.6: α-CCR2 and CL treatment significantly reduces multiple 
leukocyte populations in sdLNs local to innoculation site. 
Mouse groups were subcutaneously infected in the left hind limb with 100 
BmL3 or sham controls. Mouse groups were then either administered 
chlodronate SC into infected hind limb (L3+CL) every 3 days, anti-CCR2 
depleting antibody (L3+α-CCR2) IP every  day or PBS SC into infected hind 
limb (L3) every 2 days. 6dpi, flow cytometric immunophenotyping was 
undertaken on dissected draining LN’s and lymphatic vessels of the infected 
limb on all groups for comparison of cell populations. All graphs plot the 
mean ±SEM, each data point plotted represents a single mouse (N=4 or 5 
per group. Data is from a single experiment *=P<0.05 **=P<0.01  ***=P<0.01 
derived from a One-way ANOVA with Tukey’s multiple comparisons test.  
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4.3.6 α-CCR2 and CL treatment results in significant reductions of a 
multitude of leukocyte populations in local sdLN’s proximal to initial BmL3 
infection site. 
 
To investigate the effect of monocyte depletion on early immune cell 
dynamics to BmL3 infection, sdLNs of all mouse groups were 
immunophenotyped at experimental end point (6dpi) 
Both CL and α-CCR2 treated BmL3 infected cohorts demonstrated 
significantly reduced total sdLN cellularity compared to BmL3 infected only 
mice (Figure 4.6; 3.5x107 ± 3.1x106  and 2.7x107± 3.1x106 vs 5x107 ± 5.4x106 
cells respectively, P<0.05).In addition, CL treated groups demonstrated 
significantly reduced CD4+ T-cell populations compared to  BmL3 infected 
only (7.7x106 ± 8.4x105 vs 1.1x107 ± 1.1x106 CD4+ T-cells) (Figure 4.6). α-
CCR2 treated infected mouse cohorts demonstrated significant reductions in 
sdLN: Cd11b+Ly6C+CCR2+ monocyte (1.7x105 ± 2x104 vs 2.6x105 ± 1.8x104 
Cd11b+Ly6C+CCR2 cells, P<0.05), CD4+ T-cells ( 5.5x106 ± 3.2x105 vs 
11x107 ± 1.1x106 CD4+ T-cells, P<0.001) and B220+ B-cells (1.7x107 ± 
9.6x105 vs 2.8x107 ± 4.1x106 B220+ B-cells, P<0.05) compared to BmL3 
infected mice (Figure 4.6). Marginal non-significant decreases of total 
Cd11b+ cells were recorded when comparing α-CCR2 treated mice to 
infected only counterparts (Figure 4.6). 
4.3.7 Exposure of monocyte-derived M to live BmL3 or BmL3 extract induce 
significant LEC survival/proliferation of lymphatic endothelial cells in vitro  
 
To further investigate if monocytes/macrophages stimulated with L3 larval 
material could directly contribute to lymphatic endothelial activation, an in 
vitro co-culture proliferation assay was developed. Human THP-1 monocytes 
were differentiated into M before stimulation with BmL3 extract (BmL3E) or 
live BmL3 followed by addition in co-culture to human lymphatic endothelial 
cells (LECs). LEC survival/proliferation in the presence of unstimulated M, 
BmL3E- or BmL3-stimulated M were then compared (Schematic of co-
culture assay displayed in Figure 4.7A). 
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No significant fold change increase in LEC numbers (from basal media 
controls) were observed between LECs cultured with basal medium alone 
and LECs co-cultured with THP-1 differentiated, unstimulated M (‘M0’ 
(Figure 4.7B). LECs co-cultured with THP-1 differentiated M stimulated with 
BmL3E displayed a significantly increased fold-change in LEC cell number, 
compared to both LECs co-cultured in basal medium only (2.2± 0.3 vs 
0.9±0.03 fold-change, P<0.001) or M0 (1.1±0.04 fold-change, P<0.001, 
Figure 4.7B). Additionally, LECs co-cultured with THP-1 differentiated M 
stimulated with live BmL3 displayed a significantly higher fold-change in 
proliferation, compared to either LECs co-cultured in basal medium (1.9± 0.1 
fold-change increase, P<0.001) or LECs cultured in the presence of M0 
(1.9±0.1 fold-change increase, P<0.001, Figure 4.7B) 
 
  
165 
 
 
 
A 
B 
Day 0: Differentiate 1x10
6 
THP-1 into M0 cell 
inset/well  using 10ng/ml 
PMA for 24 hours 
BmL3E / BmL3 
Day 1: Polarise M0 with: 
10 μg/ml BmL3E or 10 live 
BmL3 for 48 hours 
Day 2: Plate 8x10
4 
LECs 
on bottom of well to adhere 
for 24 hours 
Polarised MФ cell 
inset 
Day 3: Combine polarised 
MФ cell inset with plated 
LECs  
Day 6: Following 72hr 
incubation, count LECs to 
measure LEC proliferation 
72 hour 
incubation 37°C 
5% CO
2
 
166 
 
Figure 4.7: Exposure of monocyte derived macrophages to BmL3E or 
Live L3 larvae induces a ‘lymphangiogenic M phenotype’ that drives 
significant survival/proliferation of LECs in vitro, 
A) Schematic of the developed THP-1 monocyte/macrophage co-culture 
assay with Lymphatic Endothelial Cells (LECs) B) Quantification of LEC 
proliferation, normalised as fold-change increase from basal medium control 
cultures. Horizontal bars represent the mean±SEM. Data is pooled from a 
single (live L3) or 2 (all other conditions) individual experiments with 
significance indicated as ***=P<0.01, ns=non-significant derived from a one-
way ANOVA with Tukey’s multiple comparison post-hoc test. 
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4.4- Discussion 
 
Data discussed in Chapter 2 demonstrates the rapid onset of lymphatic 
pathologies following filarial BmL3 infection, while Chapter 3 elucidated some 
of the lymphangiogenic molecules that are significantly upregulated, and 
therefore associated with pathology. The primary aim of this chapter, was to 
interrogate the cellular sources of these highly angiogenic/lymphangiogenic 
molecules and the cellular mechanisms that may regulate their release into 
the microenvironment proximal to the site of filarial infection BmL3 larval 
infection. 
Infecting B.malayi filarial larvae will be exposed to distinct cellular 
microenvironments as migration through dermal tissues, cutaneous tissues 
and peripheral lymphatics progresses in the first 24-48h (Demonstrated in 
chapter 2). BmL3 invasion and establishment into the draining pre-collecting 
lymphatic vessels, results in physical interaction with lymphatic endothelial 
cells (LECs) lining lymphatic vessels. Data from Chapter two suggests a 
robust and rapid activation of host immune responses following filarial 
infection, while there is established literature that details induction of a robust 
multi-faceted primary adaptive immune response to filarial larval infection 
(Allen and Maizels, 2011; Babu and Nutman, 2014). Resultant host early 
innate and then augmented adaptive immune activation, will expose larvae to 
a repertoire of recruited effector immune cells as part of robust anti-parasitic 
host responses, including: T-cells (Babu and Nutman, 2003), B-cells 
(Hussain and Ottesen, 1985), monocytes (Babu, Kumaraswami and Nutman, 
2009), eosinophils (Chirgwin et al., 2005; Turner et al., 2018) and neutrophils 
(Al-Qaoud et al., 2000; Tamarozzi et al., 2016) which have all been shown to 
play a role in host anti-filarial responses. 
The central hypothesis of this research chapter proposed that facets of the 
host immune response and relevant immune effector cells recruited to the 
site of larval infection are causal in induction of lymphatic pathology. This 
hypothesis was based on host-strain differences in magnitude of pathology 
development and prime / challenge infections could induce increases in 
lymphatic remodelling (chapter 2). 
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Immunophenotyping of lymphatic and lymphoid tissues proximal to BmL3 
infection demonstrated significant expansion of a typical adaptive immune 
response including T-cell and B-cells, 14 dpi. Additionally, significant 
expansions in Cd11b+Ly6C+CCR2+ ‘inflammatory’ monocytes and 
Cd11b+MHCII+F480+ M following BmL3 inoculation were observed, 
demonstrating active recruitment, or proliferation, of these myeloid cells at 
sites proximal to filarial infection. “Classical” CCR2+ monocytes are of bone 
marrow myeloid lineage that circulate in the bloodstream (Guilliams, Mildner 
and Yona, 2018). In response to infection, activated monocytes undergo 
rapid proliferation, before subsequent recruitment to areas local to infection, 
mediated by migration along chemokine gradients such as the ligand to 
CCR2, CCL2 (Shi and Pamer, 2011). Because monocytes recruited to sites 
of infection can trans-differentiate into inflammatory DC or M, which can 
subsequently drain to be retained in the local LN (Shi and Pamer, 2011), 
increases in CD11c or CD11b+MHCII+F4/80 cells observed by 14dpi may 
putatively derive from the recruited inflammatory monocyte pool.  
The marked loss of tissue residency marker Tim-4+ from the total MФ 
compartment, coupled with a significant increase of non-tissue resident Tim-
4- MФ post BmL3 infection would be indicative of the strong expansion of the 
MФ compartment in sdLNs being primarily derived from recruited 
inflammatory monocytes. With recent work questioning the reliability of Tim-4 
as a residency marker (Campbell et al., 2018), however, further studies 
including: use of other identifying tissue residency markers such as GATA6 
and CD102 (Rosas et al., 2014; Bain et al., 2016), or bone marrow chimeras 
to precisely track macrophage origin may better strengthen the assertion that 
the increase in M is inflammatory monocyte derived. Recruited monocytes 
and terminally-differentiated DC or M of monocytic origin can influence 
immune priming events in the initiation of an adaptive immune response 
within LN. Therefore, it is also plausible that recruited CCR2 inflammatory 
monocytes influence the degree of CD3 and B220 lymphocyte expansions 
recorded following BmL3 infection. 
To further investigate the possible contribution of these immune cell 
expansions in filarial lymphatic pathology, the predisposition of BALB/c and 
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CB56BL/6J mice to low or high pathology development, respectively, was 
exploited. While expansion of T-cells, B-cells and DC were all non-
significantly different between the BALB/c and C57BL/6J BmL3 infected 
mouse groups, significantly higher increases of Cd11b+Ly6C+CCR2+ 
monocytes and CD11b+MHCII+F4/80 M in the high pathology C57BL/6J 
mice was demonstrable, 14dpi with BmL3. This suggested a possible 
functional role of both CD11b+Ly6C+CCR2+ monocytes and/or 
CD11b+MHCII+F4/80 M in inducing or augmenting pathology post-filarial 
infection. 
Several studies have established the role for M in the host immune 
response to filarial infection, with evidence suggesting divergent roles 
dependent on polarisation of the macrophage. Evidence has suggested a 
pro-inflammatory role for ‘Classically activated’ M (sometimes referred to as 
‘M1’), differentiating in response to worm inhabitation and death (Rajan et al., 
1996), thus acting as an effector mechanism for filarial clearance. 
Conversely, macrophages have been implicated in facilitating chronic filarial 
infection by permitting filarial immune evasion, often through macrophage 
mediated CD4+ T-cell hypo-responsiveness/tolerance after polarisation to a 
regulatory ‘alternatively activated macrophage’ (AAM) phenotype (sometimes 
referred to as ‘M2’) (Taylor et al., 2006). This is likely to be an over 
simplification of macrophage heterogeneity following filarial infection, 
however, as recent work in our lab has identified that rapid expansion of 
macrophages, concomitant with polarisation to an AAM phenotype occurs 
following filarial infection and is crucial in recruiting eosinophils to the site of 
infection that facilitates worm expulsion (Turner et al., 2018). Further, 
variation in plasticity and origin of AAM in response to filarial infection, at 
least following parasitism of serous cavities, is implicated in relative 
susceptibility or resistance (Campbell et al., 2018) 
To investigate if the recruited CCR2+ monocytes or CD11b+MHCII+F4/80 M  
demonstrated pro-lymphangiogenic phenotype upon BmL3 infection, 
supernatants harvested from ex-vivo cultured purified cell populations from 
BmL3 or sham infected cohorts were assayed for concentrations of 
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lymphangiogenic molecules identified as increased in circulation of mice 
post-infection (chapter 3). Data from these experiments demonstrated that 
CD11b+Ly6C+CCR2+ inflammatory monocytes recruited to sites of BmL3 
infection secreted increased quantities of sALK-1, prolactin, IL-6 and 
amphiregulin, when compared to purified monocyte secretions from sham 
animals. Additionally, CD11b+MHCII+F4/80 M from BmL3 infected cohorts 
were shown to secrete significantly higher quantities of VEGF-C than sham 
controls. The evidence presented above demonstrates that the BmL3 
induced increase in the M compartment is likely driven by recruitment and 
differentiation of inflammatory CCR2+ monocytes. Together, the data is 
suggestive of a cellular mechanism by which recruited monocytes 
themselves, or their differentiation into macrophages, release a milieu of 
highly lymphangiogenic molecules which directly mediate early filarial 
associated lymphatic remodelling. In addition to the roles of M in 
immune/inflammatory mediation- recent work has identified a role for M in 
both vascular remodelling/angiogenesis and lymphatic 
remodelling/lymphangiogenesis.  
In the context of inflammatory-associated lymphangiogenesis (IAL), elegant 
studies have shown that recruited M can both secrete a milieu of factors 
that contribute to increased lymphangiogenesis (Including VEGF-C and 
Angiopioetin-2) in areas of infection (Kataru et al., 2009; Ran and 
Montgomery, 2012), as well as undergo trans-differentiation themselves into 
a lymphatic endothelial cell progenitor which facilitates in vessel sprouting 
and growth (Maruyama et al., 2005; Hall et al., 2012). Further, M drive 
changes to the extracellular matrix (ECM) through secretion of matrix 
metalloproteases, such as matrix metalloprotease 9 (MMP-9), degrading 
established ECM to facilitate novel remodelling of lymphatic and vascular 
channels during lymphangiogenesis.(Böhmer et al., 2010). In oncology, work 
has shown that macrophages recruited to the tumour microenvironment are 
‘hijacked’ into a highly angiogenic/lymphangiogenic phenotype termed 
‘Tumour-Associated Macrophages’ (TAMs). TAMs have been shown to 
degrade extracellular matrix (Huang et al., 2002) and secrete a variety of 
growth factors that facilitate vascular remodelling/angiogenesis, including 
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factors identified to be increased following BmL3 infection including bFGF-2, 
and VEGFs (Lewis et al., 2000; Ly et al., 2010; Riabov et al., 2014). 
Additionally, studies have elucidated a role for inflammatory monocytes, 
specifically Tie-2 expressing monocytes (TEMs), with the ability to drive 
lymphangiogenesis and thus remodelling of the lymphatic architecture in the 
tumour microenvironment, (De Palma et al., 2005; Venneri et al., 2007). 
Taken together, the identified pro-lymphangiogenic/angiogenic monocytes 
and macrophages that are recruited proximal to areas of BmL3 infection play 
as strong contributing role to the observed lymphatic pathology following 
filarial infection    
Purified and assayed cell secretions of CD3+ T-cells and B220+ B-cells from 
BmL3 infected cohorts demonstrated that they also secrete significant 
quantities of: amphiregulin, prolactin and IL-6 (T and B-cells) as well as 
CXCL-1 and sALK-1 (T-cells) compared to purified sham counterparts. This 
is indicative of a potential role of T and B-cells in filarial associated lymphatic 
remodelling, however the near two fold lower secreted concentrations when 
compared to monocytes and macrophages may suggest these cells are less 
important contributors to the highly lymphangiogenic milieu that is secreted in 
response to BmL3 infection and mediates the significant pathological 
remodelling observed. Previous work has implicated a role for CD4+ T-cells 
in driving fibrosis and lymphoedema, as depletion resulted in attenuated 
levels of pathology (Zampell et al., 2012). This is further supported from 
studies involving filarial infection of lymphocyte deficient mice strains, were 
lymphoedematous pathology is only manifest upon reconstitution of 
lymphocyte populations by adoptive transfer (Vincent et al., 1984; Bosma 
and Carroll, 1991). T-cells have also been implicated in inducing 
angiogenesis through direct secretion of VEGFs, driving vascular 
remodelling (Mor, Quintana and Cohen, 2004) although increased secretion 
of VEGF-s by purified CD3+ T-cells was not observed in this study.  
Alternatively, studies have shown that excess lymphangiogenesis, that 
contributes to lymphoedematous pathologies in a mouse model, requires 
cooperation between CD4+ T-cells and macrophages, with ablation of CD4+ 
T-cell populations abrogating the severity of lymphangiogenesis and 
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subsequent pathology observed (Ogata et al., 2016). This suggests that 
increased, but lower secretions of lymphangiogenic molecules in T-cells may 
synergise with monocyte and macrophage secretions to directly mediate 
filarial induced lymphatic remodelling, while it cannot be ruled out that T-cell 
‘help’ indirectly supports lymphangiogenic pathology by educating recruited 
monocytes and macrophages into a pro-lymphangiogenic phenotype 
following BmL3 infection as well as induction of a primary adaptive immune 
response. A multitude of previous work has identified a key role for B-cells in 
remodelling of the lymph node lymphatic architecture following infection 
(Kumar et al., 2010; Abe et al., 2012). Immunostaining of infected LN’s 
demonstrated B-cells as a major source of VEGF-A, and ablation of either B-
cells or administration of VEGF-A blocking antibodies reversed lymphatic 
expansion of lymph nodes following infection (Angeli et al., 2006). The 
previous work detailed therefore suggests that it is plausible that other 
contributing lymphangiogenic molecules that were observed in the data to be 
secreted by B-cells contribute to the filarial associated remodelling. It cannot, 
however be ruled out that the secretion of lymphangiogenic factors by B-cells 
is restricted to solely within the lymph node architecture facilitating lymph 
node expansion, as is observed following BmL3 infection (Chapter 2), and is 
primarily to mediate appropriate immune responses rather mediating extra 
nodal filarial associated lymphatic remodelling. Further work utilising 
immune-staining and histology to locate-cell infilitrates near to areas of 
lymphatic remodelling may help to elucidate whether a lymphangiogenic role 
for B-cells in filarial driven lymphatic remodelling exists. 
To further interrogate the importance of monocytes/macrophages in driving 
filarial associated lymphatic pathology in vivo, α-CCR2 antibody mediated 
Cd11b+Ly6C+CCR2+ monocyte depletion and CL mediated phagocyte 
depletion were administered to mice concurrent with BmL3 infection. The 
effects of these treatments on severity of lymphatic remodelling and 
insufficiency were then investigated. α-CCR2 and CL treatment significantly 
decreased circulating Cd11b+Ly6C+CCR2+ monocyte populations by 
approximately 80% and 40% respectively, while local sdLN accumulation of 
Cd11b+Ly6C+CCR2+ monocytes were significantly reduced by approximately 
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80% following α-CCR2 treatment, confirming the efficacy of both treatments 
in ablating inflammatory monocytes.  
BmL3+CL mice displayed no significant changes to PDE imaged ICG dye 
retention in the infected limb when compared to BmL3 mice, however a 
significant reduction in Evan’s blue dermal retention was observed. 
Additionally, via epifluorescence microscopy, the average lymphatic vessel 
aperture was significantly lower in BmL3+CL mice compared to BmL3 mice 
suggesting amelioration of BmL3 induced lymphatic vessel dilation, following 
CL mediated ablation of phagocytes local to BmL3 infection. Higher retention 
of ICG dye, observed in the infected limb of BmL3 infected mice, was 
significantly reduced in L3+αCCR2 mouse cohorts suggesting that ablation 
of inflammatory monocytes reverses BmL3 mediated lymphatic insufficiency. 
This was further corroborated by significantly lower dermal retention of 
Evan’s Blue in L3+α-CCR2 cohorts compared to the BmL3. Additionally, 
L3+αCCR2 mouse cohorts presented a partial reversal of BmL3 induced 
lymphatic vessel dilation, demonstrated by significantly smaller average 
aperture of Prox-1+ collecting vessels. Taken together, the data suggests 
that CL mediated ablation of phagocytic cells, such as Cd11b+MHCII+F480+ 
MФ, or ablation of Cd11b+Ly6C+CCR2+ monocytes, which are likely the 
source of increased local MФ populations, significantly ameliorated BmL3 
induced lymphatic dilation and pathological lymphatic insufficiency. This 
would indicate that the rapid expansion of pro-lymphangiogenic MФ and 
inflammatory monocytes, observed following BmL3 infection, play a driving 
role in inducing filarial associated lymphatic pathology partly by inducing 
local lymphatic insufficiency by mediating local lymphatic vessel dilation in 
response to BmL3 infection.  
Intravital PDE imaging in the intervention experiments demonstrated that 
neither L3+CL or L3+α-CCR2 mouse cohorts displayed significant changes 
in quantity of aberrant lymphatics, when compared to BmL3 infected mice 
alone, further, both L3+α-CCR2 and L3+CL groups displayed significantly 
higher aberrant lymphatics across all imaged viewpoints, compared to sham 
infection controls. Together, this data would indicate that neither 
Cd11b+Ly6C+CCR2+ monocytes or Cd11b+MHCII+F480+ macrophages are 
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implicated in lymphatic remodelling/neovascularisation associated with filarial 
infection, thus are not the sole cellular drivers of filarial pathology. As 
residual populations of Cd11b+Ly6C+CCR2+ monocytes were observed in α-
CCR2 and CL treated groups however, it cannot be discounted that the 
surviving populations may provide adequate numbers to initiate a level of 
filarial associated neovascularisation. Further, while potent depletion of 
inflammatory monocytes was observed in α-CCR2 and CL treated groups 
2dpi, much lower levels of monocyte reduction was manifest at the 6dpi 
experimental endpoint, with monocyte accumulation only reduced by 50% at 
6dpi, compared to 80% at 2dpi. The daily α-CCR2 and tri-daily CL treatment 
regimes utilised, would provide sufficient concentration of depleting antibody 
or clodronate throughout the 6 day experimental period. The drop in efficacy 
of monocyte depletion, therefore, could suggest a transient nature to 
monocyte depletion in both treatment groups, with resistance to ablating 
antibodies a well characterised phenomenon (Villamor, Montserrat and 
Colomer, 2003) The transient depletion could suggest there was sufficient 
time for the influx of ablation antibody-resistant to provide sufficient 
lymphangiogenic signalling to induce filarial lymphatic remodelling.  
Alternatively, and as demonstrated above by secretion of lymphangiogenic 
molecules from T and B-cells following BmL3 infection, other cellular sources 
are likely to contribute to the released lymphangiogenic milieu in the 
microenvironment surrounding larval infection, with T and B cell derived 
lymphangiogenic molecules either offering redundancy/compensation in the 
face of monocyte/macrophage ablation- driving neovascularisation type 
lymphatic remodelling in their absence- or are themselves more significant 
mediators of the neovascularisation observed.  
Treatment with CL and α-CCR2 markedly reduced the accumulation of sdLN 
CD4+ T-cells compared to BmL3 infected cohorts alone while, additionally, α-
CCR2 treatment significantly reduced B220+ B-cell sdLN populations. Such 
reductions may infer a role for Cd11b+Ly6C+CCR2+ monocytes and/or 
Cd11b+MHCII+F480+ MФ in effective immune priming to filarial infection, with 
monocyte derived dendritic cells and MФ both demonstrated to be necessary 
for efficient priming of T-cells to a variety of infectious agents (Schlienger et 
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al., 2000; Randolph, Jakubzick and Qu, 2008; Iijima, Mattei and Iwasaki, 
2011; Bernhard et al., 2015; Sánchez-Paulete et al., 2017; Kurup et al., 
2019) and B-cells (Tosato et al., 1988; Mueller et al., 2007; Harwood and 
Batista, 2010). Alternatively, CCR2 receptor expression has been reported 
both on T-cells (Connor et al., 2004) and B-cells (Frade et al., 1997) and “off 
target” ablation of these T and B-cell subsets by α-CCR2 administration 
cannot be discounted. Regardless of the mechanism reducing T and B-cell 
populations, data demonstrating both T and B-cells secrete significant 
quantities of highly lymphangiogenic molecules would suggest a partial role 
for both cell types in the induction of filarial lymphatic pathology, while an 
indirect role for inflammatory monocytes or macrophages in contributing to 
filarial associated lymphatic pathology, by priming T and B-cells into pro-
lymphangiogenic phenotypes, cannot be discounted. Future studies could 
utilise CCR2 monocyte conditional knockout murine strains in the developed 
BmL3 infection to more specifically demonstrate a role for CCR2 
inflammatory monocytes in the induction of lymphatic pathology. Additionally, 
use of inducible conditional, or traditional knockout murine strains that 
effectively deplete T or B cell populations in the developed model may more 
effectively elucidate the role for T and B-cells in mediating filarial lymphatic 
pathology.  
With inflammatory monocytes and monocyte derived macrophages recruited 
to areas of BmL3 infection being shown to play an important role in 
development of filarial lymphatic pathology, the capability of monocyte 
derived M to directly mediate LEC cell activation, upon stimulation with live 
BmL3 or BmL3 material was assessed. An in vitro co-culture system was 
developed in which human THP-1 monocyte derived macrophages, 
previously stimulated with live L3 or L3 extract (BmL3E) were co-cultured 
with Lymphatic Endothelial Cells (LECs) to investigate their potential to 
induce LEC proliferation. Unstimulated macrophages (M0) co-cultured in the 
presence of LECs in basal media did not significantly stimulate LEC 
proliferation compared with basal media LEC cultures alone (Basal) 
suggesting that recruited monocyte derived M initially fail to display a “pro-
lymphangiogenic” phenotype that can drive LEC proliferation. In contrast, M0 
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stimulated with BmL3E or live L3, followed by subsequent co-culture with 
LECs, yielded significantly higher levels of LEC proliferation than either M0 
co-cultured with LECs or basal media cultured LECs alone. This infers 
monocyte derived M, receiving local stimulatory cues from the invading 
filarial larvae, become polarised into a lymphangiogenic phenotype that can 
mediate significantly higher proliferation of LECs. LEC proliferation is an 
important part of lymphangiogenesis, driving post-natal lymphatic 
remodelling. As the co-culture system utilised cell insets, preventing physical 
contact between the LEC monolayer and the M, the increased proliferation 
observed is resultant of increased secretion of factors from L3/BmL3E 
polarised M that directly induce LEC proliferation. Studies providing 
corroboratory evidence to this data, were human PBMCs cultured in the 
presence of Brugia malayi adult filarial material induced significant secretion 
of growth factors such as VEGF-C. LEC cultures spiked with comparable 
concentrations of these growth factors resulted in significant 
lymphangiogenesis as measured by a number of in vitro 2D and 3D cell 
based assays (Weinkopff et al., 2014). 
Data from this chapter extends this phenomenon to products generated and 
secreted by the initial invading L3 of B. malayi. Future work could define the 
lymphangiogenic molecules secreted by L3/BmL3E polarised M that drives 
LEC proliferation by assaying the conditioned media of M exposed to filarial 
material. Cross referencing the presence of identified lymphangiogenic 
molecules with those demonstrated to be locally secreted by 
monocytes/macrophages in the filarial leg infection model or are systemically 
upregulated following BmL3 infection (Chapter 3) could strengthen evidence 
of the molecular mechanisms that drive early filarial lymphatic pathology. It is 
important to note, however, that the developed co-culture model likely 
oversimplifies the early immunological niche encompassing filarial infection, 
as macrophages are likely to receive a variety of immunological cues through 
local uptake of chemokines, cytokines and other molecules released by other 
immune cells/other cell types in the microenvironment. It is likely that 
recruited monocytes undergoing differentiation into macrophages receives a 
variety of both parasite-derived, as well as host immune-cell derived stimuli 
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which ultimately shapes the pro-lymphangiogenic M phenotype that 
contributes to filarial lymphatic pathology.  
The novel role for monocytes and M in mediating filarial lymphatic pathology 
highlights the potential of novel therapeutic strategies ,which aim to target 
monocyte/M lymphangiogenic signalling. Blocking the recruitment of 
monocyte derived, TAMs, demonstrating a highly lymphangiogenic 
phenotype, is an active area of research interest to inhibit vascularisation 
and metastasis of tumours (Qian et al., 2011). Further, chemokine receptor 
antagonists, neutralising antibodies targeting the chemokines responsible for 
monocyte recruitment, or even pharmacological small molecule inhibitors 
blocking TAM recruitment to the tumour microenvironment has yielded 
promising pre-clinical results against a range of cancers(Gazzaniga et al., 
2007; Loberg et al., 2007). The manipulation of recruited 
monocyte/macrophage phenotype is also an area of ongoing research, with 
prevention of ‘M2 angiogenic/lymphangiogenic’ MФ polarisation at tumours 
sites, by utilising Cyclo oxygenase-2 (COX-2) inhibitors, yielding interesting 
results (Na et al., 2013). A similar rationale to prevent recruitment of 
inflammatory monocytes to the immunological niche proximal to filarial 
infection, or modifying the lymphangiogenic MФ phenotype associated with 
BmL3 infection may represent an attractive target to  reduce excessive 
lymphatic remodelling and development of lymphatic insufficiency. 
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4.5- Chapter Concluding Remarks 
 
The primary objective of this chapter was to identify the cellular source of the 
milieu of highly lymphangiogenic molecules that are released following BmL3 
infection and are therefore likely implicated in the development of filarial 
lymphatic pathology. Given the established evidence demonstrating a role for 
monocytes/macrophages in lymphatic remodelling, both in reparatory and 
pathological settings, it was hypothesised that monocytes and macrophages 
may be implicated in filarial driven aberrant lymphatic remodelling and 
associated lymphatic dysfunction. The data in this chapter provides evidence 
that monocytes play an important role in the induction of lymphatic 
remodelling, that is highly associated with lymphatic dysfunction. The data 
successfully demonstrates that Cd11b+Ly6C+CCR2+ monocytes are rapidly 
recruited following filarial infection and, in addition to themselves secreting 
significant quantities of a range of pro-lymphangiogenic molecules, are also 
likely to differentiate into MФ phenotypes that further add to the pro-
lymphangiogenic millieu, implicated in the induction of filarial pathology. 
Further, other cellular sources, mainly B and T-cells were demonstrated to 
secrete lymphangiogenic molecules either following monocyte/macrophage 
priming or as an independent cellular mechanism of filarial pathology. Filarial 
exposed monocytes/M directly induced LEC proliferation, while targeted 
depletion of either monocyte or M populations significantly ameliorated 
filarial associated lymphatic insufficiency, providing strong evidence for a 
significant role for both monocytes/M in the induction of filarial lymphatic 
pathology. The novel role demonstrated suggests that specific targeting of 
lymphangiogenic monocytes/M may be a novel therapeutic strategy to 
prevent development of LF pathology.  
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Chapter 5 
The role of host adaptive immune responses in 
induction of filarial inflammatory-associated 
lymphatic pathology. 
 
The role of adaptive immunity in development of Lymphatic Filariasis (LF) 
related pathology is poorly understood. The nature of local adaptive immune 
responses following larval infection and the possible role of adaptive immune 
responses in the induction of filarial-associated lymphatic pathology was 
investigated. The murine leg pathology model was employed to characterize 
early local adaptive immune responses to BmL3 inoculation. Severe 
Combined Immuno-Deficiency (SCID), Interleukin (IL)-4 receptor alpha 
deficient (IL-4Rα-/-) and immunocompetent wild type (WT) mouse cohorts 
were utilized to compare severity of lymphatic remodeling and insufficiency in 
settings of varying adaptive immunological deficiency. At 14 days post BmL3 
infection, significant expansion of Th2 associated IL-4, IL-13 and IL-10 
expressing CD4+ T-cells were observed in skin draining lymph nodes (sdLN) 
and connecting lymphatic channels proximal to infection site. Concurrently, 
there was evidence that expanded local F4/80+MHCII+ M populations 
expressed significantly increased levels of the alternatively activated (AA) 
markers (CD206 and Relm-α) typical of IL-4 / IL-13 conditioning. Total 
ablation of adaptive immune responses (SCID) or dysfunctional Th2 adaptive 
responses (IL-4Rα-/-) resulted in significant amelioration of infection-induced 
lymphatic remodeling and insufficiency. Th2 ablation was associated with 
significantly attenuated release of lymphangiogenic molecules associated 
with induction of lymphatic pathologies, whilst significantly decreased 
recruitment of monocytes and M were observed in local lymphoid/lymphatic 
tissues proximal to infection. Human monocyte-derived M conditioned with 
recombinant IL-4 and 13 were able to induce significant increased LEC 
proliferation in a co-culture model. In conclusion, an IL-4R dependent, Th2 
adaptive immune response is critical to mediate the induction of filarial-
associated lymphatic pathology, promoting pro-lymphangiogenic secretions 
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and AAM that are functionally important in lymphatic remodelling. This 
demonstrates that dysregulated Th2-type responses contribute to 
pathological manifestations of LF. 
5.1- Introduction 
 
The previous chapters have defined rapid onset lymphatic remodelling, 
associated with lymphatic insufficiency, following filarial Brugia malayi L3 
(BmL3) larval infection. Data demonstrated a vigorous induction of 
inflammatory immune cell activation as little as 6 days post infection (6dpi), 
with characterised recruitment of Cd11b+Ly6C+CCR2+ monocytes and 
significant expansion of CD3+ T-cells and Cd11b+MHCII+F480+ macrophages 
in lymphoid / lymphatic tissues proximal to the site of initial larval invasion. 
Further a functional role of Cd11b+Ly6C+CCR2+ monocytes and/or 
Cd11b+MHCII+F480+ macrophages in mediating lymphatic insufficiency and 
pathology was identified . Together with data demonstrating differences in 
the severity of lymphatic alterations and pathology between two inbred 
murine strains with well characterised differences in anti-filarial adaptive 
immune responses, the underlying immune response to infection may play a 
key role to the induction of filarial associated lymphatic pathology. 
Adaptive Immune responses following filarial nematode infection have been 
extensively studied, both in terms of immunity to infection as well as 
implications for pathogenesis. There is general consensus that filarial 
infection is associated with the induction of strong host Th2 adaptive immune 
responses (Hoerauf et al., 2005; Babu and Nutman, 2014), as a key arm of 
anti-parasitic host defence and parasite expulsion. In vivo models have 
elegantly demonstrated that dysfunctional Th2 responses, such as in IL-4Rα 
knockout (KO) mice, render mice permissive to chronic adult filarial infection, 
while wild type counterparts remain protected (Howells et al., 1983; Devaney 
et al., 2002; Turner et al., 2018). Recent evidence, however, has 
characterised a mixed Th1/Th2 adaptive immune response following 
infection with evidence that early immune responses to filarial invasion is Th1 
dominated (Babu et al., 2000; Babu and Nutman, 2003), while it has been 
shown Th1 responses are also necessary for parasite expulsion in murine 
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models (Saeftel et al., 2001, 2003). Additionally, there is evidence of 
compartmentalised adaptive responses which are Th2 dominant towards 
filarial nematodes, while proinflammatory Th1 responses are triggered 
against their endosymbiotic bacteria Wolbachia (Gentil, Hoerauf and 
Pearlman, 2012). It has been proposed successful establishment of chronic 
filarial infection is reliant on a ‘modified’, highly regulatory and anti-
inflammatory Th2 response, dominated by high numbers of regulatory T-cells 
(Tregs) (Metenou et al., 2010; Metenou and Nutman, 2013). Despite these 
well characterised adaptive immune responses to filarial infection, the role of 
adaptive immunity to the development of filarial pathology is less well 
defined. Early work involving severe combined immune deficiency (SCID) or 
nude athymic mice, displaying loss of functional adaptive immune responses, 
demonstrated a role for adaptive immunity in filarial-associated pathology 
(Vincent et al., 1984; Nelson et al., 1991). SCID mice were observed to 
develop patent infection, with early manifestation of pathological changes, 
such as lymphangiectasia, yet failed to progress to more severe 
lymphoedematous pathology. Progression to acute pathologies were only 
observed following adoptive transfer of immune competent splenocytes or T-
cells, which recapitulated adaptive immune responses (Vickery et al., 1991), 
suggesting an important role for adaptive immunity in the onset of severe 
filarial pathology. Further, clinical studies have demonstrated that the type of 
adaptive immune response initiated upon filarial infection is important for 
pathological outcome, with asymptomatic patient cohorts displaying a 
skewed highly regulatory adaptive immune response dominated by the 
presence of Tregs and secretion of high levels of IL-10 and TGF-β (Taylor et 
al., 2005; Metenou et al., 2010; Babu and Nutman, 2014), while symptomatic 
patients demonstrate a mixed inflammatory Th1, Th2 and Th17 response 
characterised by significantly higher concentrations of relevant cytokines 
(Babu et al., 2009) as well an increased, mixed, heightened parasite specific 
effector T-cell response . 
The heterogeneous adaptive immune response outlined above demonstrates 
that the role of adaptive immunity in mediating, or protecting from, 
pathological manifestations of LF is still poorly defined. Additionally, the 
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majority of research has focused on characterisation of adaptive responses 
in the presence of chronic fecund adult filarial infections, including host 
responses to systemic circulating mf. Moreover, clinical studies of adaptive 
immune responses in symptomatic patient groups are highly variable in 
terms of type (hydrocele, limb LE) and extent (grade) of overt pathology. It is 
challenging to define precisely the initiating polarised adaptive immune 
responses that induce pathology considering the variation in patient cohorts 
and also the further confounding impact of latter secondary microbial skin 
infections. In chapter 2, the rapid manifestation of pathological lymphatic 
remodelling and associated lymphatic dysfunction following invasion by the 
infective L3 larval stage was detailed. This suggests the less well 
characterised adaptive immune responses to early invasion of L3 larvae may 
play a more significant role in the development of later pathological 
outcomes than was previously appreciated. The aims of this chapter will 
therefore be to characterise the early adaptive immune responses, locally 
and systemically, following Brugia malayi L3 (BmL3) infection. Additionally, a 
key aim will be to investigate the role of adaptive immune responses in the 
development of filarial-associated lymphatic pathology.  
These research questions will be addressed using the following objectives: 
1. Utilise the developed pathology model to investigate if lymphatic 
remodelling and associated insufficiency is modified between WT and 
SCID mice. 
2. Characterise the type of adaptive immune response, both local to 
BmL3 infection as well as systemically, at time-points where there is 
demonstrable lymphatic pathologies: (6-14dpi) 
3. Utilise a selective knockout mouse system, dependent on 
identification of immune-polarisation defined in (2), to investigate the 
impact on infection-associated lymphatic pathologies. 
4. Investigate associations between magnitude and type of adaptive 
immune response and previously identified molecular and/or cellular 
mechanisms of infection-associated lymphatic pathology. 
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5.2- Methods 
 
5.2.1-Mouse maintenance, Murine hind-limb infection model and associated 
pathological readouts 
 
Male BALB/c SCID mice were purchased from Charles River (Margate, UK) . 
Male BALB/c IL-4 receptor alpha (Rα)-/- knockout mice were purchased from 
Jackson Laboratories (USA) and subsequently bred in house for 
experimental use, while C57BL/6J IL-4rα-/- breeding pairs were a kind gift 
from Dr Cecile Benezech (University of Edinburgh) and subsequently bred in 
house for experimental use. Breeding C57BL/6J IL-4rα-/- mice were 
phenotyped for loss of IL-4Rα expression utilising flow cytometric analysis of 
lymphocytes and myeloid cell populations from relevant tail bleeds (data not 
shown) Both IL-4Rα-/- strains of mice were 6-12 weeks at the start of each 
experiment and age matched with Wild Type (WT) immunocompetent mice 
(BALB/c and C57BL/6J) purchased from Charles river (Margate,UK) in 
appropriate experiments. 
The murine experimental model of filarial-induced lymphatic remodelling and 
insufficiency, along with relevant readouts, were utilised throughout this 
chapter, methods can be accessed from chapter 2.2.1-2.2.7.  
5.2.2-Skin draining Lymph Node (sdLN) Flow cytometry and 
Immunophenotyping 
 
sdLNs, and the surrounding connecting lymphatic vasculature, of the infected 
left hind limb (popliteal, iliac and sub-iliac) were excised and processed as 
previously detailed (Chapter 2.2.1-2.2.7). Fc regions of prepared single cell 
suspensions were blocked through a twenty minute incubation with CD16/32 
Fc-block (eBioscience, Hatfield UK). Live/dead cell differentiation was 
undertaken by 30-minute incubation of samples with efluor 450 fixable 
viability dye (eBioscience, Hatfield UK) on all samples. Following live/dead 
cell differentiation and a subsequent wash and centrifugation, cell surface 
staining was undertaken for 30 minutes with the following surface markers 
used: Ly6G PE (eBioscience, Hatfield), Ly6C PerCyP5.5  (eBioscience, 
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Hatfield), Rat IgG1 APC Isotype control (eBioscience, Hatfield), Rat IgG1 
FITC Isotype control (eBioscience, Hatfield), CD4 APC (eBioscience, 
Hatfield), CD4 PerCyP Cy5.5  (eBioscience, Hatfield), CCR2 PE-Cy7 
(eBioscience, Hatfield), Cd11b AF488 (eBioscience, Hatfield), Cd11b 
PerCyP Cy5.5 (ebioscience, Hatfield) B220 APC (eBioscience, Hatfield), 
MHCII Alexa Fluor 700 (AF700) (ebioscience, Hatfield), Tim-4 PE-Cy7 
(ebioscience, Hatfield), SiglecF PE (ebioscience, Hatfield), F480 Brilliant 
Violet 711 (BV711) (Biolegend, London), CD206 APC (ebioscience, Hatfield). 
Following surface staining, cells were fixed for 40 minutes using the FoxP3 
Fixation/Permeabilisation Kit (eBioscience, Hatfield) followed by either: 
acquisition, undertaken on a BD LSRII Flow cytometer (BD Biosciences, 
Berkshire, UK) or further intracellular staining utilising, rabbit polyclonal anti-
RELM-α (Peprotech) or polyclonal rabbit anti-IgG (peprotech) fluorescently 
labelled with Zenon Rabbit IgG AF488 labelling kit (ThermoFisher, UK) for 40 
minutes. 
In other experiments, extracted single cell lymph node suspensions 
underwent a 5 hour incubation in cell stimulation cocktail (ebioscience 
Hatfield) as per manufacturer’s instructions, followed by blocking of Fc 
regions and Live/Dead differentiation as described above. Cell surface 
staining of CD4 expression was then undertaken for 40 minutes followed by 
fixation/permeabilization as previously described. Fixed and permeabilised 
cells then underwent intracellular cytokine labelling utilising the antibodies: 
IFN-γ PE-Cy7 (eBioscience, Hatfield), IL-10 APC (eBioscience, Hatfield or 
Biolegend, London), IL-13 AF488 (eBioscience, Hatfield), IL-4 PE 
(eBioscience, Hatfield). All intracellular staining was undertaken in the FoxP3 
permeabilization buffer as per manufacturer’s protocol. Data was analysed 
using Flowjo software (BD Biosciences, Berkshire, UK). 
5.2.3-Multiplex analysis of plasma or human cell secretion samples 
 
Plasma was harvested from all relevant mouse groups as detailed in chapter 
two. Plasma samples were analysed for a panel of 
angiogenic/lymphangiogenic analytes using the MAGMAP-24k milliplex full 
panel (mouse plasma) or HAGP1MAG-12K full panel (human cell secretion) 
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(Merck Millipore, East Midlands) as per manufacturer’s instructions and read 
on a Bio-Plex (Biorad, Deeside). Analyte expression was analysed by 
plotting the mean fold change of the individual analyte in infected mouse 
groups from the mean concentration of relevant sham infected controls. Cell 
secretion samples were normalised to media only controls to account for 
possible analyte contaminants in serum supplemented media. 
5.2.4-Cell culture and maintenance 
 
Cell lines utilised in this chapter were maintained and cultured as previously 
described in chapter 4.2.6. 
5.2.5-Macrophage/ LEC co-culture proliferation assay 
 
THP-1 monocytes were plated into the cell inset of 6 well trans-well plates 
(Sigma, Dorset) at 1x106 cells/well and differentiated into adherent non-
polarised “M0” macrophages using 10ng/ml PMA (Sigma,Dorset) for 24 
hours. Following differentiation, macrophage insets were washed in PBS 
before stimulation with either 5ng/ml of recombinant human Interferon-
gamma (IFN-γ) (Peprotech), 5ng/ml recombinant human interleukin-4 
(Peprotech) (IL-4) + 5 ng/ml recombinant human interleukin 13 (Peprotech) 
(IL-13) or media only (M0) for 48 hours. On the intermediate day, LECs were 
seeded separately on the bottom of fresh 6 well trans-well plates at 8x104 
cells/well. Following 48-hour stimulation, cytokine polarised macrophage 
insets and LEC adherent layers were washed, before addition of the inserts 
onto the top of LEC wells, creating a LEC/Macrophage co-culture. A 20% 
EGM-2, 80% Endothelial basal media (EGM-2 without addition of any growth 
supplements, +0.1% FBS only) mix was used as the culture media. LEC 
wells without macrophage inserts plated in: 80:20 basal media alone or full 
EGM-2 were used as negative (negligible growth) and positive (maximal 
growth) controls respectively. All LEC/Macrophage co-culture wells and LEC 
control wells were incubated for 72 hours at 37ºC, 5% CO2. Following 
incubation, macrophage inserts were discarded and LEC cells dissociated 
from wells using 1x Trypsin/EDTA solution (Thermofisher, UK). All LEC 
samples were manually counted using a haemocytometer in a 1:1 cell 
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sample: 2% Trypan Blue (Sigma, Dorset) solution for Live/Dead cell 
differentiation. A schematic summary of the assay can be found in figure 
5.7A 
In other experiments, differentiated M0’s were plated at 1x106 cells/well 
followed by polarisation with rIL-4 + rIL-13 or M0 as outlined above. 
Following 48 hours, polarised macrophages were carefully washed in PBS, 
followed by addition of fresh media and incubated for a further 72 hours. The 
72 hour conditioned media containing secretions of polarised macrophages 
were then either added to plated 8x104 cells/well LECs as a proliferation 
assay as described above, or frozen to undergo multiplex analysis of 
lymphangiogenic factors. 
5.2.6-Splenocyte recall assays 
 
14 days following BmL3 infection, harvested spleens from sham or infected 
mice were dissected and a single cell suspension created by teasing apart of 
splens on top of a 40 m cell sieve (Sigma, Dorset) followed by maceration 
of remaining spleen tissue through the sieve using the handle of 2ml 
syringes (Sigma, Dorset). The resultant single cell suspension was depleted 
of red blood cells utilising RBC lysis buffer (Biolegend, UK) as per 
manufacturer’s instructions, followed by resuspension in Roswell Park 
Memorial Institute (RPMI) 1640 media (Sigma, Dorset) supplemented with 
10% Foetal Bovine Serum (Sigma, Dorset), Penicillin / Streptomycin 100 
I.U./mL (Sigma, Dorset) and Amphotericin B 2.5mg/L 
Resuspended splenocytes were plated at a concentration of 2.5x105 
cells/well onto 96 well plates (Starlab, UK) previously coated with 1.25µg/ml 
anti-CD3 (Biolegend, UK) for a minimum of 2 hours. Following plating, wells 
were supplemented with 2 µg/ml soluble CD28 (Biolegend, UK) and 
incubated for 72 hours at 37ºC and 5% CO2. Following incubation, plates 
were centrifuged and supernatants harvested and stored at -20ºC until 
assayed. 
Splenocyte supernatants were thawed slowly and assayed for: Interleukin 
(IL)-4, IL-13, IL-10 and Interferon-gamma (IFN-γ) utilising appropriate Duo-
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set enzyme-linked immunosorbent (ELISA) assays (R&D systems, 
Abingdon) as per manufacturer’s protocol. 
5.2.7-Statistical Analysis 
 
All continuous data was tested for normal distribution using the 
Kolgmoronov-Smirnoff test for equal variance. Where data was normally 
distributed, a two-tailed independent student’s t-Test was used to test for 
significant differences between two groups. Where data was found to be not 
normally distributed, a log transformation was first attempted and data re-
tested for equal variance. If data remained non-parametric, a two-tailed 
Mann-Whitney U test was utilised to test for significant differences between 
two groups. Where more than 2 groups were being compared, a One-way 
ANOVA was utilised with a Tukey’s post-hoc comparisons test to measure 
differences in parametric data, while a Kruskal-Wallis test was used for non-
parametric data with Dunn’s post-hoc multiple comparisons test. The mean 
along with the standard error of the mean (SEM) are reported in all data 
unless otherwise stated. Significance is indicated as *=P<0.05, **=P<0.01, 
***=P<0.001 in all figures unless stated otherwise. 
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5.3- Results 
 
5.3.1- Ablation of adaptive immune responses results in significantly reduced 
lymphatic remodelling and insufficiency. 
 
To investigate a possible role of adaptive immune responses in the rapid 
onset of lymphatic pathologies observed following BmL3 infection, BABLB/c 
SCID and BALB/c WT were inoculated in the left hind limb with 100 BmL3 or 
sham inoculations and aberrant lymphatics and lymphatic insufficiency 
quantified, at both 14dpi and 35dpi (infection schematic in figure 5.1A) using 
PDE imaging and other readouts detailed in Chapter 2.2.1-2.2.7. 
Compared to WT Sham controls,  WT BmL3 infected mice demonstrated 
significantly increased aberrant lymphatics in: dorsal (67.4±25.7 vs 0.2±0.2 
A.U. P<0.05), ventral (168.5±24.6 vs 0.2±0.1 A.U., P<0.01) and Left 
(186.6±63.8 vs 0.2±0.2 A.U. P<0.01; viewpoints, comparing BmL3 inoculated 
vs sham inoculated animal limbs at 14dpi (Figure 5.1B-C) . SCID mice 
infected with BmL3 displayed no significant difference in aberrant lymphatics 
across all imaged viewpoints, compared to SCID sham-infected 
counterparts.(Figure 5.1B-C) Further, WT BmL3 mice demonstrated 
significantly higher aberrant lymphatics in the ventral viewpoint (168.5±24.6 
A.U vs 67.9±39.2 A.U., P<0.05), compared to SCID BmL3 counterparts 
(Figure 5.1B&C).  
At 14dpi, WT BmL3 mice displayed significantly higher ICG retention in 
BmL3 inoculated left limb compared to WT sham counterparts (Figure 5.1D; 
0.44±0.08 vs 1.0 ± 0.02 R/L Leg ratio, P<0.001). ICG retention in SCID 
BmL3 mice compared to SCID sham counterparts was not as profound and 
did not gain statistical significance (Figure 5.1D). Additionally, WT BmL3 
mice demonstrated significantly higher Evan’s Blue dermal retention, 
measured at OD620, than WT Sham counterparts (Figure 5.1E; 0.1±0.01  vs 
0.08±0.01 OD620, P<0.05) while no significant difference in Evan’s Blue 
dermal retention was observed between SCID BmL3 and sham inoculated 
mice (Figure 5.1E). 
189 
 
At 5 weeks post-infection, WT BmL3 mice demonstrated significantly higher 
levels of aberrant lymphatics in the ventrally PDE imaged viewpoint, 
compared to SCID counterparts, (Representative image in Figure 5.1F, 
Figure 5.1G; 143.4 ± 57.4 vs 27 ± 27 A.U, P<0.05).  
 
5.3.2- BmL3 infection induces significant expansion of IL-4, IL-13 and IL-10 
expressing CD4+ T-cells in local draining lymph nodes. 
 
Local adaptive immune responses to B. malayi L3 (BmL3) larval infection 
were characterised at 14dpi. WT mice were inoculated with 100 BmL3 and 
lymphoid cells from skin draining lymph nodes (sdLN- popliteal (pLN, iliac 
(iLN), sub-iliac (siLN)) proximal to inoculation site in the left limb were 
extracted. Subsequent intracellular cytokine flow cytometry of harvested 
sdLNs from BmL3- and sham-inoculated groups was undertaken to 
characterise CD4+ T-cell cytokine expression. Simultaneously, systemic 
adaptive immune responses were interrogated by preparing splenocyte cell 
suspensions from BmL3- and sham-inoculated groups 14dpi before 
undertaking splenocyte recall immuno-assays. 
Compared to sham control mice, BmL3-infected mice demonstrated 
significant expansions of IL-4 (0.8±0.12 vs 2.95±0.32 %IL-4+ CD4+ T-cells , 
P<0.01) IL-13 (0.86±0.11 vs 2.7±0.3 %IL-13+ CD4+ T-cells, P<0.05), and IL-
10 (0.76±0.08 vs 1±0.07 %IL-10+ CD4+ T-cells, P<0.01) expressing CD4+ T-
cells in sdLNs proximal to infection site (Figure 5.2A&B). No significant 
difference in IFN-ƴ expressing CD4+ T-cells was observed between sham 
controls and BmL3 infected mice at 14dpi (Figure 5.2A&B). Further, 
polyclonal CD3/CD28 splenocyte recall responses were significantly 
increased post-BmL3 infection compared with sham-inoculated mice in terms 
of IL-4 (1.45±0.43 vs 0.35±0.02 ng/ml, P<0.05), IL-13 (2.3±1.1 vs 0.3±0.02 
ng/ml, P<0.01), IL-10 (896.9±389.3 vs 71.2±12.8 pg/ml, P<0.01) and IFN-ƴ 
secretion (13.0±2.5 vs 2.9±0.47 ng/ml P<0.01) (Figure 5.2C). While no 
statistical significance was attained, there was a trend to suggest expansions 
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of splenocyte CD4+ t-cell expressing IL-4, IL-13 and IL-10  splenocytes 
(Figure 5.2D). 
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Figure 5.1: Defective adaptive Immune responses in Severe Combined 
Immuno-Deficient (SCID) mice results in significantly lower severity of 
lymphatic remodelling and insufficiency compared to Wild Type (WT) 
mouse counterparts, following filarial BmL3 infection.  
A) Schematic of infection experiments involving inoculation of 100 BmL3 into 
left hindlimb of BALB/c Wild type (WT) and BALB/c adaptive immune 
response deficient  Severe Combined Immune-Deficiency (SCID) mice B) 
Representative 14dpi PDE imaging of WT BmL3 vs SCID BmL3 mouse 
cohorts C) Quantification of PDE imaged: : aberrant lymphatic remodelling in 
dorsal, ventral and left leg viewpoints and D) PDE measured lymphatic 
insufficiency from quantification of ICG fluorescence retention in ROI lower 
hind limb between sham infected (SCID Sham, WT SCID) vs SCID BmL3 
and WT BmL3 groups. E) Quantification of lymphatic insufficiency utilising 
Evan’s Blue dermal retention assay. Evan’s Blue was measured at OD620 
following 14dpi in indicated groups F) Representative 35dpi PDE imaging of 
ventral viewpoint WT BmL3 vs SCID BmL3 mouse cohorts G) Quantification 
of PDE imaged aberrant lymphatic remodelling in ventral viewpoint 35dpi. 
Horizontal bars plot the mean ±SEM. Data pooled from 2 individual 
experiments (WT 14dpi) (N=5 per group) or a single experiment (SCID 
14dpi) (N=4 per group) (WTvsSCID 35dpi N=10 per group). Significance is 
indicated as *P<0.05 **P<0.01 ***P<0.001 nd=non-significant, derived from a 
one way ANOVA followed by Tukey’s multiple comparisons post-hoc test, 
between indicated groups. 
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Figure 5.2: BmL3 infection induces a strong local Th2 adaptive immune 
response, 14dpi in sdLNs proximal to inoculation site concurrent with a 
mixed Th1/Th2 systemic response. 
A) Intracellular cytokine staining gating strategy and representative flow 
cytometry plots of sdLN/splenocytes CD4+ T cells from sham- vs BmL3-
infected C57BL/6J mouse groups at 14dpi B) Quantification of sdLN IL-4+, 
IL-13+, IFN-γ+ and IL-10+ expressing CD4+ T-cells, between sham and BmL3-
infected mouse cohorts, 14dpi.. C) Splenocyte recall responses from BmL3 
and sham infected mouse groups, following a 72hour stimulation with 
immobilised anti-CD3 and soluble anti-CD28. Bar graphs demonstrate 
cytokine concentrations derived from ELISAs undertaken on cell 
supernatants. D) Quantification of splenocyte IL-4+, IL-13+, IFN-γ+ and IL-10+ 
expressing CD4+ t-cells, between sham and BmL3-infected mouse cohorts, 
14dpi, data is normalised to mean fold change of cytokine expression from 
relevant sham infected cohorts. All graphs plot the mean ±SEM, each data 
point plotted represents a single mouse (B). Data represents data pooled 
from 3 individual experiments (A + B n=9-13 mice per group) or a single 
experiment of 5 mice per group (C+D). Statistical significance is indicated as 
*=P<0.05 **=P<0.01 ***=P<0.001, derived from Student two-tailed t-tests 
comparing sham- vs BmL3-inoculated mice for individual cytokines.  
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5.3.3- Impaired Th2 Adaptive immune responses in IL-4Rα-/- mice abrogates 
filarial induced lymphatic remodelling and insufficiency following BmL3 
infection. 
 
Because adaptive immunity was implicated as necessary for the full 
development of lymphatic pathology, together with Th2 adaptive immune 
responses appearing to be upregulated locally in the sdLNs following 
infection, the role of Th2 adaptive immune responses was investigated. IL-
4Rα-/- mouse cohorts were infected alongside WT counterparts with 100 
BmL3/sham control SC in the left hind limb. 14dpi, lymphatic remodelling and 
insufficiency was quantified (as described in Chapter 2.2.2-2.2.7). Both 
BALB/c/ BALB/C IL-4rα-/- and C57BL/6J/ C57BL/6J IL-4rα-/- mouse strains 
were investigated due to the strain-dependency of lymphatic pathology 
(detailed in Chapter 2.). 
Fourteen days following BmL3 infection, BALB/c IL-4Rα-/- mouse cohorts 
displayed significantly reduced expansion of sdLN CD4+ cells expressing IL-4 
(1±0.05 vs 2.5±0.66 fold change from sham , P<0.01) IL-13 (1.0±0.15 vs 
2.5±0.4 fold change from sham, P<0.05), and IL-10 (1.6±0.43 vs 3.8±0.43 
fold change from sham, P<0.01), compared with WT counterparts (Figure 
5.3B). 
Post-infection at 14 days, BALB/C IL-4Rα-/- mice also displayed significantly 
reduced aberrant lymphatics in ventral (12.4±8.5 vs 231.6±33.0 A.U, 
P<0.001) and left (0.07±0.07 vs 150.8±44.4 A.U., P<0.01) aspects of 
infected limbs determined by contrast imaging of ICG lymphatic flow (Figure 
5.3A&C). C57BL/6J IL-4Rα-/- mice, 14dpi with 100 BmL3 larvae, also 
displayed significantly reduced aberrant lymphatics in the ventral (243.8 ± 
97.6 vs 611.6±101.6 A.U, P<0.01) aspect of infected limbs by ICG imaging 
(Figure 5.3A&C).  
BALB/C IL-4Rα-/-mice infected with BmL3 exhibited significantly decreased 
retention of ICG in the left infected limb (0.84±0.16 vs 0.44± 0.01 R/L leg 
fluorescence ratio, P<0.05, Figure 5.3A&D) compared to WT counterparts. 
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Further, in BALB/C IL-4Rα-/- mice, there was no significant alteration in ICG 
retention level between IL-4Rα-/- BmL3- and sham-infection controls.  
On the C57BL/6J background, whilst WT mice displayed significantly 
increased retention of ICG in the left infected limb compared to sham 
controls at 14 dpi (0.57±0.09 vs 0.99±0.034 R/L leg fluorescence ratio, 
P<0.001), no significant difference was observed between BmL3- and sham-
infection groups in IL-4Rα-/- mice (Figure 5.3A+D).  
BALB/c WT mice had significantly increased retention of Evan’s Blue at 
14dpi with BmL3 compared to sham-infection controls (Figure 5.3E; 
0.11±0.01 vs 0.08±0.01 OD620, P<0.001), determined at end point via the 
Evan’s Blue dermal retention assay. Corresponding, BALB/c IL-4Rα-/-mice 
infected with BmL3 displayed significantly decreased retention of Evan’s 
Blue (Figure 5.3E; 0.09±0.01 OD620 , P<0.05 vs WT BALB/c infected mice).  
C57BL/6J mice, 14dpi, also displayed significantly increased Evan’s Blue 
retention compared to C57BL/6J WT sham-infection controls (Figure 5.3E; 
0.17±0.03 vs 0.07±0.01 OD620, P<0.001). No significant difference in Evan’s 
Blue dermal retention was observed between corresponding C57BL/6J IL-
4r-/- mouse groups (Figure 5.3E). 
5.3.4- Lymphangiogenic mediators in circulation following BmL3 infection are 
altered in IL-4Rα-/- mice. 
  
The circulatory profile of a panel of lymphangiogenic markers, including 
those shown to be significantly associated with filarial-associated lymphatic 
pathology (Chapter 3), was investigated in WT and IL-4Rα-/- mice from 
BALB/c and C57BL/6J strains following inoculations with 100 BmL3.  
In C57BL/6J mice (Figure 5.4A&B), BmL3 infected WT mice displayed 
significantly increased circulating serum levels of: VEGF-C (2.47±1.3-4.3 
IQR median fold-change, P<0.01), sALK-1 (1.47± 0.8-2.9 IQR median fold-
change, P<0.05) and TNF-α ( 1.39± 1.1-2.1 IQR median fold-change, 
P<0.05) compared to sham-infection controls. Contrastingly, Endoglin was 
significantly decreased compared to sham-infection controls (0.83± 0.51-0.96 
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IRQ median fold- change, P<0.05).  In comparison, BmL3 infected IL-4Rα-/- 
mice demonstrated significantly lower levels of circulating VEGF-C (0.58± 
0.47-1.5 IQR median fold-change, P<0.05), sALK-1 (0.67± 0.5-1.9 IQR 
median fold-change, P<0.05), TNF-α (0.69± 0.14-1.3 IQR median fold-
change, P<0.05), FGF-2 (0.7± 0.48-0.84 IQR median fold-change, P<0.05) 
compared to BmL3 infected WT mice. Additionally, there was a significant 
increase in Endoglin in BmL3 infected IL-4Rα-/- (0.97± 0.9-1.2 IQR median 
fold-change) compared to WT BmL3 infected mice. Further, comparing 
circulating levels between BmL3- and sham-infected IL-4Rα-/- mice, a 
decreased level of FGF-2 was discernible (0.7± 0.48-0.84 IQR median fold-
change, P<0.05), whilst there was no significant difference in VEGF-C, 
sALK-1, TNF-α or Endoglin between BmL3-  and sham-infected IL-4Rα-/- 
mice (Figure 5.4A-B). 
 
In BALB/c mice (Figure 5.4A&C), compared to sham-infections, BmL3-
infected mice displayed significant increased circulatory sALK-1 (1.35± 1-
1.7IQR  median fold-change, P<0.001), Follistatin (1.36± 0.84-2.1 IQR 
median fold-change, P<0.01), PLGF-2 (1.16± 0.8-2 IQR median fold- 
change, P<0.05) and Leptin (1.14± 0.9-1.6 IQR median fold-change, 
P<0.05). Comparatively, IL-4Rα-/- BmL3 infected BALB/c mice displayed 
significantly reduced sALK-1 (0.9± 0.7-1.4 IQR median fold-change, P<0.05), 
Follistatin (0.7± 0.6-1.4 IQR median fold- change, P<0.05), PLGF-2 (0.69± 
0.6-0.9 IQR median fold-change, P<0.01), Leptin (0.82± 0.4-1 IQR median 
fold-change, P<0.01), FGF-2 (0.64± 0.3-0.9 IQR median fold-change, 
P<0.01) and VEGF-A (0.75± 0.5-0.9 IQR median fold-change, P<0.05) 
compared with fold-changes in WT BmL3 infected mice (Figure 5.4A&C). 
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Figure 5.3: Development of lymphatic remodelling and insufficiency 
following BmL3 filarial infection are ameliorated in the absence of IL-
4Rα immune responses. 
A) Representative PDE lymphangiograms of mice groups B) BALB/c CD4+ 
cytokine expressing T-cells in sdLN’s proximal to inoculation site were 
quantified using intracellular cytokine staining flow cytometry, graph plots 
mean fold change of the cytokine expressing T-cells populations from 
relevant sham inoculated control groups C) Quantified lymphatic remodelling, 
measured by aberrant lymphatics in: left, dorsal and ventral views from PDE 
imaging D) Quantified lymphatic insufficiency from PDE imaging, measured 
by ICG fluorescence retention in the ROI of lower hind-limbs, s. E) Dermal  
lymphatic backflow quantified utilising the Evan’s Blue dermal retention 
assay at 14dpi experimental endpoint.  Graph bars in B and horizontal bars  
in C-E plot the mean ±SEM with data pooled from 3 separate experiments 
(C-E, n=5-20 per group- data for C57BL/6J WT sham and BmL3 infected 
data has been reused from figure 2.2B&C) or a single experiment (B, n=4-5 
per group). Statistical significance is indicated *P<0.05 **P<0.01 ***P<0.001 
derived from a two-tailed student t-test comparing fold change of individual 
cytokines of infected groups  (B) or a one-way ANOVA with Tukey’s multiple 
comparisons post hoc test (C-E) 
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In addition, levels of sALK-1, Follistatin, PLGF-2 or VEGF-A were not 
significantly altered between IL-4Rα-/- BmL3- and sham-infected mice, while 
there was a significant decrease in Leptin (1.14± 0.9-1.6 IQR median fold-
change, P<0.01) and FGF-2 (0.64± 0.3-0.9 IQR median fold-change, 
P<0.01) (Figure 5.4A&C). 
5.3.5- C57BL/6J IL-4rα-/- mice demonstrate significantly lower expansions of 
MФ’s, T and B-cells in lymphoid tissue local to inoculation sites following 
BmL3 infection, than WT BmL3 infected counterparts. 
 
The impact of IL-4R-/- ablation on leukocyte cellular recruitment and/or 
proliferation in the local immune microenvironment, proximal to BmL3 
infection was investigated. Cells derived from local sdLNs and the 
connecting major afferent / efferent lymphatic channels were isolated 14dpi 
with 100 BmL3 into the left hind limb of C57BL6/J WT and IL-4Rα-/- mice. 
While both WT and IL-4Rα-/- BmL3-infected mice demonstrated significant 
increases in total sdLN cellularity compared with sham-inoculated controls, 
WT BmL3-infected mice displayed a significantly higher total cellularity than 
IL4R-/- mice (5.5x107±5.5x106 cells vs 2.4x107± 4.9x106, P<0.001 Figure 
5.5B). 
Compared to Sham controls, within the local lymphatic / lymphoid cell 
suspension, WT BmL3-infected mice demonstrated significantly higher 
increases of CD3+ T-cells (3.36±0.32 vs 1.97±0.51 mean fold-change, 
P<0.05), B220+ (CD45R) B-cells (7.4±1.42 vs 2.53±0.67 mean fold-change, 
P<0.05) and F480+ MФ’s (2.94±0.51 vs 0.56±0.16 mean fold-change, 
P<0.001) compared to IL-4Rα-/- BmL3-infected mice (Figure 5.5A&C).  
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Figure 5.4: IL-4Rα-/- mediated deficiency of Th2 adaptive immune 
responses significantly attenuates secretion of lymphangiogenic 
molecules linked with pathological filarial associated lymphatic 
remodelling, following BmL3 infection. 
A) Heatmap depicting mean fold-change increases (red) or decreases (blue), 
compared to sham-infected controls, in circulating serum 
lymphangiogenic/angiogenic factors in WT and IL-4Rα-/- mice following BmL3 
infection determined by luminex multiplex immunoassay. Separate heatmaps 
are plotted for C57BL/6J and BALB/c strains B&C) serum analytes with 
statistically significant changes between WT and IL-4rα-/-  BmL3 infected 
mice, plotted as fold-change from the mean levels in relevant strain sham 
control groups. B) C57BL/6J strain C) BALB/c strain. Horizontal bars 
represent median± Interquartile range with data pooled from 3 separate 
experiments, with WT data reused from figure 3.3. (n=4-27 per group). 
Statistical significance is represented as *P<0.05 **P<0.01 ***P<0.001 
derived from a Mann-Whitney U-test or a Kruskal Wallis test with Dunn’s 
multiple comparisons post hoc test. 
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5.3.6- Macrophages in draining lymphoid tissues local to inoculation site 
express significantly higher levels of the alternatively activated macrophage 
markers CD206 and Relm-α. 
 
To investigate if expanded macrophage populations local to the BmL3 
infection site demonstrate a ‘Th2-associated alternative activation (AAM) 
phenotype, expression of two markers of alternative activation of 
macrophages (mannose receptor; CD206 and RELM) were compared 
between C57BL/6J sham- and BmL3-infected mice at 14dpi, using flow 
cytometry. 
C57BL/6J BmL3 infected cohorts were observed to display significantly 
increased expression of CD206 and RELMα in draining lymphatic/lymphoid 
tissues, compared to sham infected controls (Figure 5.6A&B; CD206: 
85.6±2.2 vs 55.8±2.5%, P<0.001, RELM: 15.7±1.6 vs 1.3±0.2% P<0.001,). 
5.3.7- Human monocyte derived macrophages polarised with recombinant 
IL-4 and IL-13 induce significant LEC proliferation  and secrete higher 
concentrations of lymphangiogenic molecules in vitro. 
 
Analysis of the in vivo data presented above indicates a Th2 adaptive 
immune response predominates in the infection microenvironment with 
associated IL-4R-dependent increases in lymphatic remodelling, lymphatic 
dysfunction and systemic circulating lymphangiogenic mediators. Further an 
AAM expansion is apparent at the site of infection and lymphatic pathology. 
Considering data from previous chapters implicating 
monocytes/macrophages with the induction of lymphatic pathology, the 
potential of differential, cytokine conditioned macrophages to induce LEC 
proliferation was investigated. The co-culture system developed in chapter 4 
was utilised as shown in figure 5.7A with human THP-1 monocyte-derived 
macrophages stimulated with either Th1-associated recombinant (r)IFN-γ or 
Th2-associated rIL4 and rIL-13. 
The proliferation of LECs co-cultured in the presence of MФ’s stimulated with 
rIL-4 and rIL-13 (M(IL-4/13) was significantly higher than LECs cultured 
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alone in an 80% basal, 20% full growth medium (80:20) (Figure 5.7B; 
1.85±0.12 vs 1.0±0.03  mean fold-change, P<0.001), LECs co-cultured with 
macrophages receiving no cytokine stimulation (M0) (1.13±0.04 mean fold-
change from 80:20, P<0.001) or LECs co-cultured in the presence of MФ’s 
conditioned with rIFN-γ (M(IFN)  (1.14±0.08 mean fold-change from 80:20, 
P<0.001) (Figure 5.7B). No significant difference in LEC proliferation was 
observed between LECS co-cultured with M(IFN-γ) and LECs cocultured 
with either M0 or 80:20 media alone (Figure 5.7B). Conditioned media from 
MФ’s stimulated with rIL-4 and rIL-13 contained significantly increased 
concentrations of the lymphangiogenic molecules: VEGF-A (2.1 ± 0.4 vs 1± 
0.2 , P<0.05), Follistatin (1.2 ± 0.02 vs 1 ± 0.02, P<0.01) and HGF (1.2 ± 
0.05 vs 1.0± 0.03, P<001) compared to undifferentiated MФ’s (M0), while 
significantly decreased endoglin concentrations (0.89 ± 0.03 vs 1.0 ± 0, 
P<0.01) were observed (Figure 5.7C). 
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Figure 5.5: IL-4Rα-/- deficiency in C57BL/6J mice results in significantly 
reduced proliferation/recruitment of specific immune cells to local 
lymphatic / lymphoid tissues following BmL3 infection. 
A) Gating strategy utilised to phenotype immune cell populations, strategy 
depicted previously gated on live, single cell LN populations B) Quantification 
of total cellularity of pooled sdLNs and associated lymphatics through total 
cell count C) Quantified changes in local lymphatic / lymphoid cell 
populations, plotted as a mean fold-change from relevant sham control, after 
immuno-phenotyping C57BL/6J sdLN suspensions using flow cytometry. 
Bars represent mean±SEM with data from a single experiment. Statistical 
significance is represented as *P<0.05 **P<0.01 ***P<0.001 derived from a 
one-way ANOVA with Tukey’s multiple comparison post-hoc test (B) or two 
tailed student t-test (C).  
207 
 
 
  
 
A 
B 
Sh
am
Bm
L3
40
60
80
100 ***
%
 C
D
2
0
6
+
 M

Sh
am
Bm
L3
0
5
10
15
20 ***
%
 R
E
L
M
- 
+
 M

M
H
C
II
 
F480 
L
y
6
C
 
Cd11b 
C
d
1
1
b
 
MHCII 
C
d
1
1
b
 
CD206 
S
h
a
m
 
B
m
L
3
 
CD206 
58.3% 
83.2% 
1.25% 
RELM-α 
16.7% 
C
d
1
1
b
 
Relm-α 
MФ 
208 
 
Figure 5.6: BmL3 infection in C57BL/6J mice induces an ‘Alternatively 
Activated Macrophage (AAM)’ phenotype in lymphatic / lymphoid 
tissues local to the BmL3 infection site. 
A) Gating strategy and representative flow cytometry dot plots. Gating 
strategy applies to samples previously gated on live, single cells B) CD206+ 
and RELM-α+ expression as a percentage of total macrophages from 
C57BL/6J BmL3- or sham-infected mice. Horizontal bars represent the 
mean±SEM with data pooled from two separate experiments (CD206) (n=11) 
or one individual experiment (RELM-α) (n=6). Statistical significance is 
indicated as ***=P<0.001, derived from a two-tailed student’s t-test. 
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Figure 5.7: Exposure of monocyte derived macrophages to rIL-4 and 
rIL-13 induces significant proliferation of LECs in vitro 
A) Schematic of developed co-culture system utilised B) Quantified 
survival/proliferation of LEC cells when co-cultured with differential-cytokine 
conditioned macrophages: differentiated macrophages with no further 
stimulation (M0), conditioned with rIFN-γ (IFN-γ) or conditioned with rIL-4 
and rIL-13 (IL4-+IL-13) in cell insets. Data is plotted as fold-change in LEC 
number from LECs cultured in 80:20 (basal media) only. C) Conditioned 
media from experiments in B) were assayed using a multiplex panel, of 
known lymphaniogenic molecules with analytes attaining statistically 
significant concentrations shown Data is plotted as the fold change in LEC 
number from LECs cultured in basal media only (B) or fold change in analyte 
concentration from undifferentiated M0 controls (C). Horizontal bars 
represent mean±SEM with data pooled from three separate experiments 
(N=15-19 per group) (B) or two individual experiments (N=5 per group) (C) 
Statistical significance is represented as *=P<0.05, **=P<0.01 ***=P<0.001 
derived from a one- way ANOVA with Tukey’s multiple comparison post-hoc 
test (B) or a student’s two-tailed t-test (D).  
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5.4- Discussion 
 
Th2 responses are critical for eosinophil-predominated worm attrition and 
resistance to filarial re-infection in animal models of infection (Osborne, 
Hunter and Devaney, 1996; Babu et al., 2000; Spencer, Shultz and Rajan, 
2001; Taylor et al., 2005; Turner et al., 2018). Successful establishment of 
chronic filarial infections appear dependent on modifying and suppressing 
these overt anti-parasite Th2 responses. Clinically, asymptomatic, 
microfilaraemic patients presenting with patent infection commonly exhibit a 
‘modified’ Th2 response coincident with increased adaptive 
immunomodeulatory regulatory T-cell responses (Metenou et al., 2010; Babu 
and Nutman, 2012). PBMCs from permissive microfilaraemic individuals can 
be stimulated to produce elevated Th1 and Th2 cytokines to filarial antigens 
if regulatory cytokines, IL-10 and TGF− are neutralised in culture (King et 
al., 1993). Further, in permissive rodent models of filariasis, depletion of 
regulatory T cells reverses Th2 hyporesponsiveness and mediates increased 
resistance against chronic adult infection (Taylor, 2005). 
The role of anti-parasite Th2 responses in induction of filarial pathology are 
less well-defined. Filarial LE patients exhibit increased serum concentrations 
of Th2 associated cytokines (Anuradha et al., 2012). In an Athymic (nude) 
mouse model of intra-lymphatic brugian filariasis, reconstitution of adaptive 
immunity is necessary for the development of severe LF lymphoedematous 
pathology (Vickery et al., 1991). Further in a recently published ferret model 
of lymphatic filariasis, expression of mixed Th1 and Th2 responses was 
associated with development of lymphoedematous pathology(Jackson-
Thompson et al., 2018).  
Data presented in chapter two demonstrated that substantial lymphatic 
pathology occurs far earlier in the infection time-course than previously 
realised, with rapid onset observed as little as 6 days following primary B. 
malayi larval infection. An important objective of this chapter, therefore, was 
to investigate adaptive immune control of the initiation of filarial-infection 
induced lymphatic pathology. Utilising the developed pathology model, SCID 
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mice, with impaired adaptive immune responses ((Bosma and Carroll, 1991; 
Nelson et al., 1991)) were compared against immune-competent 
counterparts to measure differences in lymphatic remodelling and associated 
lymphatic dysfunction. SCID mice were less prone to initiation of lymphatic 
pathologies post-infection. Additionally, lymphatic insufficiency was shown to 
be partially ameliorated in SCID mice post-infection. Taken together, these 
data promote a role for the initial adaptive immune response, to larval 
lymphatic infection, in mediating lymphatic remodelling and associated 
lymphatic dysfunction. This partially emulates studies of adult Brugia 
infections within T-lymphocyte deficient (athymic) nude mice, demonstrating 
LF related pathology only occurs following adoptive transfer of adaptive 
immune competent splenocytes/T-cells (Vickery et al., 1991) but indicates 
that larval infection can trigger pathology much earlier in the B. malayi 
infection time-course. Interestingly, a non-significant trend may suggest that 
early lymphatic pathology was not completely abrogated in SCID mice. 
Localised lymphatic dilation (lymphangectasia) has been detailed in 
lymphopenic mice post-infection with B. malayi (Vincent et al., 1984; Nelson 
et al., 1991; Vickery et al., 1991). Therefore, either filarial-induced changes 
and/or innate immune processes may contribute to a minor degree in 
development of lymphatic activation post-filarial parasitism. Indeed, in 
chapter 4, it was determined that B. malayi live L3 or L3 extracts (BmL3E) 
could activate human monocyte-derived M to trigger LEC proliferation. 
It was thus important to characterise the type of adaptive immune responses 
that were initiated by B. malayi larval intra-lymphatic infections. Intracellular 
cytokine staining of sdLN’s proximal to inoculation sites demonstrated 
significant upregulation of IL-4, IL-13 and IL-10 CD4+ expressing T-cells in 
BmL3 infected mice, compared to sham controls. The presence of an IL-4, 
IL-13 and IL-10 dominated local environment is highly indicative of a 
localised Th2 polarised adaptive immune response (Corthay, 
2006)(Osborne, Hunter and Devaney, 1996; Osborne and Devaney, 1998; 
Babu et al., 2000; Spencer, Shultz and Rajan, 2001; Babu and Nutman, 
2014). Systemic immune responses, examined using splenocyte recall 
responses indicated a more mixed Th1/Th2 response, with significantly 
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higher secretion of Th1 related IFN-γ as well as IL-4, IL-13 and IL-10 
observed in BmL3 infected mice. Whilst it is presently unclear why splenic 
adaptive immune responses may be more mixed, previous studies have 
noted similar, mixed Th1/Th2 observations following filarial infection (Babu et 
al., 2000; Saeftel et al., 2003). Mixed adaptive immune responses may be 
potentially driven by parasite (Th2) stimulation, including responses to their 
secretions, concurrently with inflammatory (Th1) antigenic stimulation to the 
intracellular symbionts Wolbachia (Gentil, Hoerauf and Pearlman, 2012; 
Nutman, 2013) following death and disintegration of larvae. Further evidence 
for this hypothesis comes from studies showing that addition of Wolbachia 
derived lipoprotein alone was sufficient to deviate the strong Th-2 polarising 
potential of filarial material in dendritic cells (Turner et al., 2009). BmL3 larval 
death has been demonstrated to occur at the early 6-day time point in the 
developed model whilst there is no evidence of patent adult infections in 
immune-intact mice (Chapter 2) demonstrating that murine hosts would be 
subjected to both  Th2 polarising filarial material, as well as Th1 polarising 
Wolbachia antigens at the time points analysed.  
The known role of Th2 responses in anti-filarial immunity, together with 
evidence of strong Th2 responses in areas local to infection, remodelling and 
insufficiency, resulted in a hypothesis that Th2 responses may be necessary 
in the full induction of filarial-associated lymphatic pathology. To investigate 
this, IL-4Rα-/- mice, deficient in IL-4 and IL-13 signalling and thus displaying 
severely dysfunctional Th2 responses (Barner et al., 1998)(Stanton et al., 
2015), from both C57BL/6J and BALB/c strains were utilised. Both strains 
were selected in experiments because of the pronounced strain-variation in 
degree of lymphatic pathology identified in chapter 2. The IL-4Rα-/- mice 
displayed significantly reduced Th2 adaptive immune responses, in terms of 
IL-4 and IL-13, compared to WT controls, post-infection. Together these data 
confirmed ablation of Th2 responses in IL-4Rα-/-  mice local to infection, 
presumably due to nullification of autocrine IL-4/IL-13 –IL-4R positive 
feedback during the polarisation of Th2 CD4+ T cells. Via NIR optical imaging 
of infected limbs and ICG lymphangiography, significantly lower lymphatic 
remodelling, determined by a significantly lower level of aberrant lymphatic 
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channels, was apparent in the absence of IL-4Rα signalling. Concomitantly, 
IL-4Rα deficient mice displayed significantly less lymphatic dysfunction in 
terms of impeded lymphatic drainage / dermal backflow patterning usually 
observable in WT mice post-infection. Together, the data suggests polarised 
Th2 responses local to the infection site are functionally important in 
mediating aberrant lymphatic remodelling and insufficiency, induced by 
BmL3 infection. The reproducibility of these findings across the ‘high 
pathology’ C57BL/6J, as well as the ‘low pathology’ BALB/c strains further 
strengthens the primacy of IL-4/13-IL-4R adaptive immune response to 
filarial infection as necessary for the initiation of lymphatic pathology. 
Th2 adaptive immune responses have been shown to be important in wound 
healing and tissue repair, particularly as a primary defence to the overt 
damage inflicted by a range of extracellular parasites, including helminths 
(Taylor et al., 2006). Migrating BmL3 larvae and their death within lymphatic 
tissues will cause a level of tissue damage which will presumably invoke a 
local Th2 immune response. The data suggests however, that these repair 
mechanisms may be a double-edged sword, with the results suggesting 
‘runaway’ Th2 stimulation results in off-target lymphatic remodelling events 
that induce a state of lymphatic dysfunction. The ‘runaway’ magnitude of the 
localised Th2 response, inducing pathological consequences, might also be 
positively influenced by the delivery of a rich Th2 polarising potential (ie a 
bolus of somatic and excreted/secreted filarial helminth antigens) ‘delivered, 
en masse’ into and immediately adjacent to the local skin draining lymphoid 
tissues. While ablation of Th2 responses appears protective from early 
induction of filarial-associated lymphatic pathology, further work is required to 
investigate the long-term consequences, particularly how an absence of 
early Th2 mediated tissue repair could contribute to potential later 
development of pathology. Of more importance to future therapeutic 
strategies, regulation / modulation of the ‘strength’ of the Th2 response 
following initial infection may be of interest, as pre-clinical and clinical data 
suggests a strong correlation between asymptomatic, lack of clinical 
pathology, patient outcome and a skewed, highly immunoregulatory Th2 
response (Hoerauf et al., 2005; Taylor et al., 2005; O’Regan et al., 2014). 
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Inducing a more balanced, modified Th2-based immunity with correct levels 
of wound healing, may be important for preventing the induction of LE 
pathology. The mechanisms by which filarial larvae can induce these 
‘modified’ Th2 responses, particularly on effector immune cells may also be 
an area of future interest, as shown by previous findings (Allen and Loke, 
2001; O’Regan et al., 2014), along with work highlighted in chapter four 
demonstrating how parasite material can induce monocytes and 
macrophages to induce lymphatic endothelial proliferation directly. 
Interestingly, utilisation of parasite material has been shown to strongly 
induce regulatory immune responses, with potential therapeutic applications 
against autoimmune disorders currently an area of intense research 
(Hewitson, Grainger and Maizels, 2009; McSorley, Hewitson and Maizels, 
2013). Utilisation of immunoregulatory parasite materials, or increasing the 
availability of filarial derived immunomodulatory proteins may prove useful in 
“resetting” immune responses or modulating  “runaway” Th2 immune 
responses responsible  for lymphatic pathology. As these proteins are 
mechanisms used by helminths for immune evasion, however it will be 
important to achieve a balance between controlling “wound healing” Th2 
responses, while still achieving sufficient levels of anti-parasitic Th2 
responses to allow worm expulsion 
The cellular and molecular mechanisms by which Th2 responses induce 
lymphatic pathology remain to be fully defined. Alongside data presented in 
chapter 3 demonstrating strong upregulation of a milieu of circulating 
lymphangiogenic factors following BmL3 infection, it was hypothesised that 
Th2 adaptive immune signalling may be necessary to induce the secretion of 
lymphangiogenic factors, local to infection, that are important in inducing 
lymphangiogenesis and dilation. To investigate this, IL-4Rα-/- and WT mouse 
serum lymphangiogenic profiles were compared following BmL3 infection. 
Lymphangiogenic factors associated with induction of lymphatic pathology in 
WT mice failed to show similar levels of upregulation in BmL3 infected IL-
4Rα-/- mice. Specifically, upregulation of VEGF-A, C, sALK-1, Follistatin TNF-
α, Leptin, PLGF-2, Endoglin and FGF-2 were significantly attenuated in the 
absence of IL-4R signalling. Some of these factors were impaired in both 
216 
 
background strains in the absence of IL-4R signalling (ALK-1 and VEGFs) 
whilst others were strain-dependent, suggesting a complex inter-dependent 
or redundant series of receptor-ligand pathways in inducing pathological 
lymphatic remodelling. Nevertheless, the data supports a requirement for IL-
4R Th2 immune signalling to mediate the release of a complex milieu of 
lymphangiogenic factors, some of which alone or in combination may be 
fundamental to induce activation, sprouting, migration and even trans-
differentiation of lymphatic endothelium/ progenitors leading to pathological 
remodelling. 
Chapter four discussed data demonstrating BmL3 infection results in 
expansion of monocytes and macrophages in sites proximal to infection and 
secrete significant concentrations of multiple lymphangiogenic molecules. 
This identified a potential role of monocytes/macrophages in the induction of 
lymphatic dysfunction, as depletion of either monocytes or macrophages 
lead to the amelioration of pathology. Macrophages express IL-4R (Weng et 
al., 2018), which once ligated by IL-4 or IL-13, result in polarisation to a 
functionally distinct AAM phenotype (Gordon and Martinez, 2010). AAM 
are defined by strong downregulation of nitric oxide production (Mills, 2012), 
concurrent with strong expression of arginase enzyme (Rath et al., 2014). 
Additionally, expression of the secreted molecules chitinase-like 3 (Ym-1) 
and Resistin-like molecule alpha (RELM-α) are only observed following 
polarisation to a AAM phenotype (Raes et al., 2002). AAM are shown to be 
strongly induced following helminth infection including filarial Brugia malayi 
(Loke et al., 2002; Hoerauf et al., 2005; Babu, Kumaraswami and Nutman, 
2009; Turner et al., 2018), as well as Heligmosomoides polygyrus, 
Nippostrongylus Brasiliensis and Litomosoides sigmondontis (Anthony et al., 
2006; Nair, Guild and Artis, 2006; Taylor et al., 2006). AAM play a key role 
as effector cells in the host response to helminth infection, inducing Th2 
inflammatory responses which, following Brugia malayi infection, are key to 
parasite clearance and worm expulsion (Turner et al., 2018). AAM, 
particularly following helminth infections, also play a key role in tissue repair 
and wound healing directly (Freedman et al., 1994; Allen and Wynn, 2011; 
Chen et al., 2012), through the secretion of factors such as matrix 
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metalloproteases (MMP’s) (Krzyszczyk et al., 2018) and members of the 
vascular endothelial growth factor (VEGF) family (Vannella and Wynn, 2017). 
Indirectly, AAM contribute to tissue repair by preventing excessive damage 
following inflammation, orchestrating its resolution through release of a milieu 
of anti-inflammatory/immunoregulatory molecules such as TGF-β, PDL-1 and 
IL-10 (Wynn and Barron, 2010; Wynn, Chawla and Pollard, 2013). In the 
context of helminth infection, it has been recently shown that AAM 
expression of Ym-1 and RELM-α is vital in lung tissue repair following the 
migratory stage of N. brasiliensis infection. IL-4Rα deficient mice, thus 
lacking AAM induction, demonstrated more severe lung tissue damage 
following infection compared to WT, while this was reversed with adoptive 
transfer of WT macrophages to IL-4Rα deficient mice.(Sutherland et al., 
2018)  
A preliminary question was to understand if ablation of Th2 responses 
significantly impacted on increased populations of macrophages and 
monocytes following filarial infection. At the local lymphatic and lymphoid 
tissues proximal to lymphatic invasion sites of BmL3 infection, IL-4R-
deficiency resulted in a significantly lower expansion in macrophages. This 
would suggest that Th2 adaptive responses are important in either mediating 
the recruitment of monocytes following filarial infection or activating 
macrophages as an effector mechanism to respond to filarial infection. The 
reduced macrophage/monocyte populations coincident with reduced 
lymphatic pathology in IL-4Rα-/- mice, together with the previously identified 
role for monocytes/macrophages in induction of lymphatic insufficiency 
(Chapter 4), suggests a role for Th2 adaptive responses in positively 
regulating the monocyte/macrophage cellular mechanism of pathology. 
When examining the phenotype of macrophages in lymphatic / lymphoid 
tissues proximal to sites of infection, significantly increased expression levels 
of the alternatively activated macrophage markers: CD206 (mannose 
receptor) and RELMα were evident, suggesting the significantly expanded 
macrophage population following BmL3 infection are polarising to an 
alternatively activated phenotype. 
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Mannose receptor and MHCII have prior been identified as markers of 
inflammatory monocyte recruited populations of AAM in situations of serous 
cavity and hepatic helminth-mediated Th2 inflammation, including filarial 
infection (Smith et al., 2004; Anthony et al., 2006; Mylonas et al., 2009; 
Jenkins and Allen, 2010). Whilst more experiments would be required (such 
as development of bone marrow chimeras) to formally prove the provenance 
of AAM at the filarial lymphatic pathology site, high MHCII and MR 
expression, together with a significantly decreased expression of tissue 
residence marker (Tim-4-)(Chapter 4) are evidence that these macrophages 
are recruited from the blood prior to alternative-activation and thus may be 
derived from CCR2+ recruited monocytes. 
To further interrogate the ability of IL-4/13 activated AAM to directly induce 
lymphatic remodelling, monocyte-derived macrophages conditioned with IL-
4/IL-13 recombinant cytokines were scrutinised for their ability to stimulate 
LEC proliferation in an in vitro co-culture system (see chapter 4). Monocytes 
recently differentiated to macrophages with no further stimulation, or 
conditioned with the Th-1 associated cytokine, IFN-γ, did not mediate 
significant proliferation of LEC cells, In contrast, monocyte derived 
macrophages, conditioned with rIL-4 and rIL-13 induced ~2-fold increases in 
LEC proliferation. This suggests that in a local environment dominated by 
Th2 adaptive responses, such as following early filarial infection, IL4/13 
conditioned AAM can induce LEC proliferation, enabling lymphatic 
remodelling to occur. Assaying of media conditioned by M’s stimulated with 
rIL-4 and rIL-13 demonstrated significantly increased secretion of a milieu of 
lymphangiogenic molecules, identified to be increased systemically in the 
murine model (Chapter 3) including: VEGF-A, Follistatin, HGF as well as 
significantly decreased Endoglin. While the replication from the murine model 
to the human in vitro system further highlights a role for these factors in 
mediating remodelling, it also demonstrates AAM’s actively secrete 
lymphangiogenic products that drive lymphatic remodelling and downstream 
insufficiency, presumably in a Th2 dominated environment. The data 
presented concurs with observations in oncology, where tumours can ‘hijack’ 
recruited macrophages into ‘tumour associated macrophages’ (TAM’s)- a 
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modified macrophage phenotype sharing characteristics with alternatively 
activated macrophages (Mantovani et al., 2002; Sousa et al., 2015; 
Yamaguchi et al., 2016). These modified ‘AAM like’ TAM’s mediate tumour 
survival through vascularisation of tumours (both through induction of 
angiogenesis and lymphangiogenesis (Lin et al., 2006; Du et al., 2008; 
Mazzieri et al., 2011; Riabov et al., 2014)) as well as metastasis (Sangaletti 
et al., 2008; Zhang et al., 2009; Qian and Pollard, 2010). This, together with 
the data discussed strengthens the assertion that the strong local Th2 
response that monocyte/macrophage effector cells are exposed to following 
BmL3 infection induces the AAM phenotype which is functionally important 
in lymphatic remodelling post-filarial infection. Additionally, in concert with 
highly polarised Th2 responses, filarial larvae may be able to directly polarise 
monocytes and/or macrophages into a lymphangiogenic phenotype  through 
parasite-host signalling (ie release of excretory secretory vesicles (Weinkopff 
et al., 2014; Jothi et al., 2016)). Evidence of this, concurring with the 
highlighted work above, was demonstrated in the same co-culture system in 
chapter 4. 
With data demonstrating a mechanism whereby Th2 adaptive immune 
signalling leads to recruitment and development of a pro-lymphangiogenic 
monocyte-macrophage lineage to induce lymphatic pathology, new 
therapeutic strategies that target or modulate Th2 responses/signalling may 
become of interest. While still in it’s infancy, nanoparticles that specifically 
target TAMs (such as through CD206 uptake), and deliver 
immunomodulatory molecules such as anti-IL10  or siRNA’s against iκβα  
were successful in cancer preclinical models at “re-educating” TAMs to an 
“M1” phenotype, which correlated with tumour regression (Huang et al., 
2012; Ortega et al., 2016). As eluded to above, it is possible that 
overstimulation of the Th2 anti-parasite response, potentially as a 
consequence of macro-parasitic infection within the ‘heart’ of the lymphatic 
system, may result in undesirable off-target effects such as overstimulated 
tissue repair pathways, leading to aberrant lymphatic remodelling. 
Therapeutic targets that aim to modulate the strength of Th2 responses to 
filarial infection, such as administration of anti-inflammatory medications or 
220 
 
blocking/depleting antibodies specific for Th2 responses, may be useful in 
preventing the overstimulation of the Th2 mediated lymphangiogenic 
pathways. Important consideration of such methods is necessary, however, 
with Th2 responses clearly an important facet of host defence to filarial 
infection, while later ‘regulated / modified’ Th2 responses even seem to be 
common in asymptomatic patient cohorts. This suggests the temporal 
induction, appropriate strength and type of Th2 responses may be key 
determinants of a pathological or asymptomatic outcome. Targeting the 
specific cellular or molecular effector mechanisms regulated by Th2 
signalling that mediate lymphatic pathology induction may therefore be a 
more promising approach. ‘Re-education’ of local monocyte/macrophage 
populations- as hypothesised in tumour associated macrophages (Noy and 
Pollard, 2014; Josephs, Bax and Karagiannis, 2015; Huber-Ruano et al., 
2017)- may help to prevent excessive remodelling, thus modifying the 
maintenance and progression to a state of LE, through limitation of the pool 
of lymphangiogenic mediators in the microenvironment back to levels more 
appropriate for wound healing only. 
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5.5- Chapter concluding remarks 
 
The objective of this chapter was to investigate the types of host adaptive 
immune responses present in the early time frame following filarial larval 
infection. More pertinently, it was important to understand if there was any 
association between induction of identified adaptive immune responses and 
the observed lymphatic remodelling and insufficiency post experimental B. 
malayi larval infection. Finally, the research aimed to investigate whether 
host adaptive responses are functionally important in the development of 
filarial-associated lymphatic pathology. The data clearly identifies a strong 
induction of localised Th2 adaptive immune responses following larval 
infection that it is temporally and spatially coincident with the induction of 
lymphatic dysfunction and concomitant increases in pro-lymphangiogenic 
mediators. Further, the data presented demonstrates Th2 signalling induces 
the expansion of a local population of AAM and provides in vitro evidence 
that IL-4/13 conditioned macrophages can directly stimulate lymphatic 
endothelial proliferation. 
While host Th2 adaptive immune responses are crucial for defence to filarial 
infection, off-target ‘runaway’ Th2 mediated mechanisms can contribute to 
pathology. Inappropriately strong induction of Th2 mediated ‘tissue repair’ 
pathways, can lead to aberrant lymphatic remodelling that contributes to 
filarial-infection lymphatic dysfunction. Consequently, Th2 adaptive 
responses can be viewed as a ‘double edged sword’ and the temporal 
induction, strength of and type of Th2 responses induced following filarial 
larval infection may act as key determinants to later manifestations of 
pathology in patients. Ultimately, this reveals potential novel therapeutic 
strategies whereby modulation of Th2 anti-filarial responses could be 
targeted to ameliorate pathological LF outcomes. 
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Chapter 6 
 
Concluding remarks 
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6.1- A new perspective on the role of lymphatic remodelling in filarial 
associated lymphatic pathology. 
 
Lymphatic remodelling is a “hallmark” of filarial infection, with alterations to 
the lymphatic architecture observed in both symptomatic and asymptomatic 
patient groups. It is therefore not certain what role lymphatic remodelling 
plays in the development of future filarial pathology, with evidence in other 
models of lymphatic disease suggesting not only a contributing role to 
pathology, but also a possible compensatory “wound healing” response by 
the host to repair lymphatic damage and restore homeostatic lymphatic 
function. A major obstacle to investigating the mechanism and 
consequences of filarial lymphatic remodelling is the lack of animal models 
that allows longitudinal interrogation of changes to the lymphatic architecture, 
following filarial infection. While recent development of a ferret limb 
pathology model (Jackson-Thompson et al., 2018) has provided promising 
insights, the lack of reagents or genetic knockouts strains in ferrets limits 
findings to temporal development of lymphatic remodelling, with a lack of 
ability to adequately investigate the mechanisms driving filarial lymphatic 
remodelling. 
The development of the novel murine inflammatory leg pathology model in 
immune-competent strains in this thesis demonstrated that profound 
alterations to the lymphatic architecture can be observed rapidly (as little as 
6 days) following infection, and in response to the infective L3 larval stage of 
filarial infection. Further, lymphatic remodelling was concomitant with 
lymphatic dilation and significant lymphatic insufficiency, all of which 
persisted long-term and post-clearance of filarial infection. It was previously 
hypothesised that lymphatic remodelling is a consequence of long term 
habitation of adult worms in lymphatic channels and, when combined with 
subsequent death events initiating inflammatory reactions, results in 
lymphatic alterations which contributes to a pathological outcome (Rajan et 
al., 1999; Figueredo-Silva et al., 2002; Bennuru and Nutman, 2009b). In 
contrast, the evidence presented within this thesis suggests lymphatic 
remodelling occurs far earlier than previously anticipated, with significant 
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remodelling occurring in response to initial infective larval stage of filarial 
infection. The accompanying pathology, the consistency with which these 
lymphatic alterations were observed (almost 100% of infected animals 
displayed degrees of remodelling and pathology) and persistence long term, 
post clearance of infection, suggests this early subclinical pathology is an 
important feature of filarial infection. A number of clinical studies have 
demonstrated significant lymphatic alterations, even in asymptomatic LF 
patients (Noroes et al., 1996; Shenoy et al., 2008; Kar et al., 2017). Further, 
subclinical, pathological changes to the lymphatics and changes in tissue 
fluid retention in clinically asymptomatic patients have also been observed 
(Douglass et al., 2017). Together, the work in this thesis demonstrates a 
previously underappreciated role of infective L3 filarial Larvae in the rapid 
induction of lymphatic remodelling which quickly results in “covert” subclinical 
pathological lymphatic insufficiency. 
6.2- BmL3 infection induces changes in expression of lymphangiogenic 
molecules which are implicated in lymphatic remodelling and pathology. 
 
With the successful development of a novel murine leg pathology model, a 
primary objective of the thesis was to characterise the mechanisms that 
induce the rapid lymphatic remodelling and pathology, observed following 
filarial infection. Assaying plasma against a focused panel of 27 growth 
factors and other molecules implicated in angiogenesis / lymphangiogenesis 
in various inbred murine strains and immune deficient animals revealed a 
milieu of factors which display significant upregulation/downregulation, 
concurrent with filarial lymphatic pathology. Further evidence strengthening a 
role for these lymphangiogenic factors was demonstrated by clear 
associations between: number of infection events or severity of lymphatic 
remodelling (with confirmed differences between inbred murine strains) and 
levels of upregulation/downregulation of these molecules. A summary of the 
key molecules that are most consistently altered, and thus demonstrate 
importance in mediating filarial lymphatic pathology can be seen in Table 1. 
Clinical studies have previously characterised increases of lymphangiogenic 
molecules such as: VEGF’s, Angiopoietins and FGF-2 in response to filarial 
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infection in humans (A Y Debrah et al., 2007; Debrah et al., 2009; Bennuru et 
al., 2010). The work in this thesis reasserts the importance of these identified 
molecules, with the same lymphangiogenic molecules observed to be 
significantly upregulated in the murine model. Interestingly, the data also 
reveals an important role for less well characterised lymphangiogenic 
molecules such as: TGF-β superfamily members (ie  sALK-1), Prolactin and 
Follistatin in driving filarial associated lymphatic remodelling and pathology.  
                                SEVERITY OF LYMPHATIC REMODELLING 
 
C57BL/6J 
BmL3x2 
WT 
C57BL/6J 
WT 
BALB/c 
WT 
C57BL/6J 
IL-4Rα-/- 
BALB/c 
IL-4Rα-/- 
VEGF-C / 
+++ 
*** 
+ 
* 
- + 
VEGF-A / +++ + - - 
sALK-1 
++++ 
* 
+++ 
* 
+ 
*** 
/ / 
Prolactin 
++++ 
* 
+++ 
* 
++ +++ 
+++ 
* 
Follistatin ++ 
++ 
* 
+ 
** 
++ 
* 
/ 
Angiopoietin II / 
++ 
* 
/ / 
+ 
* 
FGF-2 + 
++ 
* 
+ 
- 
* 
-- 
** 
Endoglin - 
- 
* 
- / - 
TNF-α / 
++ 
* 
/ - - 
CXCL3 
-- 
** 
+ + / 
++ 
** 
HGF 
++++ 
* 
- 
+ 
* 
-- / 
SDF-1 + ++ 
- 
* 
- / 
Leptin ++ + + ++ 
- 
** 
PLGF-2 - / 
+ 
* 
- 
* 
- 
 
Chapter 3 Chapter 5 
++++ +++ ++ + / - -- 
*=P<0.05, **=P<0.01, ***=P<0.001 vs sham control counterparts 
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Lymphangiogenic molecules displaying consistent changes in circulating 
serum concentrations are summarised across all the varying murine wild 
type (WT) and Th2 deficient (IL-4Rα-/-) strains. Red and blue shadings 
demonstrate varying degrees of upregulation or downregulation compared to 
sham controls.  
6.3- Host inflammatory Th2 adaptive immune responses to filarial infection- 
too much of a good thing? 
Investigation into the cellular mechanisms of filarial associated lymphatic 
remodelling and pathology in this thesis provided evidence for a role for 
immune inflammatory cells namely: Inflammatory monocytes, macrophages 
and, to a lesser extent, B and T-cells in secreting significant concentrations 
of lymphangiogenic molecules that contribute toward the milieu that 
potentially drives filarial associated lymphatic remodelling and pathology. An 
abundance of work has characterised innate and adaptive immune 
responses to filarial infection, with skewing of responses to inflammatory Th-
1/Th-2/Th-17 responses correlating with a pathological outcome while 
“modified/regulatory/anti-inflammatory” Th-2 responses is more frequently 
observed in asymptomatic patients (Babu and Nutman, 2012). However, with 
the previously underappreciated role of the ability of infective larval infection 
to drive profound lymphatic remodelling, contributing to pathological 
lymphatic insufficiency, a final objective of the thesis was to better 
understand how early immune responses to filarial larval infection may 
contribute to the development of the rapid lymphatic remodelling and 
pathology observed. 
Significant local expansions of IL-4+,IL-13+ and IL-10+ CD4+ T-cells, 
indicative of a strong Th2 adaptive immune response, were demonstrated as 
little as 14 days post infection with BmL3 larvae. Comparing 
immunocompetent wild type infected mice to heavily adaptive Th-2 deficient 
IL-4Rα-/- infected counterparts demonstrated significant amelioration of 
lymphatic remodelling and pathology. Further many of the key 
lymphangiogenic signals showing consistent upregulation in Wild Type 
infected mice fail to show measurable changes following infection in IL-4Rα-/- 
infected counterparts. This provided associative evidence that adaptive Th2 
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immune responses play a role, likely through specific recruitment/polarisation 
of “Th-2 effector” immune cells that secrete significant quantities of 
lymphangiogenic molecules, in driving filarial lymphatic pathology. With 
previous work showing a vital role for Th2 responses in anti-filarial immunity 
(Babu and Nutman, 2014; Turner et al., 2018), the “strength” of the initiated 
Th-2 response and the extent to which regulatory responses are co-
incidentally triggered (inflammatory Th-2 vs anti-
inflammatory/immunoregulatory Th-2) might be important in the severity of 
observed filarial lymphatic remodelling and pathology. This can be 
demonstrated by the significant difference in severity of remodelling and 
pathology observed between the higher lymphatic pathology C57BL/6J 
murine strain (which has a well characterised,  more “vigorous” or 
strengthened immune response- making them resistant- to filarial infection 
(Shenoy et al., 1998; Rajan et al., 2002) and lower lymphatic magnitude 
BALB/c murine strain (demonstrating a more “immune-regulatory” Th-2 
skewed phenotype which makes them permissive to certain filarial infections 
(Graham et al., 2005; Taylor et al., 2005; Campbell et al., 2018). Thus, 
stronger, less well-regulated “runaway” inflammatory Th-2 adaptive immune 
responses appear to be implicated in filarial associated lymphatic 
remodelling and pathology. A balance, therefore, seems to be important 
between initiation of appropriate Th2 responses, necessary for worm 
expulsion, and appropriate immune-regulatory pathways to limit “collateral” 
lymphatic pathology that occurs in response to strengthened Th2 responses. 
6.4- Induction of filarial associated lymphatic remodelling and pathology- a 
conceptual model. 
The data presented throughout the thesis has provided evidence for a 
conceptual model that summarises how filarial lymphatic pathology is 
induced in response to filarial infective larvae. Filarial infected mosquitoes 
take a blood meal resulting in delivery of BmL3 infective larvae into host 
dermal tissues. The larvae rapidly migrate into main pre-collector or collector 
lymphatic vessels proximal to the original infection site (as little as 3 hours 
after infection; Chapter 2) which results in activation of robust host adaptive 
Th2 immune responses, both in the local microenvironment of worm 
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habitation and to a lesser extent systemically (Chapter 5). The local, 
microenvironment encompassing the larvae residing in lymphatic pre-
collector/collector channels will therefore be highly Th2 dominated with high 
local concentrations of Th-2 associated IL-4, IL-13 and IL-10 cytokines and 
related chemokines (Chapter 5). Filarial habitation of these vessels results in 
rapid recruitment of inflammatory CCR2+ monocytes into the 
microenvironment (Chapter 4). While these inflammatory monocytes 
themselves secrete significant quantities of lymphangiogenic molecules 
(Chapter 4), differentiation from monocytes to macrophages (M) rapidly 
occurs (Chapter 4). The newly differentiated macrophages will be exposed to 
the local, Th2 dominated, microenvironment proximal to larval habitation, 
ligation of these Th2 IL-4 and IL-13 cytokines to the IL-4Rα receptor on M 
results in M polarisation to the “type 2” associated alternatively activated 
macrophage (AAM) (Chapter 5). The resultant BmL3 polarised ‘BmL3AAMФ’ 
secretes high concentrations of lymphangiogenic molecules (Chapter 4) and, 
together with other Th2 effector cells (such as T and B-cells) contribute to a 
localised, concentrated milieu of lymphangiogenic molecules which are 
shown to be highly upregulated following BmL3 infection, concurrent with 
high levels of lymphatic remodelling and pathology (Chapter 3). 
The resultant localised Th-2 dominant environment, together with Th-2 
associated effector cell release of high concentrations of lymphangiogenic 
molecules, results in significant alterations to the local lymphatic architecture. 
Additionally, signalling from the larvae themselves (i.e. larval excretory 
secretory extracellular vesicles (Weinkopff et al., 2014) may promote filarial-
specific M activation which can also drive lymphatic proliferation (chapter 4). 
This strong “runaway” lymphangiogenic signalling results in inappropriate 
levels of lymphatic remodelling, ultimately contributing to observed 
pathological lymphatic insufficiency and dysfunction (Chapter 2). Figure 6.1 
summarises the conceptual model graphically. 
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Figure 6.1: A conceptual model of early BmL3 associated lymphatic 
remodelling and pathology 
 
6.5- Future directions 
 
6.5.1 Future experimental work to further characterise the drivers of filarial 
lymphatic pathology 
 
The work described in this thesis has described a novel murine filarial 
infection model that enabled detailed investigation of the interaction between 
the early infecting larvae and the lymphatic architecture. Further the thesis 
describes a novel Th2/IL-4Rα – Monocyte/Macrophage – lymphangiogenic 
signalling (VEGF-C,sALK-1, Prolactin) signalling axis that is crucial for the 
development of early filarial lymphatic remodelling and pathology. Filarial 
larval infection consistently resulted in significant levels of remodelling and 
lymphatic pathology in all infected mice, yet none displayed clinical 
manifestations such as observable lymphoedema- strengthening the idea of 
a “Stage 0” ‘covert’ or sub-clinical level of pathology in which levels of 
lymphatic dysfunction/pathology exist, and may be at future risk to develop 
clinical symptoms especially considering vulnerability to repeat filarial 
infectious challenges (Freedman et al., 1995; Noroes et al., 1996; R K 
Shenoy et al., 2007; Douglass et al., 2017). While work in the thesis 
demonstrated the importance of this “seeding” covert pathology, emulating 
clinical manifestations such as lymphoedema was beyond the scope of the 
project. Long term 12-week single infections demonstrated no clear 
pathology was manifest and after clearance of infection, however future work 
may want to drive larger levels of “covert” pathology utilising “trickle infection” 
(multiple weekly infections for example) methods to drive observable clinical 
pathologies. Such methods has recently driven clinical pathology in a ferret 
model (Jackson-Thompson et al., 2018) yet driving these levels of pathology 
in the murine model provides a much easier platform to further investigate 
the driving mechanisms lymphatic pathology, building upon findings in this 
thesis. Longitudinal characterisation of the circulating lymphangiogenic 
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milieu, as well as local and systemic immunophenotyping in this transition 
between covert to clinical pathology may yield a better mechanistic 
understanding of filarial lymphatic pathology. 
With it now apparent that “covert” pathologies manifest rapidly and are much 
more common in filarial infected patients than previously appreciated, a key 
future research question centres around the concept of what are the 
diverging mechanisms/events that determine whether patients fully progress 
to clinically apparent pathologies (the symptomatic patient cohorts) and 
those who are arrested at this covert pathology, but clinically asymptomatic 
stage. The characterisation of a “low pathology” BALB/c murine strain and 
“high pathology” C57BL/6J strain in this thesis provides a viable model to 
begin to study the differences between those who may be assumed to 
represent this asymptomatic cohort (BALB/c) and those at higher risk of 
developing overt pathology (C57BL/6J). While preliminary work has identified 
strain-dependent differences in terms of: strength of immune 
responses/immune cell recruitment and lymphangiogenic molecule secretion, 
which may relate to levels of pathology, future work aiming to thoroughly 
characterise immunological, molecular and even genetic differences could 
yield a better understanding of the mechanisms which are risk factors for a 
lymphoedematous  pathological outcome.  
A large lymphangiogenic multiplex panel was utilised in the model to begin to 
investigate molecular mechanisms of filarial lymphatic remodelling and 
pathology, yet this is limited to what is relatively a small number of well-
defined mediators of angiogenesis/lymphangiogenesis. Future work could 
employ the model and utilise far more expansive transcriptomic and 
signalling pathway analysis of tissues/immune cells local to infection to far 
more comprehensively investigate molecular regulation of filarial associated 
remodelling. Additionally, cell sorting techniques employed in the model to 
isolate possible cellular mediators could be utilised to employ single cell RNA 
sequence analysis, thus far more accurately characterise the role of 
examined cells in regulating filarial lymphatic remodelling. Finally, work 
detailed in this thesis focused on the role of only a limited number of immune 
cell populations and future work may utilise the model and further cell sorting 
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experiments to isolate a more comprehensive pool of local cell populations. 
Together with the aforementioned transcriptomic, pathway and single cell 
RNA sequence analysis, this could yield a better understanding of the role of 
immune (and other) cell populations in regulating filarial lymphatic pathology. 
6.5.2 Potential for novel anti-morbidity strategies against LF  
 
The work undertaken in this thesis would advocate a novel therapeutic 
strategy to prevent development of, or even reverse, clinical LF pathology 
using interventions designed to block further development of, or even repair, 
filarial associated lymphatic pathology at the “covert”, sub clinical stage. 
Strengthening of this rationale has been demonstrated in studies in which 
early intervention at the “covert” LF pathology stage resulted in marked 
amelioration of tissue fluid retention as well as other early markers of 
lymphatic pathology (Douglass et al., 2019). The consistency and 
reproducibility of the described novel in vivo model provides a tractable 
platform to begin to screen or test the efficacy of therapeutic interventions 
towards this purpose, as candidates that are able to ameliorate the observed 
lymphatic pathology could become novel anti- morbidity drugs against LF 
pathology, even perhaps within patients who have already developed ≥ stage 
1 LE. A whole milieu of upregulated circulating lymphangiogenic factors are 
observed, coincident with development of filarial associated pathology and 
strategies aiming to inhibit the signalling of these lymphangiogenic molecules 
could be a promising starting point. Previous studies have already 
demonstrated that doxycycline treatment reduces VEGF-C/A plasma 
concentrations and this was associated with reversal of lower grade LE in 
filarial infected patients. (Debrah et al., 2006, 2009; Mand et al., 2012). 
Doxycycline intervention studies utilising the developed model to investigate 
its effect on VEGF signalling and early filarial lymphatic pathology may 
strengthen the evidence for repurposing doxycycline or other next generation 
tetracyclines as a future LF anti-morbidity drug. Further, “anti-
angiogenic/anti-lymphangiogenic” drugs which target a host of 
lymphangiogenic molecules are already used with success in the clinic 
against a range of pathologies including cancer and Age-related Macular 
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Degeneration (AMD). The targets of these treatments significantly overlap 
with lymphangiogenic mediators demonstrated to be upregulated following 
filarial infection, including VEGF-A/C/D (Holash et al., 2002; Hurwitz et al., 
2004; Ferrara and Adamis, 2016 (Ferrara, Hillan and Novotny, 2005; 
COHEN, 2009) ) and ALK-1 (Jimeno et al., 2016; Burger et al., 2018). 
Repurposing such drugs(or development of novel drugs against the less well 
characterised lymphangiogenic mediators of filarial pathology (such as those 
shown in Table 1) to prevent filarial associated lymphatic 
remodelling/neovascularisation could yield a novel anti-morbidity mode of 
action for LF. Utilisation of such drugs as interventions in the developed 
model could provide proof of principal for further downstream drug 
development.    
With a Th2/IL-4R – monocyte/AAM signalling pathway clearly implicated as 
an important mediator of early filarial pathology, therapeutic strategies aimed 
at modifying the strength, or even type of immune responses that occur 
following filarial infection could provide another attractive novel anti-morbidity 
strategy. Administration of anti-inflammatories with the intention of 
modulating the strength of ‘runaway’ Th-1/Th-2 adaptive immune responses 
observed following filarial infection may be beneficial to ameliorate filarial 
lymphatic pathology. A potential anti-inflammatory/immunomodulatory mode 
of action for doxycycline and other tetracyclines has been reported (Griffin et 
al., 2010; Bahrami, L. Morris and H. Pourgholami, 2012) which may explain 
its efficacy in reversing low grade filarial pathologies as already discussed. 
Future utilisation of anti-inflammatories, such as non-steroidal anti-
inflammatory drugs (NSAID), steroids, or even tetracyclines in the model to 
investigate any effect on both the development of filarial lymphatic pathology 
and the characterised immune response, may provide proof-of-concept for 
this therapeutic strategy. Conversely, more targeted inhibition of 
inflammatory pathways such as cyclo-oxygenase-2 (COX-2), prostaglandins 
and leukotrienes may show promise, due to their potential role in 
lymphangiogenic pathways, with preliminary work showing reversal of 
secondary lymphoedema in a mouse model following intervention against 
these targets (Tian et al., 2017) and any effects of compounds targeted at 
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these pathways on development of filarial lymphatic pathology in the model 
may be of great interest. Manipulation of the type of immune responses has 
recently shown clinical promise in cancer, specifically “immune re-education” 
of Th-2 associated AAM’ like Tumour associated M into a  Th-1 ‘M1’ 
phenotype reduces metastasis and vascular remodelling (Josephs, Bax and 
Karagiannis, 2015; Ortega et al., 2016). Targeting of specific AAM surface 
markers, such as mannose receptor, may be beneficial in this regard. Similar 
strategies that attempt to modify the “runaway” Th-2 responses or the “Th-2 
effector cells” observed following filarial infection may show success. Future 
work could attempt to blockade Th-2 cytokines with biological therapies as a 
therapeutic strategy in the model as a follow on from the experiments 
showing lack of filarial lymphatic pathology in Th-2 deficient mice, thus 
providing proof-of-concept .Finally, attempts to characterise immune evasion 
mechanisms utilised by helminths to enable chronic infection has yielded a 
host of parasite derived proteins which are highly immunomodulatory 
(Hewitson, Grainger and Maizels, 2009; McSorley, Hewitson and Maizels, 
2013). Parasite excretory secretory proteins results in strong induction of 
regulatory T-cells (Tregs), dampening both Th1 and Th2 immune responses 
(Grainger et al., 2010; Johnston et al., 2017). Utilising parasite derived 
immunomodulatory materials to regulate “runaway” Th2 responses could 
therefore result in a therapeutic approach were, the very same parasites that 
induce filarial lymphatic pathology, could contain the materials necessary to 
halt, or even reverse filarial LE. 
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Appendices 
 
Appendix 1- Table of utilised flow cytometry and fc fusion chimeras with 
relevant manufacturers and clones. 
 
Antibody Fluorophore Clone Manufacturer 
CD3 PerCpCy5.5 17A2 ebioscience 
Ly6C PerCpCy5.5 Hk1.4 ebioscience 
CD11b PerCpCy5.5 M1/70 ebioscience 
IFN-γ PE-Cy7 XMG1.2 ebioscience 
Tim-4 PE-Cy7 RMT4-54 ebioscience 
CCR2 PE-Cy7 SA203G11 ebioscience 
IgG1 Rat isotype PE-Cy7 eBRG1 ebioscience 
CCR2 AlexaFluor700 SA203G11 Biolegend 
Ly6C APCeFluor780 Hk1.4 ebioscience 
F480 BV711 BM8 ebioscience 
IgG1 Rat isotype APC eBGR1 ebioscience 
IgG2A APC eBR2a ebioscience 
CD206 APC MR6F3 Invitrogen 
CD11b APC M1/70 ebioscience 
B220 APC RA3-6B2 ebioscience 
MHCII APC M5/114.15.2 ebioscience 
SiglecF APC ES22-10D8 Miltenyi 
IL-10 APC JES5-16E3 Biolegend 
IgG1 PE eBRG1 ebioscience 
IgG2A PE TRFK5 ebioscience 
CD3 PE 145-2c11 ebioscience 
IL-4 PE 11b11 ebioscience 
SiglecF PE E50-2440 BD Bioscience 
Ly6G PE RB6-8C5 ebioscience 
IgG1 AlexaFluor 488 eBRG-1 ebioscience 
IgG2a AlexaFluor 488 eBR2a ebioscience 
CD11b AlexaFluor 488 M1/70 ebioscience 
CD11c AlexaFluor 488 N418 ebioscience 
CD206 AlexaFluor 488 C068C2 Biolegend 
IL-10 AlexaFluor 488 JES5-16F3 ebioscience 
IL-13 AlexaFluor 488 eBio13A ebioscience 
RELM-α N/A 500-P214 Peprotech 
Mouse sVEGFR-
3-Fc Chimera 
N/A N/A R&D Systems 
Mouse ALK-1-Fc 
Chimera 
N/A N/A R&D Systems 
 
  
236 
 
Appendix 2- USB drive of relevant representative movies. 
 
The attached USB drive in this thesis contains an electronic PDF copy of this 
thesis, along with representative movies of lymphangiogram PDE intravital 
imaging which were utilised to quantify lymphatic remodelling and 
insufficiency. 
Also included is representative movies of filarial worms filmed inside 
lymphatic channels 24 hours post SC infection into the left hind limb. 
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